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Abstract
Free oligosaccharides in human milk (HMO) are complex carbohydrates structurally based on lactose 
and present at concentrations of 5–20 g/L. They are considered to be resistant to digestion in the 
breastfed infant’s stomach and small intestine, and to serve as energy source selectively for beneficial 
microbiota in the bowel. Apart from this prebiotic effect, HMO have been found to exert various biolog-
ical activities in numerous in vitro studies, that indicate not only local functionality in the gut, but also, 
e.g. immunomodulatory or anti-infective, effects within the body. However, a direct link between struc-
ture and function in vivo has not yet been provided. This, in turn, is due to the enormous structural 
diversity of HMO: More than 150 different structures have been characterized to date. 
In this work, the metabolic pathways and excretion profiles of HMO were investigated in vivo to extend 
our knowledge on the sites of HMO utilization or modification and thereby to provide hints on the struc-
ture-function relationship of HMO in the infant. Therefore, a platform based on solid phase extraction 
and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) for 
a high throughput-profiling of oligosaccharides from human milk, infants’ urine and feces was estab-
lished, complemented by isomer separation via liquid chromatography. It was used to follow the time 
course and possible metabolites of 13C-enriched and non-enriched oligosaccharides in milk and infant 
urine from ten mother-infant pairs during 36 hours after the application of 13C-galactose to the moth-
ers. Intestinal absorption and subsequent renal excretion of intact structures, in particular (fucosylated) 
hexaoses, could be deduced for all infants. However, in some infants, excretion was delayed, pointing 
at a longer gut passage or systemic circulation of those certain structures. Moreover, structure-specific 
modifications and utilization in the upper parts of the gut, where absorption is thought to take place, 
were hypothesized. The overall oligosaccharide profiles in the feces of breastfed infants could be cat-
egorized into three groups, i.e. i) high diversity with many HMO-like structures, ii) only one or a few 
oligosaccharides with rather low signal intensity, and iii) no HMO. The patterns showed some associa-
tion with the infants’ age. However, further research is needed to investigate the underlying causes, 
e.g. gut maturity or stool frequency. 
Novel metabolites were identified in both, infant urine and feces. They could be characterized as acet-
ylated HMO or HMO degradation/modification products, generated by the infants or by their gut micro-
biota, such as secretor- or Lewis-specific HMO in the feces/urine of infants fed nonsecretor or Lewis-
negative milk. Lacto-N-tetraose as a major oligosaccharide in milk was significantly reduced especially 
in fecal samples. Moreover, the secretor-specific structure lacto-N-fucopentaose I, which is highly 
abundant in secretor milk, was not detected in the urine of the infants fed Lewis b secretor milk, which 
indicates a selective utilization of this specific structure. 
IV
Abbreviations
%RSD relative standard deviation
2-AA 2-aminobenzoic acid
2-AB 2-aminobenzamide
Ac acetyl residue
ACN acetonitrile
ATT 6-aza-2-thiothymine
C(G)E capillary (gel) electrophoresis
CID collision-induced dissociation
CV coefficients of variance
ESI electrospray ionization
fAM+1 fractional abundance of the isotopomer M+1
FL fucosyllactose
Fuc fucose(s)
FucT fucosyltransferases(s)
Gal galactose
GlcNAc N-acetylglucosamine
GlcNAcT N-acetylglucosaminyltransferase(s)
Hex hexose
HexNAc N-acetylhexosamine
HILIC hydrophilic interaction liquid chromatography
HMO human milk oligosaccharide(s)
HPAEC high-performance anion-exchange chromatography 
IRMS isotope ratio MS
LC liquid chromatography
LID laser-induced dissociation
LIF laser-induced fluorescence detection
LN(n)H lacto-N-(neo)hexaose
LNdFH lacto-N-difucohexaose
LNFP lacto-N-fucopentaose
LNnT lacto-N-neotetraose
LNT lacto-N-tetraose
MALDI matrix-assisted laser desorption/ionization
MS mass spectrometry
OS oligosaccharide(s)
PAD pulsed amperometric detection
PGC porous graphitized carbon
RBC red blood cells
RP reversed-phase
SPE solid phase extraction
TFA trifluoroacetic acid
TOF time-of-flight
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Chapter 1
1 Introduction and scope*
Mother’s milk is the first and sole natural nutrition in a mammal’s life. Exclusive breastfeeding during 
the first 4–6 months after birth is recommended from the World Health Organisation and the European 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition (Agostoni et al. 2009; Kramer and 
Kakuma 2001). This is due to various health benefits of breastfeeding compared to formula-feeding, 
despite significant improvements of infant formulae since the invention of the ‘Soup for infants’ by 
Justus von Liebig in 1865. For a long time, human/mother’s milk has been the gold standard for infant 
nutrition, the composition of which was the reference for milk formulas. However, recently pediatricians 
regard the performance of the breastfed infant as a more suitable reference measure, i.e. physiologi-
cal, biochemical and functional parameters, since the adaptation of formula to human milk’s macro-
and micronutrient composition has still not resolved the large differences in performance between 
breastfed and formula-fed infants (Hernell 2011). This may partly be due to confounders like psycho-
social aspects of breastfeeding, but also to specific ‘functional’ compounds of human milk, which are 
low-concentrated or even absent in bovine milk, the common basis for infant formula. Those are, for 
example, leukocytes, nucleotides, long-chain polyunsaturated fatty acids and glycolipids, glycopro-
teins, as well as free oligosaccharides (OS) (Hernell 2011; Schack-Nielsen and Michaelsen 2007). 
The major beneficial effects of breastfeeding include protection against various types of infections
during infancy, and as long-term effects a lower prevalence of immune-related diseases, such as type 
I diabetes and atopic dermatitis, a lower risk of hypertension and obesity, and enhanced cognitive 
development (Agostoni et al. 2009; Verduci et al. 2014). Due to their potential anti-infective, prebiotic 
and immune-modulating properties as found in numerous in vitro, animal and some observational 
human studies, free OS from milk seem to be a key to our understanding of the protective mecha-
nisms of breastfeeding.
1.1 Quantitative and structural aspects of glycans present in infant gut
Glycan is a “generic term for any sugar or assembly of sugars, in free form or attached to another 
molecule” (Varki et al. 2009). The most prominent milk glycan is 4-O-ß-D-galactopyranosyl-D-
glucopyranose, commonly known as lactose (Fig. 1-1). It is a major energy source for the breastfed 
infant and an important osmoregulator during milk secretion from the mammary gland, comprising the 
most abundant solid fraction in human milk.
In addition, lactose is the starting building block for the formation of free human milk oligosaccharides 
(HMO) (Grollman et al. 1965). HMO are the third major component of human milk, whereas the quanti-
ty and structural variety of bovine milk OS is notably lower (Table 1-1).
* Manuscript in preparation combined with Chapter 6
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As described in detail in Chapter 2, the biosynthesis of complex HMO starts with the enzymatic elon-
gation of the lactose core by iβ1-3-N-acetylglucosaminyltransferase. The consecutive action of β1-3-
or β1-4-galactosyltransferase results in the major core structure lacto-N-tetraose (LNT) (Fig. 1-1), or
its neo-form (LNnT), respectively. Further elongation and branching, in addition to the peripheral at-
tachment of fucose(s) (Fuc) and/or N-acetylneuraminic acid(s) to lactose or the complex cores, results 
in a unique variety of 100–200 distinct structures, as described for human milk (Urashima et al. 2009; 
Wu et al. 2011; Wu et al. 2010). However, only a few of the most abundant structures comprise over a 
half of the total HMO amount, and the biological functions seem to be as multi-faceted as the structur-
al variety. The biological role as investigated so far is presented in more detail in Chapters 1.3 and 
2.3.
Table 1-1 Macronutrients and functional glycans in human milk
Human Bovine References
Lactose 56–69 g/La) 46–48 g/kg b) (Coppa et al. 1993; Jensen et al.
2012; Thurl et al. 2010)
Lipids 18–34 g/L a) 37–61 g/kg b) (Gidrewicz and Fenton 2014; Jensen
et al. 2012)
- sialylated glycolipids 0.001–0.020 g/L 0.004–0.011 g/L (Georgi et al. 2013; Jensen 2002)
- neutral glycolipids 5 µM >27 µM
0.020 g/L
(Newburg and Chaturvedi 1992)
(Jensen 2002)
Free oligosaccharides
- neutral
- sialylated
7.7–20.9 g/L a)
5.6–10.5 g/L a)
2.2–2.5 g/L a)
0.001–0.003 g/L a)
0.050–1.5 g/L a)
(Coppa et al. 1993; Thurl et al. 2010)
(Kunz et al. 1999; Thurl et al. 2010; 
Urashima et al. 2013)
Glycosaminoglycans 0.41 g/L 0.06 g/L (Coppa et al. 2011a)
Protein
- glycoproteins
9–20 g/L a)
~70% of total 
protein
33–45 g/kg (Gidrewicz and Fenton 2014, Jensen 
et al. 2012)
(Froehlich et al. 2010)
a) mean values, varying by lactation period or other factors; b) variation range
Free lactose as a product from the action of the enzyme complex lactose synthetase is known to be 
formed only in the lactating mammary gland (Brew et al. 1968). However, various glycosyltransferases
are expressed in various tissues and organs and can form HMO-like substructures attached to lipids or 
proteins in non-lactating individuals as well. Examples are the lacto- and the neolacto-subfamiliy of 
glycosphingolipids, which are located in cell membranes, especially in secretory tissues (Schnaar et 
al. 2009). Structural examples for some common glycans as also found in human milk are given in . 
Glycosphingolipids are the major class of glycolipids detected in human milk, mainly as part of the milk 
fat globule membrane. The concentration of sialylated glycolipids is substantially lower in bovine milk 
and the composition differs from human milk (Newburg and Chaturvedi 1992; Pan and Izumi 2000). 
LactoseLacto-N-biose Fig. 1-1 Chemical structure of the milk 
oligosaccharide lacto-N-tetraose with its 
notation according to the recommenda-
tions of the Consortium for Functional 
Glycomics (drawn using Accelrys Draw 
4.2 and GlycoWorkbench 1.1, respective-
ly)
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However, the major fraction of human milk lipids is not glycosylated and serves as main energy source 
for the breastfed infant (Table 1-1).
Proteins constitute about 1% of human milk (Table 1-1), with whey proteins and caseins being the 
most abundant protein fractions, followed by peptones and milk fat globule membrane proteins (Khan
et al. 2012). The quantitative and qualitative composition of the human milk proteome as well as the 
glycoproteome can vary significantly over the course of lactation and with other factors (Froehlich et 
al. 2010). A comprehensive review of the total human milk proteome reported on 285 distinct gene 
products, 106 of which were identified as conserved protein core, also found in the bovine milk prote-
ome (D'Alessandro et al. 2010). Glycosylation is a common posttranslational modification in proteins; it 
occurs in most secreted and membrane-bound proteins, including a major part of human milk proteins.
Approximately 70% of the human milk proteins may be glycosylated (Froehlich et al. 2010). Oligosac-
charides are covalently attached to polypeptide chains by specific glycosyltransferases in one of two 
possible mechanisms: either to a threonine or serine residue via O-glycosidic bond or to an aspara-
gine during N-glycosylation (Fig. 1-2).
Fig. 1-2 Structural examples of human milk glycans, free (HMO) or attached to lipids/proteins, soluble or em-
bedded in the milk fat globule membrane (MFGM). Secretory IgA and mucin schematics (green line for poly-
peptide chain), and glycosaminoglycans (GAG) as free hyaluronan or attached to protein (blue and yellow lines 
for heparin and chondroitin sulphate) are shown. Glycan symbols depicted using GlycoWorkbench (Ceroni et al.
2008)
The human milk glycoproteome is therefore highly complex. Hence, the glycans of only few human 
milk glycoproteins have been characterized so far, e.g. lactoferrin, secretory immunoglobulin A, and 
bile salt-stimulated lipase (Huang et al. 2015; Mechref et al. 1999; Smilowitz et al. 2013b). Neverthe-
less, since these glycoproteins are among the most abundant proteins in human milk, their contribu-
tion to the total pool of complex glycans ingested by the breastfed infant is appreciable (Froehlich et 
al. 2010). Attempts have also been made to characterize the glycoproteome of milk mucins and milk 
fat globule membrane proteins (Wilson et al. 2008).
The glycan structures bound to proteins and in particular to glycolipids in milk as well as those synthe-
sized endogenously by intestinal epithelial cells have structural similarities (see Fig. 1-2 and (Tailford
et al. 2015)). That may lead to ambiguous results when analyzing the metabolic fate of exogenous 
free oligosaccharides, i.e. HMO. However, the presence of such complex HMO-like substructures 
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released from endogenous or milk glycoconjugates would require specific endoglycosidases, which 
have not been described to be present in the infant gut to date, as further discussed in Chapter 4. 
Another glycoconjugate class detected in human milk is that of glycosaminoglycans (mucopolysaccha-
rides). That are anionic heteropolysaccharides containing repeating units of hexosamine and hexuron-
ic acid (Fig. 1-2). Except for hyaluronic acid, glycosaminoglycans are bound to polypeptide chains, 
forming large proteoglycan macromolecules (Esko et al. 2009). The composition and quantities of 
glycosaminoglycans are significantly different in human and bovine milk and change over lactation, as 
can be seen in most other milk glycan families as well (Table 1-1).
Monosaccharides have also been detected in human milk, ranging in concentrations from about 0.7 
µM for UDP-galactose and 1.5 mM for glucose (Arthur et al. 1991), building the precursors used for 
the biosynthesis of lactose and other milk glycans.
Overall, human milk contains substantial amounts of glycans from all common mammalian glycan 
classes with substantial structural and quantitative differences compared to bovine milk, which com-
monly is the basis for formula (Fig. 1-2, Table 1-1). The group of unbound oligosaccharides, i.e. HMO, 
is of particular interest, since no other body fluid or tissue in humans contains as high concentrations 
as found in human milk. As also is known for various glycoconjugates exhibiting certain structural mo-
tifs, HMO have been linked to defense mechanisms against pathogens, which is crucial in the first 
months after birth when the naive immune system of an infant faces a vast variety of harmful, but also 
beneficial microorganisms. Hereby, histo-blood group antigens synthesized by the products of the 
Secretor (Se) and Lewis (Le) genes seem to play a key role as explained in the following.
1.2 Histo-blood group antigens ABH, Secretor and Lewis
A variety of certain recognition epitopes can be found on glycoconjugates throughout many species. 
The best-known among them are the ABH (also called ABO) epitopes determining the blood group of 
an individual (Fig. 1-3). Although various tissues and blood contain ABH antigens on their glycopro-
teins and glycolipids, the A and B-antigens seem not to play such a significant role in human milk as in 
blood (Egge 1993; Gustafsson et al. 2005). Secretory organs such as salivary or mammary glands 
express an alpha1,2-fucosyltransferase (FucT) encoded by a gene that is distinct from the alpha1,2-
FucT-encoding gene in non-secretory tissues. Therefore, it is referred to as the Se gene, which is 
active in approx. 80% of Europeans (Grubb 1948). However, even in Se-positive lactating women, 
who are able to synthesize the precursor for A and B antigens, i.e. H substance, in their secretions, A 
and B epitopes are barely found on HMO (Rudloff and Kunz 2012). Instead, the products from the 
activity of the FucT encoded by the Lewis gene, in addition to those synthesized by the Se-gene relat-
ed FucT (Fig. 1-3), determine the oligosaccharide profile in human milk (see also Fig. 2-1).
Se status and Le blood group were linked to certain HMO structures in human milk already in the 
1960’s (Grollman and Ginsburg 1967). This resulted in a classification of human milk into four different 
groups according to the concentrations of HMO structures with Se and/or Lewis epitopes: Se+/Le+ 
(also called Leb), Se-/Le+ (Lea), Se+/Le- (Le0 Se), or Se-/Le- (Le0 non-Se) (Erney et al. 2000; Kobata 
2010; Stahl et al. 2001; Thurl et al. 2010). The serological incidence among Europeans is approxi-
mately 70%, 20%, <10%, and <1%, respectively (Oriol et al. 1986; Race and Sanger 1975). However, 
these numbers are only rough estimations, since the determination of the Le and Se type via serotyp-
ing appears ambiguous in many cases, especially during changes of physiological conditions, such as 
cancer, pregnancy, and infancy (Hammar et al. 1981; Hirano et al. 1987; Lawler and Marshall 1961). 
This is, in part, due to the fact that the antigen-bearing glycosphingolipids which react with the antibod-
ies in the serotyping test are not expressed in erythrocytes, but are acquired secondarily, mainly from 
intestinal cells (Marcus and Cass 1969). Moreover, the expression of the enzymes alpha1,2-FucT2 
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and alpha1,3/4-FucT3, which are the products of the Se and Le genes, respectively, has been found 
to vary significantly between different tissues and secretions (Orntoft et al. 1991; Watkins 1995). 
Fig. 1-3 Formation of blood group ABO and Lewis antigens. FucT, fucosyltransferase; Le, Lewis; Se, secretor. 
Dashed, red-crossed arrows indicate inadmissible reactions. Compiled from (Watkins 1995). Glycan symbols 
depicted using GlycoWorkbench (Ceroni et al. 2008).
Gastrointestinal expression of the various blood group glycosyltransferases has been linked to OS 
modifications observed in breastfed infants’ feces (Albrecht et al. 2011a; Albrecht et al. 2011b). There-
fore, the variety of structures being excreted in a breastfed infant’s feces not only depends on the 
HMO and overall glycomic profile in its mother’s milk, but also on the infant’s blood group and Se sta-
tus and age, as was first described by Arne Lundblad’s group referring to fecal OS data from in total 
nine infants (Table 1-2). For example, mother 1 was Se-/Le+, blood group 0, and her infant’s feces 
contained Se-specific OS, although they were not expected to be expressed in milk. This was linked to 
the infant’s Se+ phenotype and a possible expression of alpha1,2-FucT2 in its gastrointestinal tract 
((Sabharwal et al. 1988a), 1st three rows of Table 1-2). In infant 5, who had the same phenotype as its 
mother, i.e. Se+/Le+, blood group A, no Se or Le-specific OS were detected in its feces, in spite of 
their presence in mother’s milk. Furthermore, larger A-active OS, i.e. penta- up to heptasaccharides, 
were detected in feces only. This indicates intense utilization/absorption and modification in the in-
fant’s gut ((Sabharwal et al. 1991), Table 1-2).
All this resulted in considerations of an alternative concept for the understanding of the role of Le/Se 
epitopes, less rigid than the classification of the ABH blood groups, which is essential in transfusion, 
but may possibly obscure crucial aspects of the biological significance of these carbohydrate motifs. In 
Chapter 2.5 the inter-individual variability of the HMO pattern according to the anticipated biosynthe-
sis pathways and its possible significance for the breastfed infant are discussed in more detail. Fur-
thermore, Chapter 2 as a whole shows how modern glycoanalytical methodologies can promote re-
search in that complex field. Not only is the knowledge on the potential biological effects of distinct 
glycans in breast milk crucial for our understanding of their biological role in the infant (see Chapters
1.3 and 2.3), but it is also essential to elucidate the pathways and mechanisms of HMO utilization and 
metabolization for a better understanding of the processes in vivo. Hereby, glyco-analytics capable not 
only to characterize possible novel metabolites, but also to discriminate them according to their Le/Se 
specificity, will play a significant role in future HMO research, as demonstrated in Chapter 4. 
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Table 1-2 ABH blood group (BG) and Lewis/secretor-specific oligosaccharides in mother’s milk and infant feces 
according to Lundblad and coworkers
Se Le A B Remarks Reference
1. Mother o x o o Milk data not reported (Sabharwal et al. 1988a)
infant x x o x 15 weeks pp
feces ╬ x o o
2. Mother x x o o 2-3 weeks pp. (Sabharwal et al. 1991)
milk x x o -
infant x x x -
feces x x o -
3. Mother x x o o 2-3 weeks pp. (Sabharwal et al. 1991)
milk x x o -
infant x x x o
feces x x o -
4. Mother x x x o 2-3 weeks pp. (Sabharwal et al. 1991)
milk x x x -
infant x x o o
feces x x x -
5. Mother x x x o 5 weeks pp. (Sabharwal et al. 1991)
milk x x x - A-tetrasaccharide, but no larger
infant x x x o
feces o o x - A-tetrasaccharide and larger
6. Mother x x x x 2-3 weeks pp. (Sabharwal et al. 1991)
milk x x x -
infant x x x o
feces x x x -
7. Mother - - - - BG/milk data not reported (Sabharwal et al. 1984)
infant x - x o 4 weeks pp.; Le BG not reported
feces o o x - no HMO detected
8. Mother - - - - pooled milk (Sabharwal et al. 1988b)
infant o x x o preterm
feces o x o -
9. Mother - - - - pooled milk (Sabharwal et al. 1988b)
infant x x x o preterm
feces o x x - Various HMO detected; A-active not 3 
days pp., but after 8 weeks
x, presence of BG oligosaccharides and ╬ indicating obvious modification in infant’s gut; o, not detected; -, not 
reported
1.3 Functional aspects of human milk glycans
Beyond the nutritive value of lactose as main carbohydrate source, a prebiotic property is anticipated 
for all the complex carbohydrate classes, i.e. HMO, glycosaminoglycans, glycolipids and glycopro-
teins. This is evidenced by studies showing that common infant gut bacterial strains are able to utilize 
human milk glycans for growth and do possess respective glycosidases, as further discussed in Chap-
ter 1.4.2. Moreover, a substantial part of HMO has been found in the feces of breastfed infants, sup-
porting the general opinion of HMO being non-digestible by human enzymes and serving as carbohy-
drate source to the infant intestinal microbiota (see also Chapter 1.4). Other, specific biological effects 
– with some links to Se status – have been described for the different glycan motifs contained in hu-
man milk, as recently reviewed in (Coppa et al. 2013; Etzold and Bode 2014; Georgi et al. 2013; Kunz
et al. 2014; Newburg and Grave 2014). These include i) anti-adhesive, anti-microbial, anti-viral,
ii) intestinal cell-response modulating, iii) immune-modulating effects, as mainly found in vitro in addi-
tion to some animal studies and observational studies in humans in vivo. 
In addition to the lactose’s function as osmotic regulator during milk secretion, non-digestible oligosac-
charides, including HMO, may regulate the consistence and water content of the bolus during gut pas-
sage and prevent constipation in infants (Scholtens et al. 2014). Second, glycosylation protects certain 
milk proteins from proteolysis in stomach and intestine (Davidson and Lonnerdal 1987). Subsequently,
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they can exert their specific functions, such as defense against pathogens, modulation of organ devel-
opment and immune response within the infant’s gut. After the absorption of the bioactive (gly-
co)peptides even systemic effects are possible (Froehlich et al. 2010; Georgi et al. 2013).
Since the different classes of glycans present in human milk often share specific structural motifs,
such as the Se epitope (s. Chapter 1.2), in vitro biological activity of glycolipids, glycoproteins, gly-
cosaminoglycans and primarily HMO against various pathogens has been shown, e.g. as anti-
microbial agents (Herrera-Insua et al. 2001; Newburg et al. 1995; Ruiz-Palacios et al. 2003; Ruvoen-
Clouet et al. 2006). Several extensive reviews on the functions of HMO were published recently (Bode 
and Jantscher-Krenn 2012; Castanys-Munoz et al. 2013; Kunz et al. 2014; ten Bruggencate et al.
2014), and a brief overview on Le and/or Se-related effects is given in Chapter 2.3. Therefore, only 
some specific features from very recent publications are summarized in Table 1-3.
Table 1-3 Overview on recent findings on structure-specific effects of human milk oligosaccharides
Functional 
property
Structural 
feature(s)
(Model) organism Reference
Prebiotic
2’-FL, 3-FL, di-FL, 
3’-SL, 6’-SL
In vitro: Bifidobacteria spp. (B.), Bacteroides spp., 
Lactobacillus spp., Clostridium spp., Enterococcus spp., 
Streptococcus spp., Staphylococcus spp., Enterobacter spp., 
E. coli
(Yu et al.
2013)
Total HMO, LNT, 
LNnT, 2’-FL, 3-FL, 
3’-SL, 6’-SL 
In vitro: 24 B. breve strains isolated from infant feces, B. 
longum infantis ATCC 15697 and B. animalis lactis JCM 
10602 as positive & negative controls
(Ruiz-
Moyano et 
al. 2013)
Cell interaction 
bacteria-
intestinal cell
HMO (vs. lactose
as negative con-
trol)
B. longum infantis, B. bifidum isolated from infants; Caco-2, 
HT-29 cells
(Chichlowski
et al. 2012)
Anti-microbial
Total HMO Enteropathogenic Escherichia coli (EPEC) in intestinal cell 
line and in vivo in mice 
(Manthey et 
al. 2014)
2’FL, 6’SL, LNnT Enterobacteriaceae (do not grow on these HMO) (Hoeflinger
et al. 2015)
Total, neutral, 
acidic HMO, 3'SL
Uropathogenic E. coli in human bladder epithelial cells (Lin et al.
2014)
Bioengineered 2’-
FL and 3-FL
Campylobacter jejuni, EPEC, Salmonella enterica serovar 
fyris, Pseudomonas aeruginosa in human intestinal Caco-2 
and respiratory epithelial cell lines
(Weichert et 
al. 2013)
Anti-viral
32 individual HMO 
(out of 247 tested)
Rotavirus attachment proteins (Yu et al.
2014)
Total HMO, 3’-SL, 
6’-SL, LNnT
Rotavirus-infected cell lysates in MA-104 cells and in situ in 
piglets
(Hester et al.
2013)
Gut motility 2’-FL and 3-FL Mouse distal colon segments (Bienenstock
et al. 2013)
Immune-
modulation
Total HMO, FL-
mix, SL-mix, 2’-FL, 
LNnT
Peripheral blood mononuclear cells from piglets (ex vivo) (Comstock
et al. 2014)
HMO, 2’FL Various intestinal epithelial cell lines and mice upon inflam-
mation
(He et al.
2016)
Protecting HIV-
transmission
Total HMO con-
centration
HIV-infected, breastfeeding women (Bode et al.
2012)
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1.4 HMO digestion and metabolization
1.4.1 Oral and gastrointestinal digestibility and absorption
According to a recent review on glycan degradation in breastfed infants (Dallas et al. 2012), a few
enzymes present in the human digestive tract may be able to degrade human milk glycans. Those are 
exoglycosidases, detected in human saliva (β-galactosidase), homogenized gastric mucosa or ho-
mogenized brush border tissue. However, most likely they do not play a quantitatively significant role, 
since i) linkage-specificity is not determined or not matching human milk glycans in several cases, and 
ii) data from homogenized tissue does not assure their presence on cell surface with possible contact 
with the substrates (Dallas et al. 2012).
These considerations are supported by in vitro digestibility studies showing HMO to be resistant to the 
whole range of conditions and enzymes present in the human oro-gastrointestinal tract, as summa-
rized in Table 1-4. Engfer and colleagues obtained similar results by applying human and porcine in-
testinal brush border membranes and human duodenal aspirates to digest neutral and acidic HMO 
fractions or single HMO standards in vitro (Engfer et al. 2000).
Table 1-4 In-vitro digestibility of HMO and related carbohydrates
Substrate a) Salivary 
amylase b)
HCl pH 2.5 c) Pancreatic 
amylase c)
BBMV pH 5-7 d) PBS c)
Neutral HMO 0% 0% 0% 2 h: +monosaccharides
4-24 h: +lacto-N-triose, Lac,
monosaccharides
0%
Acidic HMO 0% Slightly
(+NeuAc, Lac) 
0% <5%
(+monosaccharides)
0%
Lactose (Lac) 0% 100%
Lactulose 12%
a) Fractions extracted from human milk or single HMO standards were used; Lac as positive control for lactase 
from BBMV, lactulose as non-digestible reference carbohydrate; b) incubated at 37°C for 1 min at pH 7.0 and for 
2 h at pH 5.5; c) incubated at 37°C for 2 h. d) BBMV, brush border membrane vesicles from porcine small intestine.
Compiled from (Gnoth et al. 2000).
In-vivo or ex-vivo studies on the digestibility of HMO are rare due to practical and ethical reasons. 
However, a few investigations do exist. For example, a study in suckling neonatal rats showed signifi-
cant modifications of the oligosaccharide patterns throughout all the segments of the small intestine, 
when being fed HMO (Jantscher-Krenn et al. 2013). 
Substantial amounts of HMO were detected many years ago in feces and urine from breastfed infants 
(Table 1-2, (Chester et al. 1981; Rudloff et al. 1996)). Therefore, the absorbability of HMO has also 
been examined previously. LNT and lacto-N-fucopentaose (LNFP) I were shown to be transported and 
retained from the apical to basolateral compartment of intestinal cells in vitro (Gnoth et al. 2001). An-
other study found 3% of the apically applied LNT in the basolateral compartment after 90-min incuba-
tion (Eiwegger et al. 2010).
Indirect evidence for the absorption of various HMO structures in vivo by detecting HMO structures in 
the urine of breastfed infants has been provided (Rudloff et al. 1996). Absorption has been determined 
at 1–3% via intrinsic isotopic labeling of HMO and isotope-ratio (IR) MS analysis of the total OS frac-
tion in urine (Rudloff et al. 2006; Rudloff et al. 2012). Recently, two independent investigations detect-
ed higher concentrations of several neutral HMO structures in the blood of breastfed vs. formula-fed 
infants (Goehring et al. 2014; Ruhaak et al. 2014). This indicates the uptake of OS ingested via moth-
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er’s milk for the former, but also the presence of endogenous or formula-derived HMO-like structures
in the latter, as discussed in Chapter 4.5. An origin from sources other than mother’s milk can be de-
duced particularly from the high abundance of sialylated OS in formula-fed infants as reported in
(Ruhaak et al. 2014). Since complex HMO structures are based on other (core) structures which are 
also present in human milk in high amounts (Chapter 2.2), a discrimination of intact human milk-
derived vs. degraded HMO, in practice, can only be achieved via, e.g. stable-isotopic, labeling of the 
OS prior to ingestion in vivo, as successfully applied by our group and reported in Chapter 3.
1.4.2 HMO metabolism
Due to the assumed non-digestibility of HMO in the upper digestive tract and their possible function as 
the so-called ‘Bifidus factor’ (historical review in (Kunz 2012)), i.e. their possible prebiotic properties, 
HMO metabolization is thought to mainly take place in the infant colon, where concentrations of mi-
crobial organisms range from approximately 108–1010 rRNA gene copies/g as deduced from fecal
sample analyses (Palmer et al. 2007). Thus, numerous studies on the in-vitro metabolization of oligo-
saccharides and other glycans from human milk by various bacterial species and strains have been 
performed to date. Major focus is on Bifidobacteria and Bacteroides, since they represent highly 
abundant genera especially in newborns and have been shown to grow well on HMO fractions and 
single compounds as sole carbohydrate source (Marcobal et al. 2010; Yu et al. 2013). The genome of 
Bifidobacterium longum subsp. infantis strains contains gene clusters with capacity to bind, import and 
cleave milk oligosaccharides, e.g. by intracellular fucosidases and sialidases (LoCascio et al. 2010).
Further bacterial enzymes putatively involved in HMO degradation are summarized in (Garrido et al.
2013; Kitaoka 2012). Other bacterial species are not able to assimilate complex HMO, but secrete 
extracellular hydrolases prior to the translocation of degraded smaller HMO fragments instead. There-
fore, the HMO-utilizing breastfed infant’s gut microbiome is thought to be comprised of a complex co-
operative mixed-species consortium (Sela and Mills 2010). HMO utilization between different 
Bifidobacteria species and even within the same species, but between different strains, has been 
found to be highly structure-specific (Ruiz-Moyano et al. 2013; Strum et al. 2012). Conceivably, the 
metabolic profile from glycan degradation in the infant’s gut in vivo should vary immensely due to indi-
vidual differences in microbiota composition and quantity (Fallani et al. 2010; Penders et al. 2005). 
Taken into account the structural diversity of the OS pattern and quantity in human milk, as well as a 
contribution of endogenous glycans and possible modifications by the infant’s gut cells, the variety of 
OS structures excreted in breastfed infants’ feces must be enormous, as indicated in a few profiling 
studies (Albrecht et al. 2011b; De Leoz et al. 2013). Furthermore, fecal OS profiles seem to undergo 
dynamic changes in association with the infants’ age, with an increasing number and amount of me-
tabolites occurring from 3–4 months after birth (Albrecht et al. 2011a).
However, in vivo metabolites data in literature are limited to publications including only few study sub-
jects and detected OS structures (Table 1-2). To obtain more information on the in-vivo processes of 
OS metabolization and modification in the infant gut, two sets of fecal samples from 30 infants in total 
were analyzed, as reported in Chapters 4 and 5. Moreover, possible HMO metabolites after absorp-
tion, along with hypotheses on the sites of modification and utilization, are presented in Chapter 4 by 
urinary OS data, which is unique so far.
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1.5 State-of-the-art HMO analytics
Since human milk is a highly complex mixture of heterogeneous compounds, as presented in Chap-
ter 2, the analysis of milk components including HMO is challenging. Therefore, multiple purification 
steps are often necessary. Traditionally, after delipidation (only milk) and protein precipitation, size 
exclusion and ion-exchange chromatographic purification were performed prior to analysis by gas, 
paper, affinity or thin-layer chromatography (Hallgren et al. 1977; Kobata 2010; Rudloff et al. 1996; 
Sabharwal et al. 1991). The preferred strategies for purification and analysis of milk components by 
(glyco)proteomic, (glyco)lipidomic and glycomic approaches were briefly reviewed recently (Dallas et 
al. 2013). 
Currently used strategies for purification, separation and detection of HMO and related OS as relevant 
for this work are described in the following. Of note, a brief overview of various methods for HMO 
analysis published before 2012 is given in (Ruhaak and Lebrilla 2012).
1.5.1 Sample preparation strategies
During the last decade, solid phase extraction (SPE) has widely been used for OS purification, as it 
allows high-throughput operation and the use of various stationary phases. Ion-exchange resins were 
traditionally applied for the retention of polar compounds as are glycans. However, they have mainly 
been replaced by other materials that are easier to handle (Hanai 2003). For example, porous graphi-
tized carbon (PGC) is widely used to purify non-derivatized HMO and related OS (Albrecht et al.
2011b; Blank et al. 2011; De Leoz et al. 2013; Dotz et al. 2015), as it is highly selective for glycans
(Koizumi 1996). PGC material is highly stable over the whole pH range, and it has a homogenous 
structure as compared to silica or ion-exchange resins (Hanai 2003). The retention mechanisms are 
complex and not completely understood (Ruhaak et al. 2010b), but are thought to base mainly on 
hydrophobic and electrostatic interactions (Gu and Lim 1990). Hydrophobicity is higher than in other 
reversed-phase (RP) materials (Koizumi 1996), enabling an elution of the hydrophilic glycans while 
hydrophobic compounds are still retained. Hydrophilic interaction liquid chromatography (HILIC) mate-
rials are gaining increasing popularity in OS purification, as they are non-expensive and widely appli-
cable also for glycopeptides as well as derivatized glycans (Reiding et al. 2014; Ruhaak et al. 2010b; 
Selman et al. 2011). However, HILIC SPE has not been applied on HMO or related OS from urine or 
feces so far.
Various derivatization methods have been developed for different purposes in OS analysis, as re-
viewed in (Harvey 2011; Ruhaak et al. 2010b). In context of HMO, permethylation and reductive ami-
nation by fluorescent tags have mainly been applied as derivatization techniques. Permethylation has, 
among others, the following advantages in MS analysis of OS: i) enhanced signal intensi-
ties/sensitivity, ii) preservation of labile sialic acids, iii) simultaneous detection of both neutral and si-
alylated OS species in the positive ion mode, iv) enhanced cross-ring fragmentation during tandem 
MS (MS/MS) (Alley et al. 2013). Furthermore, increasing the hydrophobicity of OS allows liquid chro-
matography (LC) separation via RP materials, as enabled by permethylation or the attachment of hy-
drophobic tags such as 2-aminobenzamide (2-AB) (Alley et al. 2013; Ruhaak et al. 2010b). The latter, 
2-AB, has the advantage of allowing for a straightforward quantitative LC-fluorescence OS analysis, 
which is extensively used in glycomics, especially in HILIC-mode LC (Ruhaak et al. 2010b). This has 
also been demonstrated for animal milk OS profiling (Albrecht et al. 2014), for the quantitation of HMO 
consumption from rat intestines (Jantscher-Krenn et al. 2013), and for in-depth structural characteriza-
tion of novel HMO (Blank et al. 2012b). 2-Aminobenzoic acid (2-AA) is another very popular fluores-
cent tag in OS analytics, since it provides a single negative charge and enhances MS ionization and 
detection (Ruhaak et al. 2010b). Furthermore, 2-aminoacridone has been applied for on-line fluores-
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cence-electrospray ionization (ESI)-MS detection of HMO in HILIC-mode separation on an amide 
HPLC column (Galeotti et al. 2012).
However, most approaches applied in HMO research did not imply derivatization techniques to keep 
sample preparation as simple and fast as possible, especially in the context of high-throughput analy-
sis. In the following, the analytical techniques as used in this work are presented in more detail, fol-
lowed by a brief overview of other methods found in literature within the field of HMO research.
1.5.2 High-performance anion-exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD)
As mentioned above, fluorescently labeled OS can be isomer-separated and detected via HILIC- or 
RP-HPLC after appropriate derivatization. Alternatively, effective isomer separation and quantification 
of non-derivatized HMO can be performed in HPAEC-PAD (Dotz et al. 2015; Erney et al. 2000; Kunz
et al. 1996; Rudloff et al. 2006; Thurl et al. 2010). In the hydroxide-containing mobile phase, oxyanions
are formed from carbohydrates at pH >12, and thus are separated via a sodium acetate gradient on 
polystyrene-divinylbenzene beads, which act as anion-exchange resin (Rohrer et al. 2013). Retention 
is based on charge and size of the OS molecules. At alkaline conditions oligosaccharides are oxidized 
on a gold electrode and generate a current, which is registered by the PAD, resulting in sensitivity at 
picomolar range (Rohrer et al. 2013). Identification is done via external calibration based on retention 
time (Chapter 4). However, coupling to a mass spectrometer after thorough desalting has also been 
shown useful in the analysis of OS from infants’ urine (Bruggink et al. 2010). In the current work data 
from HPAEC-PAD with the advantage of isomeric separation were combined with the structurally in-
formative and rapid MS analysis via MALDI-TOF-MS as shown in Chapter 4.
1.5.3 MALDI-TOF-MS
MS approaches are rapidly emerging, also in the field of glycan and HMO analysis. Known as soft-
ionization techniques, MALDI- and ESI-MS are widely used for HMO profiling, characterization, and 
(relative) quantitation. From the obtained m/z values monosaccharide composition can be directly 
calculated (Table 1-5). After fragmentation via MS/MS, structural features of the molecules of interest 
can further be evaluated. This is a major advantage compared to LC alone that relies only on the re-
tention time of the analytes lacking structural information. Nevertheless, co-detection of isobaric struc-
tures and ion suppression are major limitations of direct MS, resulting in decreased signal intensities. 
This occurs to a high extent in direct ESI-MS of analyte mixtures obtained from complex biological 
matrices, where residual salts and other interfering compounds affect OS ionization and moreover 
lead to complex mass spectra due to multiple charge states (Zaia 2010). In contrast, MALDI-TOF-MS
is the preferred technique for profiling complex samples, especially from large-scale clinical studies, 
due to its ease-in-use and high-automation and high-throughput potential (Blank et al. 2012a; Zaia 
2010). The multi-facetted aspects of glycan analysis via MALDI-TOF-MS were extensively reviewed 
recently (Harvey 2015).
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Table 1-5 Mass increment values of carbohydrate structures and possible metal ion adducts relevant in HMO 
analysis
Carbohydrates Mass increment
Deoxyhexose (e.g. fucose) 146.06
Hexose (e.g. glucose or galactose) 162.05
N-acetylhexosamine (e.g. N-acetylglucosamine) 203.08
N-acetylneuraminic acid 291.10
Adduct ions
Sodium 22.99
Potassium 38.96
The principles of the Ultraflex TOF/TOF instrument from Bruker Daltonics, as used in this work, are
shown schematically in Fig. 1-4. The purified oligosaccharide (mixture) is being co-crystallized with the 
MALDI matrix substance, e.g. 2,5-dihydroxybenzoic acid (DHB), on a sample target plate. Under vac-
uum conditions the sample-matrix co-crystals are excited by a nitrogen laser emitting at 337 nm
(Suckau et al. 2003). In the positive ion mode this usually results in desorption and ionization of the 
OS molecules as singly charged quasimolecular ions after alkali metal adduction. The ions are accel-
erated applying 25 keV/8 keV in MS or MS/MS mode, respectively, and are subsequently separated 
according to their m/z value during their drift in the field-free TOF region. Through the timed ion selec-
tor only the precursor ion with its fragments can pass through if MS/MS mode is active and the m/z of 
the respective precursor has been set. In source 2, precursor and fragment ions are post-accelerated, 
since their potential energy is ‘lifted’ by additional 19 keV in LID MS/MS mode (s. Chapter 1.5.4).
Subsequently, in TOF2 region the ions are separated according to their m/z, since the smaller frag-
ments have had lower initial energy, which is proportional to their mass and deduced from the initial 8 
keV in the precursor. An ion mirror (reflectron) focuses and redirects the ion-beam and extends the 
flight length, which results in higher resolution in the dual micro channel plate detector (Suckau et al.
2003).
Fig. 1-4 Schematic of the MALDI-LIFT-TOF/TOF mass spectrometer. TOF1 ranges from the MALDI ion 
source to the LIFT cell, TOF2 from the second accelerator stage in the LIFT cell to the reflector [Reproduced 
with kind permission from Springer Science+Business Media (Suckau et al. 2003)]
MALDI-TOF-MS has not only been used for rapid OS profiling in human milk, infant urine and feces 
(Dotz et al. 2015), Chapters 4 and 5, but has also been shown useful for monitoring dynamic urinary 
excretion of HMO intrinsically labeled by the stable isotope 13C (Dotz et al. 2014), s. Chapter 3.
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1.5.4 Tandem MS
Tandem MS provides the additional value of structural elucidation of the analytes, although the ob-
tained information is often limited in case of oligosaccharides as compared to polypeptides. This is 
due to the high structural diversity of glycans with variable branching, linkage and modification possi-
bilities, as described for HMO in Chapter 2. Therefore, no universal database or software for fragment 
spectra interpretation of the human glycome is available so far (An and Lebrilla 2011), though at-
tempts have been made towards such tools also in the context of HMO (Totten et al. 2014; Wu et al.
2011; Wu et al. 2010). 
In HMO analysis, the following tandem MS methods have recently been applied for structural charac-
terization: collision-induced dissociation (CID) (Albrecht et al. 2010; Blank et al. 2012b; Ferreira et al.
2010; Jovanovic et al. 2014; Wu et al. 2010), laser-induced dissociation (LID) (Blank et al. 2011; Dotz
et al. 2015), infrared multiphoton dissociation (De Leoz et al. 2013; Wu et al. 2010), and – very novel 
for glycan fragmentation studies – electron-transfer dissociation (Han and Costello 2011). Glycosidic 
bond cleavages, resulting mainly from low-energy CID in ion trap instruments, provide monosaccha-
ride compositional and sequential information. According to the widely used nomenclature from
(Domon and Costello 1988), B and C, or Y and Z fragments are generated, containing the reducing or 
the non-reducing end, respectively. For the determination of branching and linkage patterns, cross-
ring cleavages generating A and X fragments, are necessary. Those are more abundant in techniques 
which allow higher energy transfer (Zaia 2010). However, the specific structure of the OS highly af-
fects dissociation behavior in the respective MS/MS instrument (Alley et al. 2013). An unusual exam-
ple is given in Chapter 4, where highly abundant cross-ring fragments of a possible HMO metabolite 
were obtained by LID in MALDI-TOF/TOF MS/MS analysis.
1.5.5 Other recent analytical techniques for OS originating from milk
In addition to the previously mentioned classic OS analysis methods by fluorescence HPLC and 
HPAEC-PAD as well as our more recent MALDI-TOF-MS approach, the following recent develop-
ments should not remain unmentioned. 
LC-ESI-MS is known to be superior to most other techniques for the structural characterization of gly-
cans due to the possibility of separation of structural isomers, e.g. prior to MS/MS for acquiring addi-
tional structural information. LC column materials commonly used for OS separation are PGC and 
HILIC, as already described in Chapter 1.5.1 for OS purification. PGC has been used for quantifica-
tion of major OS in human milk (Bao et al. 2013), in bacterial fermentation samples via triple-
quadrupole MS (Yu et al. 2013), or in nanoLC-chip-TOF MS for quantification of bacterial HMO con-
sumption via deuterated internal OS standards (Strum et al. 2012). The latter approach has been ex-
tended to infant fecal and urine (De Leoz et al. 2013) as well as plasma samples (Ruhaak et al. 2014). 
HILIC-LC-MS has been applied for the quantification of OS from infant plasma and urine via triple-
quadrupole MS (Goehring et al. 2014) and in Orbitrap-MS to quantify the major OS in bovine milk (Liu
et al. 2014).
A promising alternative to LC-based approaches for OS profiling is capillary (gel) electrophoresis, ei-
ther in multiplexed high-throughput manner with laser-induced fluorescence detection (CGE-LIF) 
(Kottler et al. 2013), or as CE-LIF with the possibility of additional MS characterization (Albrecht et al.
2010). The latter approach has revealed unprecedented insights into the possible metabolization of
HMO in the breastfed infant (Albrecht et al. 2011a; Albrecht et al. 2011b), which have generated hy-
potheses that among others were intensively studied in this current work (s. Chapter 1.6).
Other approaches include off-line PGC-LC-MALDI-TOF-MS (Yu et al. 2014), direct ESI-ion trap-MSn
(Ashline et al. 2014), and MALDI-quadrupole-TOF-MS (Jovanovic et al. 2014). Furthermore, nuclear 
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magnetic resonance has been applied for metabolic profiling of human milk (Pratico et al. 2014), for
quantification of major HMO (Smilowitz et al. 2013a), to determine Le and Se epitopes from HMO (van 
Leeuwen et al. 2014), or to characterize OS from milk of different primates (Taufik et al. 2012). Moreo-
ver, for an unambiguous in-depth structural characterization, a combination of the described tech-
niques with more laborious traditional strategies, such as linkage-specific exoglycosidase digestion
(Albrecht et al. 2014) or GC-MS of permethylated, hydrolyzed, peracetylated HMO still has its place in 
modern HMO analytics (Blank et al. 2012b; Wu et al. 2010).
1.6 Project scope and objectives
The examination of the metabolic fate of HMO in the exclusively breastfed infant is the superior objec-
tive of this work. This implies two major scientific questions:
1) What individual HMO structures are found in breastfed infants’ urine, as evidence for their in-
testinal absorption and indication for systemic and local effects of certain HMO structures with-
in the infant’s organism?
2) Which possible metabolites (next to intact HMO) can be found in particular in infants’ urine 
and feces, describing the metabolic fate of HMO?
The first question is based on the hypothesis that in addition to small, fucosylated and non-fucosylated
compounds even large, very complex, multiply fucosylated HMO structures may be absorbed, as was 
deduced from the detection of such structures in fast atom bombardment-MS after gel filtration of in-
fant urinary OS (Rudloff et al. 2012). IR-MS data of urine from infants fed 13C-enriched mother’s milk 
supported this. However, by analyzing the mass isotopomer enrichment of 13C-labeled urinary OS
over time in the current project by means of MALDI-TOF as an organic MS method, both, the milk 
origin and the structural composition of the detected molecular species, can be assured within the 
same measurement. Therefore, an analytical approach had to be developed allowing for i) reliable 
determination of OS isotopomer distribution from human milk and infant urine and ii) rapid sample 
preparation and sensitive analysis, since hundreds of samples with only small analyte amounts (urine)
had to be analyzed from the 36 h cohort (Chapter 3; Fig. 1-5). To introduce the reader to the chal-
lenges and potentials of modern HMO analytics in the context of large-scale clinical studies, Chap-
ter 2 further gives an overview on the structural and functional features of HMO, with focus on the Le 
and Se epitopes.
The second question arose from the few data available in literature indicating intense modification and 
degradation of HMO in the lower gut due to altered OS patterns in infants’ feces, as demonstrated by 
the studies of Lundblad’s group (Table 1-2) and more recently in (Albrecht et al. 2011a). In addition, 
Chaturvedi and colleagues claimed that no modifications in the upper intestine seem to take place, as 
deduced from urinary OS profiles resembling the milk ones (Chaturvedi et al. 2001). In order to prove 
these hypotheses, the methods established for the preparation and analysis of milk and urinary oligo-
saccharides in the first part of this project had to be adjusted to enable sensitive MS analysis of OS 
from infant feces (Fig. 1-5). Subsequently, oligosaccharide profiles could be compared, providing indi-
cations on the metabolic fate of the oligosaccharides ingested via mother’s milk. Supportively, the 
presence of Le and Se-specific OS in milk, urine and feces, by means of an established HPAEC-PAD 
method, capable to separate isomers, was analyzed. Using MALDI-TOF/TOF-MS the structural com-
position of possible metabolites as deduced from profile MS measurements was proven (Chapter 4; 
Fig. 1-5).
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Fig. 1-5 Schematic of the strategy for OS analysis in human milk and infants’ urine and feces
Additional fecal samples from another cohort comprised of breastfed as well as formula-fed infants of 
two different ages were analyzed to strengthen the findings described in Chapter 4. Moreover, the 
MALDI-TOF-MS method has been modified to enable automated, rapid and simple high-throughput 
OS analysis from infant feces in future investigations (Chapter 5).
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2 Human milk oligosaccharides and Lewis blood group –
Individual high-throughput sample profiling to enhance con-
clusions from functional studies (Manuscript 1)
2.1 Abstract
Human milk oligosaccharides (HMO) are discussed to play a crucial role in an infant’s development. 
Lewis blood group epitopes, in particular, seem to remarkably contribute to the beneficial effects of 
HMO. In this regard, large-scale functional human studies could provide evidence of the variety of 
results from in vitro investigations, although increasing the amount and complexity of sample and data 
handling. Therefore, reliable screening approaches are needed. To predict the oligosaccharide pattern 
in milk, the routine serological Lewis blood group typing of blood samples can be applied due to the 
close relationship between the biosynthesis of HMO and the Lewis antigens on erythrocytes. Howev-
er, the actual HMO profile of the individual samples does not necessarily correspond to the serological 
determinations. This review demonstrates the capabilities of merging the traditional serological Lewis 
blood group typing with the additional information provided by the comprehensive elucidation of indi-
vidual HMO patterns by means of state-of-the-art analytics. Deduced from the association of the sug-
gested HMO biosynthesis with the Lewis blood group, the matrix-assisted laser desorption/ ionization 
time-of-flight mass spectrometry profiles of oligosaccharides in individual milk samples exemplify the 
advantages and the limitations of sample assignment to distinct groups.
2.2 Introduction
Free lactose-derived oligosaccharides in human milk are present at concentrations ranging approxi-
mately from10 to 20 g/L; hence, several grams of these unique components pass through the breast-
fed infant’s gut daily (Rudloff et al. 2012; Thurl et al. 2010; Urashima et al. 2012). Various health pro-
tective actions have been deduced from in vitro investigations, i.e., prebiotic, anti-infective, or immune 
effects (Bode 2009; Kunz et al. 2000), which might partially be associated with the presence of fuco-
sylated oligosaccharide structures. Those are determined by the expression of the Se and Le genes in 
the mammary gland. Hence, distinct patterns of milk oligosaccharides according to the Le/Se types 
Le(a+b-) non-Se, Le(a-b+) Se, and Le(a-b-) Se or non-Se genes have been described by several in-
vestigators (Erney et al. 2001; Kobata 2010; Thurl et al. 2010). The prevalence in white individuals
averages 22%, 72%, and 6%, respectively (Race and Sanger 1975), whereas 80% of the Europeans 
secrete ABH substances in saliva and other secretions; thus, they are typed as Se (Grubb 1948; Schiff 
1932). Observational studies indicate that certain HMO from secretor are associated with various pre-
ventive effects, such as reducing diarrhea and promoting intestinal maturation in preterm neonates 
(Morrow et al. 2011; Newburg et al. 2004).
The final evidence of the functionality of the Le-related HMO compounds in humans has to be con-
firmed by intervention studies with large numbers of participants. Therefore, reliable high-throughput 
screening methods are needed to determine the oligosaccharide profiles in individual milk samples. 
Due to high inter- and intra-individual variations in HMO expression, the relationship between the sero-
logically detectable Le blood group and the corresponding oligosaccharide pattern in milk can only be 
used for a crude milk classification, even though serological detection as a routine method is rapid and 
highly practicable. Nevertheless, detailed information on the HMO composition in milk samples pro-
vides a more accurate indication of the substances actually ingested by the infant. For this purpose, 
new developments in the field of glycomics have great potential for facilitating the handling of large 
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sample and data sets from follow-up investigations on the correlation of Le-active components in in-
fants’ feeding and their health (Liu et al. 2010; Rakus and Mahal 2011; Ruhaak et al. 2010a).
In this review, we demonstrate the correlation of the serologically detected Le blood group and the 
expressed HMO pattern in the milk of the donors and show how this information can be enhanced by 
recent high-throughput HMO screening methods. On the basis of the suggested biosynthesis of HMO, 
specific variances in the HMO pattern are taken as examples to highlight the necessity of careful indi-
vidual milk sample analysis.
2.3 Biosynthesis of Le and Se gene-related oligosaccharides in milk
In the past years, the structures of the major HMO have been thoroughly characterized (Urashima et 
al. 2011; Wu et al. 2010). From these data, some structural rules have been deduced and the biosyn-
thetic pathways of the neutral HMO have been proposed (Fig. 2-1). Unfortunately, experimental data 
on the biosynthesis of HMO are lacking to date.
Because the reducing end of the unbound oligosaccharides from milk consistently contains lactose, 
which is the major macronutrient in human milk, this disaccharide is assumed to be the initial substrate 
for HMO synthesis. Lactose is formed in the Golgi apparatus by the action of the lactose synthase 
complex containing α-lactalbumin and β1–4-galactosyltransferase (Brew and Hill 1975). UDP-
activated galactose (Gal) is attached to glucose-I-P with high affinity due to the presence of α-
lactalbumin, which is only expressed in the lactating mammary gland of mammals.
We speculate that analogous to the O-glycosylation of proteins in the Golgi of submaxillary and gas-
trointestinal secreting cells, the glycosyltransferases for HMO synthesis might occur as membrane-
bound glycoproteins and process the oligosaccharide sequentially by the addition of a single mono-
saccharide from sugar nucleotides. Those are synthesized in the cytosol and conveyed to the Golgi 
lumen via specific membrane antiporters, e.g., GLUT1 for monophosphorylated glucose (Brockhausen 
1995; McManaman and Neville 2003; Roth 1995).
Thus, elongation (a), branching (b), and fucosylation (c) of lactose and derived structures might be 
performed by the concerted action of (a) iβ1–3-N-acetylglucosaminyltransferase and β1–3- and β1–4-
galactosyltransferase for type 1 and type 2 chains, respectively, and (b) Iβ1–6-N-acetylglucosaminyl-
transferase as depicted in Fig. 2-1. Following the suggested rules of HMO synthesis, no further elon-
gation is observed for a terminal type 1 chain (indicated by a no entry sign in Fig. 2-1) (Almeida et al.
1997; Kobata 2010; Sasaki et al. 1997). The final fucosylation and Le antigen formation is achieved by 
the consecutive action of α1–2-, α1–3-, or α1–3/4-fucosyltransferases (FucT) (c), as summarized in
Fig. 2-2.
The presence of at least 1 functional allele of the Le gene results in the expression of an α1–3/4-FucT 
(FucTIII), which is able to attach GDP-activated Fuc in the O-4 position to GlcNAc in type 1 (Galβ1–
3GlcNAc) chains, resulting in Le epitopes, as shown in Fig. 2-1. The same enzyme forms O-3-Fuc 
units at the GlcNAc residue of type 2 (Galβ1–4GlcNAc) chains yielding Lex and, in secretors, Ley
epitopes, however with lower specificity than for type 1 substrates due to steric aspects (Khare et al.
1985). The O-3-fucosylation of the reducing glucose residue is known to be accomplished by the Le-
gene–dependent FucTIII as well (Eppenberger-Castori et al. 1989). Furthermore, the formation of Lex
and Ley epitopes can also be performed by different α1–3-FucTs, i.e., FucTIII–VII and FucTIX (Koda
et al. 2001).
Although secretory tissues and fluids have predominantly FucTII activity encoded by the Se gene, i.e., 
milk (Betteridge and Watkins 1985; Shen et al. 1968; Watkins 1995), saliva, or stomach tissue 
(Chester and Watkins 1969), in human serum, both FucTII and the H gene–controlled FucTI are pre-
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sent (Le Pendu et al. 1985). Both enzymes transfer GDP-activated Fuc in α1–2-position to β-D-
galactosides prior to the formation of Leb and Ley epitopes (Fig. 2-1).
Fig. 2-1 Biosynthesis of neutral complex human milk oligosaccharides (HMO). The assumed biosynthetic path-
way starts from the activated monosaccharides and includes the most important enzymes only [N-
acetylglucosaminyltransferases (GlcNAcT)]: iβ3GlcNAcT attaches N-acetylglucosamine (GlcNAc) in the β1–3 
position to terminal galactose (Gal), Iβ6GlcNAcT attaches GlcNAc in β1–6 position to terminal Gal. Galactosyl-
transferases (GalT): β3GalT attaches Gal in the β1–3 position to GlcNAc and β4GalT attaches Gal in the β1–4 
position to GlcNAc. Fucosyltransferases (FucT): α2FucT attaches fucose (Fuc) in the α1–2 position to terminal 
Gal, secretor (Se) enzyme, α3FucT attaches Fuc in the a1–3 position to GlcNAc, α3/4FucT attaches Fuc in the 
α1–3/4 position to GlcNAc and in the α1–3 position to Glc of the lactose core, Lewis (Le) enzyme. The no entry 
signs mean that no further elongation takes place. Fucosylation is indicated exemplarily for terminal type 1 and 
type 2 chains. Glycan structures are depicted according to the recommendations of the Consortium of Functional 
Glycomics using the GlycoWorkbench software tool (Ceroni et al. 2008).
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The Le and Se gene-encoded FucTs compete for the substrates so that in secretors Lea structures are 
also found in milk and other secretions, but not on erythrocytes or in plasma (Daniels 2002; Watkins 
1995).
Fig. 2-2 The Lewis (Le) and secretor (Se) gene–
related glycan epitopes. The Le and Se epitopes, 
which are characteristic for the Le phenotype in 
red blood cells and in human milk, are synthesized 
by the listed fucosyltransferases (FucTs). The Le 
and Se genes code for the active FucTs in presence 
of at least 1 functional allele (heterozygous with 
Lele or Sese, homozygous with LeLe or SeSe). 
The prevalence of the Le phenotypes is conferred 
to Europeans (Race and Sanger 1975). Fuc, fu-
cose; Gal, galactose; GlcNAc, N-
acetylglucosamine.
Individuals with mutations resulting in the nonfunctional FucTs FucTII and FucTIII are usually typed as 
non- Se and Le negative or Le(a-b-), respectively (Bhende et al. 1952; Koda et al. 2001), and there-
fore should not secrete α1–2- and/or α1–4-fucosylated structures into milk.
2.4 Functional aspects of Le blood group–related HMO
Despite the fact that the Le histo-blood group system was discovered more than half a century ago, 
our knowledge about its biological functions is based mainly on speculations. In contrast, the role of 
the α1–3-FucTs IV and VII, which synthesize Lex and Ley epitopes, seems to be proven because their
corresponding genes are highly conserved among mammals and contribute to the formation of selec-
tin ligands (Marionneau et al. 2001).
Considering that the Le and Se genes are mainly expressed in secretory tissues, which are in contact 
with the environment and, therefore, with a large number of various microorganisms, the manifold 
carbohydrate antigens in secretions and epithelial cells might provide protection against pathogens
(Daniels 2002; Marionneau et al. 2001). Marionneau et al. suggested that providing different cell sur-
face receptors for several pathogens, Lea antigens accomplish resistance against Leb-binding patho-
gens and vice versa (Marionneau et al. 2001). Microbial lectins recognize host glycans in the gut, 
which are presented by mucins and glycolipids, enclosing ABH and Le blood group recognition sites. 
This promotes colonization, which may have adverse health effects in case of pathogen adhesion 
(Lane et al. 2010). HMO bearing Le epitopes and other recognition sites attach to the pathogens and 
inhibit their adherence to intestinal cell surfaces. Subsequently, the pathogen-HMO complex can be 
excreted (Garrido et al. 2011; Kunz et al. 2003).
Many attempts have been made to investigate the functions of HMO, including Le-specific structures; 
however, most of these studies were conducted in vitro. A brief overview is given in Table 2-1. HMO 
have antiadhesive properties, possibly resulting in the reduction of infections with Campylobacter je-
juni, Escherichia coli, Vibrio cholerae, Shigella, and Salmonella species or in a decrease in HIV-1 
mother-to-child transmission. The bifidogenic effect of HMO, which has been known for decades, 
might also be assisted by the interaction of bifidobacteria with the Le epitopes because Bifidobacte-
rium infantis is able to both use and bind different glycans from human milk and intestinal cells in vitro, 
including Le-specific structures (Garrido et al. 2011) (see also other symposium papers).
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Because the availability of HMO compounds adequate for interventional clinical trials has been limited 
to date, in vivo functional studies are rare. Nevertheless, data from observational investigations give 
an insight into the possible associations between the Le or Se phenotypes and diseases. α1–2-
fucosylated HMO decreased Campylobacter jejuni infections in mice in vivo (Ruiz-Palacios et al. 2003)
and significantly prevented diarrhea in breast-fed infants in a dose-dependent manner (Morrow et al.
2004; Newburg et al. 2004). Furthermore, low or non-Se status was strongly associated with adverse 
outcomes in preterm infants, e.g., mortality and necrotizing enterocolitis (Morrow et al. 2011), and with 
Crohn’s disease (McGovern et al. 2010), giving further indication for the involvement of α1–2-
fucosylated structures in the immune-related processes of gut development and health.
Table 2-1 Effects of Lewis and secretor gene–related factors a)
Effect Factor Investigated in Method Reference
in 
vitro
Bifidogenic Lewis a, type 1 
H-trisaccharide
B. longum ssp. infan-
tis
Genotyping;
Glycan array
(Garrido et 
al. 2011)
Anti-adhesive HMO, i.a. Lewis
epitope bearing
C. jejuni,
E. coli,
Vibrio cholerae,
Shigella,
Salmonella,
HIV-1
Various Reviewed in 
(Bode 2009)
Anti-adhesive vs. 
C. jejuni
α1-2-Fuc-HMO Carcinoma-derived 
human epithelial cells
Bacterial adherence assay (Ruiz-
Palacios et 
al. 2003)
ex 
vivo
Anti-adhesive vs. 
C. jejuni
α1-2-Fuc-Lac,
neutral HMO
Fresh human intesti-
nal mucosa Bacterial adherence assay
(Ruiz-
Palacios et 
al. 2003)
in 
vivo
Colonization with 
C. jejuni reduced
α1-2-Fuc-OS Pups of transgenic
mice
CFU counting after intestinal 
resection
(Ruiz-
Palacios et 
al. 2003)
Preventive vs. 
diarrhea from 
C. jejuni, Calicivi-
rus
α1-2-Fuc-HMO infants Serological blood group 
classification;
HPLC (HMO quantification)
(Morrow et 
al. 2004)
Preventive vs. 
diarrhea from
E. coli
α1-2-Fuc-HMO infants Serological blood group 
classification;
HPLC (HMO quantification)
(Newburg et 
al. 2004)
Association with 
mortality, gram 
negative sepsis 
and necrotizing 
enterocolitis
Low or non-
secretor status
preterm infants Genotyping;
phenotyping (enzyme im-
munoassay in saliva)
(Morrow et 
al. 2011)
Association with 
Crohn’s disease 
Non-secretor
status
pediatric/adult indi-
viduals
Genotyping (McGovern
et al. 2010)
a) CFU, colony-forming units; Fuc, fucose; HMO, human milk oligosaccharides; Lac, lactose.
Considering the potentially important role of Le and Se epitopes in the infant’s digestive tract, it is 
noteworthy that infants are typed Le(a-b-) in the first months of life, as discussed in the following sec-
tion. This could be due to a reduced Le and Se antigen expression in the immature gut of neonates 
because gastrointestinal epithelial cells are suggested to be the main source for Le-specific glycolipids 
in blood after reabsorption (Hanfland and Graham 1981; Ramsey and Sherman 2000). Nevertheless, 
strong Lea activity has been detected consistently in the fecal samples collected after birth (meconium) 
as well as at the 6-mo follow-up. Leb reactivity, if present, was complementary to Lea activity. Even 
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though the investigation was not representative, it is striking that the feces of the formula-fed neonates
exhibited slightly lower Le reactivity than their exclusively breast-fed counterparts (Larson et al. 1990).
Because several grams of HMO pass through the breastfed infant’s gut daily, they may compensate 
for the initial lack of Le and Se antigens in the neonate’s intestine.
In addition to the lower production of Le and Se antigens in the newborn, there are also observations 
of decreased Fuc content of fecal glycans in younger infants (Pang et al. 1987) and formula-fed in-
fants compared with older and breast-fed infants, respectively (Albrecht et al. 2011b). Fucosylated 
HMO in milk of Se but not in Lea non-Se decrease steadily in the first 3 mo of lactation (Thurl et al.
2010), which might be due to an adaptation of the oligosaccharide composition in milk to the infant’s 
gut maturity. Interestingly, HMO seem to be involved in the infant’s intestinal cell maturation (Kuntz et 
al. 2009). In a recent study, the fecal oligosaccharides of mixed-fed infants resembled the breast milk 
oligosaccharide patterns with few modifications. In contrast, the fecal oligosaccharide profiles from 
exclusively breast-fed preterm infants were substantially different from those of their mothers’ milk, 
showing an intense metabolism in the digestive tract. Interestingly, the authors reported the additional 
modification of the HMO with ABH epitopes several weeks postpartum (Albrecht et al. 2011a), a phe-
nomenon first described by Lundblad as well (Lundblad 1993). Albrecht et al. explained these time-
dependent variations in the infant’s individual gastrointestinal adaptation to enteral food (Albrecht et al.
2011a).
Le-specific HMO might also contribute to the protective effect of breastfeeding against urinary tract 
infections (Marild et al. 1990) because uropathogenic E. coli has been found to attach to glycolipids in 
non-Se women, presumably causing more urinary tract infections than in Se, in whom the receptor is
masked by the additional α1–2-Fuc (Stapleton et al. 1992). Some of the Le and Se-specific HMO 
structures have been detected in the urine of lactating women (Lundblad 1978; Zopf et al. 1979) and, 
more recently, also in the urine of breast-fed infants. The data suggest that the intact compounds 
reach the circulation after absorption in the infant’s gut and might, therefore, display systemic and
local effects in the infant (Rudloff et al. 2012; Rudloff et al. 1996).
2.5 Identification of Le blood group–related compounds
Traditionally, Le blood group determination is performed by serological methods, which can become a 
challenging task. Cross-reactions of the commonly used antibodies are described as well as the pres-
ence of side products leading to misinterpretation of results (Henry et al. 1995b). For example, healthy 
Le (a-b-) and Le(a+b-) individuals can show a slight expression of Leb epitopes in plasma, which may 
be due to mutation with incomplete inactivation of FucTIII and FucTII, respectively (Bjork et al. 1987; 
Henry et al. 1994; Miller et al. 1954). The saliva of Lea non-Se can also contain Leb antigens as a re-
sult of slight FucTI activity in the salivary glands (Wang et al. 1994).
Red blood cells (RBC) do not synthesize Le antigens themselves, but acquire them secondarily from 
tissues (Marcus and Cass 1969; Sneath and Sneath 1955). Therefore, the serological phenotyping of 
RBCs does not necessarily describe the Le genotype of a donor because the Le epitope expression 
may differ in various tissues (Mollicone et al. 1994b; Orntoft et al. 1991; Yazawa et al. 1996). Genetic 
factors and several conditions such as diseases, infections, transfusions, and bone marrow transplan-
tations can lead to alterations in the Le phenotype, hence, leading to misinterpretation of the blood 
group determination (Hirano et al. 1987; Langkilde et al. 1990; Makni et al. 1987; Needs et al. 1987; 
Stigendal et al. 1984).
In pregnancy, the prevalence of Le(a-b-)-typed women can increase threefold, which is most likely due 
to an increased attachment of Le-active glycolipids to plasma lipoproteins with a subsequent decrease 
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in the antigen quantity on erythrocytes (Hammar et al. 1981; Yazawa et al. 1996). In these individuals, 
discordant Le phenotypes can be detected on RBC and saliva.
A similar situation can be observed in neonates. Most of them are typed Le(a-b-) by serological detec-
tion on RBC, whereas in saliva, Le- and Se-related epitopes are already expressed, according to the 
genotype of the infant (Lawler and Marshall 1961). Several weeks after birth, Lea antigen can also be 
detected on erythrocytes, whereas Leb antigens are fully present in blood only at the age of 6 y due to 
delayed activation of the Se gene-controlled FucTII (Jordal 1956).
Because of the discrepancies and the numerous influencing factors of the Le phenotype determination 
in various tissues and body fluids, the data obtained from RBC phenotyping for Le blood group identi-
fication need to be regarded with suspicion (Henry et al. 1995a). Nevertheless, as routine method in 
the clinical sector, it is convenient for screening purposes. For the assignment of milk samples to the 
distinct Le groups, the serological RBC-based typing of the milk donors remains a valuable tool to 
roughly estimate the HMO pattern expressed in milk. The link between the Le blood group and the 
oligosaccharide profile in milk is explained by the correspondence between the biosynthesis of the Le-
active glycans present on RBC and the formation of free fucosylated oligosaccharides in the mamma-
ry gland (see previously). However, because of the described variations in serological phenotyping as 
well as individual and lactation time-specific alterations in HMO expression, serology by itself is not 
sufficient to predict the relative amount of single Le-type oligosaccharides in milk. Detailed information 
on the expressed oligosaccharide patterns might be a more appropriate basis for future research on 
HMO, especially for functional clinical studies and investigations on the metabolism and the biological
activity of HMO.
HMO monitoring of individual samples and sample mixtures is an important research topic about which 
excellent studies were conducted in the past. Various methods starting from paper chromatography, 
HPLC, and HPAEC over MS methods to latest developments in HPLC-chip-MS and CGE-LIF tech-
niques have been applied (Albrecht et al. 2010; Blank et al. 2011; Kobata et al. 1969; Kunz et al.
1996; Leo et al. 2009; Marino et al. 2011; Ninonuevo et al. 2008; Thurl et al. 1997; Viverge et al. 1990; 
Wu et al. 2010; Yang et al. 2011). All these powerful methods provide detailed insights into the oligo-
saccharide pattern of individual milk samples, frequently paired with further information about the rela-
tive amount of single isomers. Some of these techniques require sophisticated and time-consuming
sample preparation procedures and/or large quantities of sample material, which is a drawback for 
large sample sets. The combination of a simple, automated, and standardized sample workup proce-
dure combined with standard MALDI-TOF-MS analysis provides the analytical power needed for a 
high-throughput glycomics approach for HMO profiling (Blank et al. 2011).
2.6 Variation of the HMO pattern
Automated MALDI-TOF-MS(/MS) as an HMO screening method enables the Le blood group correla-
tion of a large milk sample set and delivers, at the same time, the distinct HMO pattern of each milk 
sample with high reliability (Blank et al. 2011).
Recent findings in the oligosaccharide pattern of single milk samples show the necessity of individual 
sample monitoring. The discrepancy described between the serologically detected blood group and 
the expression of Le antigens in other body fluids and tissues seems to be conferrable to Le-type oli-
gosaccharides in human milk.
From the genetic point of view, a more consistent oligosaccharide pattern might be expected within a 
distinct Le blood group (Mollicone et al. 1994a). However, several studies showed that the proportion 
of distinct oligosaccharide structures can vary greatly among individual milk samples, depending on
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the lactation period and/or Le status (Blank et al. 2011; Kobata et al. 1969; Kunz et al. 2000; Stahl et 
al. 2001; Thurl et al. 2010; Viverge et al. 1990).
The results of the MALDI-TOF-MS(/MS) screening of 40 milk samples from mothers with serologically 
determined Le blood group underlined these findings. Fig. 2 3 displays mass spectra from 2 Le(a-b-) 
and 2 Le(a-b+) donors, which differ markedly in their HMO pattern. The 95% CIs calculated for each 
signal within an Le blood group are indicated by shaded and open bars. In case of coincidence 
be¬tween the measured signal intensity and the predicted interval, the bar is shaded; otherwise, the 
CI is shown by an open bar. Each signal represents a distinct oligosaccharide composition with sever-
al structural isomers.
Fig. 2-3 Matrix-assisted laser desorption/ionization time-of-flight MS profile spectra of 4 individual milk sam-
ples. Spectra displayed were obtained from 4 women: 2 serologically typed as Le(a-b-) (A,B) and 2 as Le (a-b+) 
(C,D), respectively. The signals represent sodium adducts. The 95% CI, calculated for each human milk oligo-
saccharide composition, base on data from 40 individual milk samples. CIs are illustrated by open bars if the 
measured signal intensity is not in the expected range and by shaded bars if it is. Relative CIs are described in 
(Blank et al. 2011) and are applied to the measured signal intensities. Due to high variance in the signal intensi-
ties of the high molecular weight HMO, CIs were only calculated for signals up to m/z 1533. Compositions are 
calculated using GlycoPeakfinder software (Maass et al. 2007).
The HMO pattern of a serologically Le(a-b-)-typed woman is depicted in Fig. 2-3A. A strong overex-
pression of LN(n)T (m/z 730), as well as the monofucosylated lacto-N-(neo)hexaose (LN(n)H) (m/z
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1241) was apparent. The multiply fucosylated species, such as difucosyllactose (m/z 657), difucosyl-
ated LN(n)T (m/z 1022) and the trifucosylated LN(n)H (m/z 1533) were substantially lower than ex-
pected or even absent. All of these 3 structures should contain a remarkable amount of α1–2-Fuc, 
whereas monofucosylated and difucosylated LN(n)H might contain mainly α1–3/4 fucosylated com-
pounds. This leads to the conclusion that the donor might have an inefficient α1–2-FucT in the mam-
mary gland, which is Se-gene dependent. Two explanations are possible for the anomaly in the de-
picted mass spectrum: i) this donor might belong to the rare subgroup of Le(a-b-) non-Se and ii) the 
donor’s Le phenotype is actually Le(a+b-) because the HMO profile resembles that of an Le(a+b-) 
pattern with regard to the calculated CIs (data not shown).
The second Le(a-b-) sample showed the opposite phenomenon (Fig. 2-3B). The nonfucosylated pre-
cursor for the complex HMO, LN(n)T (m/z 730) and its monofucosylated form redundant (m/z 876) 
were underexpressed, whereas the multiply fucosylated species difucosylated LN(n)T (m/ z 1022) and 
trifucosylated LN(n)H (m/z 1533) were overexpressed. Moreover, unusually intensive signals up to a 
mass of 2500 Da were detected in high abundance in this specific sample. This suggests that this 
donor expressed several highly efficient glycosyltransferases as well as FucTs forming a diverse HMO 
pattern also in the higher mass range, conforming to an Le(a-b+) HMO pattern rather than the ex-
pected Le(a-b-)-specific one. Because the HMO spectra shown in Fig. 2-3A and B are atypical 
Le(a-b-) and resemble those characteristic of Le(a+b-) and Le(a-b+), respectively, the suspicion is 
raised that the milk HMO profiles may also reflect the partial discordance of the serological RBC- and 
saliva-based Le phenotyping in pregnant women, as discussed previously.
Fig. 2-3C shows the HMO spectrum of an Le(a-b+) donor expressing an atypical HMO pattern, which 
cannot be assigned to any Le blood group. All signals from m/z 657 to 1022 were expressed in sub-
stantially lower intensity than expected, whereas the signals in the mass range from m/z 1095 to 1533 
were overexpressed. Hence, a shift to high molecular weight HMO can be observed for this particular
sample. As already discussed for Fig. 2-3B, also in this example highly efficient glycosyltransferases 
might be responsible for the observed variation.
Only slight deviations in the Le(a-b+) spectrum are seen in Fig. 2-3D, except for the unexpectedly high 
proportion of difucosyllactose (m/z 657).
The demonstrated variations in the MALDI-TOF-MS profile spectra confirm the conclusion of (Thurl et 
al. 2010) that each lactating woman expresses an individual HMO pattern, even though an assignment 
of the HMO profiles to the distinct Le blood groups was applicable for the majority of the milk samples 
in our investigations (see later).
The importance of screening methods to detect the individual oligosaccharide profile is further empha-
sized by the tandem mass spectrometry analysis of the precursor m/z 1022 in a milk sample from a 
woman typed Le(a+b-) (Fig. 2-4). As a major isomer, an LN(n)T core bearing 1 Fuc at the reducing 
end and the Lea/x epitope at the nonreducing end is expected in a milk sample from an Le(a+b-) donor. 
The most intensive fragment signals at m/z 730 (Y4βB4α) and m/ z 876 (Y4β) result from the dissociation 
of 1 and 2 Fuc residues, respectively [fragment ions are designated in accordance with the nomencla-
ture of (Domon and Costello 1988)]. In addition, the signals m/z 696 (B3α), m/z 511 (Y2α), and m/z 365
(Y2αB4α) underline the presence of the likeliest precursor structure. Strikingly, an indication for the 
presence of an Leb/y epitope is given by the signal m/z 680 (B2α), a difucosylated N-acetyllactosamine 
unit. The serologically detected Le blood group does not explain the presence of an Leb/y epitope be-
cause of the lack of the Se gene–dependent FucTII in Le (a+b-) individuals. Nevertheless, the difuco-
sylation of either a terminal type 1 or 2 N-acetyllactosamine unit in this milk sample is an indication for 
α1–2-FucT activity. This finding confirms the unexpected presence of α1–2-fucosyl HMO in 2 serologi-
cally typed Le(a+b-) donors by Newburg et al. (Newburg et al. 2004). These findings might be ex-
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plained by a slight activity of the H gene–controlled FucTI, which has been detected at least in the 
saliva of Le(a+b-)-typed individuals (Wang et al. 1994). The application of the fragmentation analysis 
of individual oligosaccharides for structural characterization is described for various MS techniques 
(Albrecht et al. 2010; Amano et al. 2009; Broberg 2007; Ferreira et al. 2010; Ninonuevo et al. 2006; 
Pfenninger et al. 2002; Wu et al. 2011; Wu et al. 2010; Yamagaki et al. 2006; Yang et al. 2011). 
Hence, tandem MS analysis can also provide additional structural information for individual HMO 
compositions in the case of HMO screening.
Fig. 2-4 Matrix-assisted laser desorption/ ionization time-of-flight MS/MS analysis of purified human milk oli-
gosaccharides of a Lewis (a+b-) donor. Inset shows range from m/z 650 to m/z 720 at 50× magnification. The 
obtained fragment ions were assigned according to the recommendations of the Consortium of Functional Gly-
comics using GlycoWorkbench (Ceroni et al. 2008). Fragment ions are designated in accordance with the no-
menclature of (Domon and Costello 1988). In some cases, fragments may be formed by different fragmentation 
pathways, only 1 of which is illustrated. All fragment ions represent sodium adducts. The unexpected signal is 
circled in red.
The presented examples demonstrate the drawbacks of serological Le blood group classification and 
emphasize the need for individual sample mapping. Le phenotyping in human milk by MALDI-TOF-
MS(/MS) analysis and subsequent statistical data evaluation provide the opportunity not only to assign 
the specimens to definite groups, but also to reveal unusual tendencies for each individual milk sam-
ple, including its unique HMO profile (Blank et al. 2011).
Fig. 2-5 shows the results from a discriminant analysis of 40 individual milk samples measured three-
fold. Using the new screening approach, 95% of the samples were correctly assigned to the serologi-
cally detected Le phenotype in blood by at least 2 of 3 measurements. Specifically, 99% of all serolog-
ically Le(a-b+), 100% of the Le(a-b-), and 68% of the Le(a-b-) typed samples were assigned to the 
previously determined Le blood group. Nevertheless, the partial inhomogeneity of the Le-specific HMO 
profiles described previously is also evident from the wide distribution of the samples within the Le 
blood groups. The overlapping area of the Le(a-b+) and Le(a-b-) typed samples, in particular, displays 
the similarity of the oligosaccharide profiles in several specimens with a different Le phenotype, most 
likely resulting from their Se gene activity. However, the fact that the majority of the milk samples were 
matched to the serologically detected Le blood group shows that a classification using both approach-
es can be useful despite the variations in the expression level of single oligosaccharide composition in
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milk. The location of each breakpoint in the coordinate plan therefore provides information about the 
Le phenotype tendency of a distinct milk sample and at the same time information about its actual 
oligosaccharide pattern. Consequently, the new MS screening approach provides a fast and material-
saving option for individual milk sample mapping with detailed information on the expression level of 
individual oligosaccharide compositions.
Fig. 2-5 Discriminant analysis. The results 
obtained for 113 single matrix-assisted laser 
desorption/ionization time-of-flight MS and 
redundant MS/MS measurements of 40 milk 
samples underwent discriminant analysis. 
Discriminant function 1 is plotted on the x-
axis and discriminant function 2 on the y-
axis. Open diamonds, red squares, and green 
triangles represent HMO samples from Le(a-
b+), Le(a+b-), and Le(a-b-) donors, respec-
tively. The distribution of each group is 
indicated by colored shading. Reproduced 
with kind permission from Springer Sci-
ence+Business Media (Blank et al. 2011), 
Figure 7.
2.7 Conclusion
Serological Le blood group determination can only offer a first indication of the expressed oligosaccha-
ride pattern in human milk. Modern high-throughput screening methods can support the traditional 
serological RBC analysis and provide detailed information on the relative abundance for each oligo-
saccharide composition, thus, enhancing or qualifying the conclusions of functional studies. In particu-
lar, the capability of individual glycan epitope recognition and its relationship to observable, biologically
relevant effects will be of great benefit. Furthermore, reliable Le phenotype screening, e.g., by the 
MALDI-TOF-MS approach presented here, can replace serological determination on erythrocytes if no 
blood sample is available.
The variations between the serologically detected Le blood group and the Le phenotype in other body 
fluids and tissues, which are frequently reported in literature, were also detectable in human milk using 
the novel screening approach. Based on the determined individual HMO patterns, some speculations
about the activities of certain glycosyltransferases in the milk donors were deduced by taking into con-
sideration the information from the suggested HMO biosynthetic pathway.
The combination of the traditional serological Le blood group detection supported by modern milk 
screening methods will lead to a solid glycan characterization as the basis for future research on the 
effects of HMO from native milk.
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3 13C-labeled oligosaccharides in breastfed infants’ urine: Indivi-
dual-, structure- and time-dependent differences in the excre-
tion (Manuscript 2)
3.1 Abstract
Human milk oligosaccharides (HMO) have been paid much attention due to their beneficial effects 
observed in vitro, e.g., prebiotic, anti-infective and anti-inflammatory properties. However, in vivo in-
vestigations with regard to HMO metabolism and functions are rare. The few data available indicate 
that HMO are absorbed to a low extent and excreted via urine without noteworthy modifications, 
whereas the major proportion reaches infant’s colon undigested. Via intrinsic 13C-labeling of HMO 
during their biosynthesis in the mammary gland of 10 lactating women, we were able to follow the fate 
of 13C-labeled oligosaccharides (OS) from their secretion in milk to the excretion in the urine of their 
breastfed infants. To a certain extent, we could therefore discriminate between original HMO and non-
labeled OS derived from degradation of HMO or endogenous glycoconjugates. By means of our novel, 
rapid, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS)-
based approach, we found a homogeneous time pattern of isotopomer enrichment in milk among all 
subjects and between single OS species. In contrast, the time curves from infants’ urine varied strong-
ly between individuals and OS species, though the overall MALDI-TOF-MS profile resembled those of 
the mothers’ milk. Our data suggest that neutral HMO might be processed and/or utilized differentially 
after or upon absorption from the gut, as deduced from their structure-dependent variation in the ex-
tent of tracer enrichment and in the retention times in infant’s organism. This sheds new light on the 
role of HMO within infant’s body, beyond the intestine and its microbiota alone.
3.2 Introduction
It is well known that breastfed infants have various health benefits compared with formula-fed babies, 
e.g. less-frequent autoimmune diseases and fewer or less severe infections of the respiratory, intesti-
nal and uro-genital tract (Pisacane et al. 1992; Schack-Nielsen and Michaelsen 2007). In this regard, 
HMO are supposed to contribute to these beneficial outcomes through their prebiotic, anti-infective 
and immunomodulatory effects, as revealed from numerous in vitro and few animal and human obser-
vational studies (Bode 2012; Kunz et al. 2000). Since HMO are products of the action of different gly-
cosyltransferases in the mammary gland and, therefore, evolve large structural variety, it is not surpris-
ing that their efficacy and absorption have been found to be dependent on the individual structures 
(Bode 2012; Gnoth et al. 2001), including specific sites of fucosylation (Morrow et al. 2011) or sialyla-
tion (Bode et al. 2004). Lactose as the backbone of HMO can be elongated with GlcNAc and Gal resi-
dues to form GlcNAcβ1-3Gal or GlcNAcβ1-4Gal units, the former resulting in the main core structure, 
LNT, the latter in neo-LNT or LNnT. These structures can be further elongated and branched, or also 
modified by the attachment of α1-2-/α1-3- or α1-4-linked fucose and/or N-acetylneuraminic acid, the 
latter forming acidic HMO (Kobata 2010). 
Although OS are the third largest component of human milk with concentrations ranging from 5 to 20 
g/L (Coppa et al. 2011b; Thurl et al. 2010), their metabolism and functions in vivo are poorly under-
stood. This is partly due to several practical and analytical limitations. In previous studies with and 
without the use of stable isotopes, we found a renal excretion of 1–3% of individual HMO in exclusive-
ly breastfed infants (Rudloff et al. 2012; Rudloff et al. 1996). Over the last years, various state-of-the-
art methodologies have emerged enabling a sophisticated identification of the majority of the >200 
distinct OS structures found in human milk, infant feces and urine. These techniques include chroma-
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tography (Chaturvedi et al. 2001; Rudloff et al. 2012), capillary electrophoresis (Albrecht et al. 2011a; 
Shen et al. 2000), mass spectrometry (Klein et al. 1998; Kogelberg et al. 2004) as well as on-line cou-
pled combinations of those (De Leoz et al. 2013; Galeotti et al. 2012).
Practical constraints of clinical studies on HMO include their limited availability and affordability for the 
use in humans (Rudloff and Kunz 2012). Ethical considerations are also impeding the much-needed 
functional studies, since infants as well as lactating women are particularly vulnerable subpopulations. 
Consequently, study design and sampling procedures should be of minimal discomfort and risks for 
mother and child. Therefore, we used intrinsic stable isotope labeling as an established and straight-
forward, noninvasive technique (Davidsson and Tanumihardjo 2011).
Breastfeeding women ingested 13C-Gal, which was incorporated into HMO during their synthesis in the 
mammary gland. Subsequently, we were able to track the stable isotope tracer over the course of time 
including its renal excretion in the breastfed child by measuring 13C-enrichment in whole or fractionat-
ed mother’s milk and infants’ urine by means of IRMS (Rudloff et al. 2006; Rudloff et al. 2012). Al-
though IRMS is very sensitive in the determination of isotope enrichment, it does not distinguish be-
tween single compounds, unless they were isolated prior to analysis in a tedious procedure requiring 
large sample volumes, in particular, in case of urinary OS. Hence, we have developed a rapid MALDI-
TOF-MS-based approach (see also (Blank et al. 2011)) for the determination of isotopomer enrich-
ment in nonderivatized, neutral OS from human milk and infants’ urine, enabling us to discriminate 
between the renal excretion of labeled, intact OS originating from milk (HMO) and nonlabeled OS of 
endogenous origin or resulting from HMO degradation. A dynamic insight into the metabolic fate of 
individual OS species in lactating women and their breastfed children over time is provided, and 
thereby indication is given for their functionality within infant’s organism and the structures of active 
compounds.
3.3 Results
Directly before and up to 36 h after an oral application of 13C-Gal to 10 lactating mothers, milk and 
their infants’ urine were collected at each nursing, yielding >200 single milk and urine samples in total 
(Fig. 3-1). 
Fig. 3-1 Workflow of the in vivo isotope labeling experiment 
with mass isotopomer distribution evaluation via MALDI-
TOF-MS. 13C-Gal was ingested by 10 lactating women and 
found to be incorporated into milk OS. Labeled and unla-
beled OS were, in part, excreted in the urine of their breast-
fed infants. Enrichment of OS with 13C was followed over 
time by comparing the fractional abundances of the mass 
isotopomers at 0 < t < 36 h with those at baseline.
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Some of the single urine samples could not be used for the analyses due to their insufficient volume or 
to fecal contamination in the diaper, causing discontinuations in the time course during the 36 h exam-
ination period. To adjust for the high variation of the urine volume and, therefore, analyte concentra-
tion prior to OS extraction, we determined creatinine concentration in each urine sample, since it is 
commonly used as reference parameter in clinical studies. The concentrations ranged from 30 to 250 
mg creatinine/L of infants’ urine. A urine volume corresponding to 0.1 mg creatinine was found to be 
optimal for OS extraction and MS analysis.
After SPE, the OS profile of each individual sample was acquired by MALDI-TOF-MS in positive ion 
mode (Fig. 3-2). The OS species in milk and urine which could be detected in any of the 36 h samples 
of an individual are listed in Table 3-1 (page - 34 -). OS profiles showed high interindividual variability, 
particularly in urine. For example, the molecular species with nominal mass 2044 for the lightest isoto-
pomer [M+Na]+, referring to the glycan composition Hex5HexNAc3Fuc4, was only detected in the milk 
of women 3–9 and the urine of children 5 and 6. The m/z values, shown in the present work, represent 
nominal masses for sodiated glycans as detected in MALDI-TOF-MS. MALDI mass spectra provide 
mass isotopomer patterns of individual OS structure compositions (Fig. 3-1 and Fig. 3-2). Those were 
the basis for the determination of fractional abundances, fAM+1 in %, in single OS components after 
tracer administration. For example, LNT and its structural isomer LNnT with 12C2513C1H4514N16O21 or 
12C261H442H14N16O21 or 12C261H4515N16O21 are part of the same isotopomer M+1 with calculated nominal 
masses of 708, or 731 when detected in MALDI-TOF-MS as sodiated ions. 
Fig. 3-2 MALDI-TOF-MS profiles of OS in human milk and infants’ urine of mother–child pair 6 after 13C-Gal 
administration. The m/z values are given as nominal mass for [M+Na]+ ions; for structural compositions see 
Table 3-1. Maltoheptaose was used as internal standard (m/z 1175).
An internal standard, maltoheptaose with m/z 1175 [M+Na]+, was added prior to each MS measure-
ment as control substance with constant isotopomer distribution (Fig. 3-2). The fAM+1 value of the 
samples collected prior to tracer application was regarded as baseline, except for woman 9 and in-
fants 1, 8–10. Since no baseline sample was available from these subjects, theoretical fAM+1 values, 
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as calculated from the chemical formula of the OS and the natural isotope abundances of H, C, N and 
O, were applied to the statistical tests instead.
3.3.1 Time course of biosynthesis of milk OS over 36 h
For all 10 lactating women, an increase in fAM+1 could be observed in many OS species over time after 
13C-Gal ingestion. Some variability occurred in terms of the time pattern and the magnitude of tracer 
enrichment between both, subjects and single OS species. However, the overall time pattern of the 
fAM+1 values in Fig. 3-3 is rather uniform with two or even three maxima within 36 h. Fig. 3-3A shows 
data averaged from all 10 women, i.e., means of all fAM+1 determined in samples collected within a 4-h 
time interval. The coefficients of variance (CV) of the fractional abundances in larger OS with m/z ≥ 
1242 were ≤5% at most time points. Those OS species, which were most abundant in milk, i.e. isoto-
pomers at m/z 731, 877, 1023, varied by 3−9%. The time pattern of fucosyllactose (m/z 512) showed 
highest inter-individual variations (3.43 ≤ CV ≤ 21.03%). An example of the time course of isotopomer 
enrichment in HMO of a single donor is depicted in Fig. 3-3C. The isotopomer abundances exhibit a
consistently clear double-maximum time pattern in the milk of woman 3, even in case of fucosyllactose 
at m/z 512 (Fig. 3-3C).
Fig. 3-3 Fractional abundances of the oligosaccharide isotopomer M+1 (fAM+1) in milk during 36 h after oral 
13C-Gal intake. Values were calculated from isotopomer abundances of M and M+1 (see Fig. 3-1), as analyzed 
by MALDI-TOF-MS, and shown as means of the measurements from all women (A), and woman 3 alone with 
mean values of the triplicate measurements (C). Theoretical fAM+1 values were calculated from the chemical 
formula of the glycan and natural H, C, N, O isotope abundances (B). The m/z values of OS are given for 
[M+1+Na]+ ions. For structures see Table 3-1; m/z 1176 refers to the internal standard maltoheptaose.
In order to confirm the significance of the isotopomer enrichment in milk and urine, we evaluated 
whether the MALDI-TOF-MS fAM+1 values of the individual triplicate measurements from each sample 
at a certain time point differ significantly from baseline (Table 3-2). The individual data were grouped 
into 4-h intervals after statistical evaluation. The significant enrichment in the first half of the 36 h col-
lection period persisted for ≤12 h in milk, starting directly at ≤4–8 h after tracer ingestion. Enrichment 
in the later period was more widely distributed over time and was significant in fewer OS species, indi-
cating a third peak enrichment in women 2, 3 and 10. A slightly deviating time pattern was seen in milk 
samples of subject 5, in which the second maximum was more pronounced than the first (Table 3-2).
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Table 3-1 Neutral HMO detected in 10 mother–child pairs by MALDI-TOF-MS over 36 h
m/z Chemical 
composition
Structural
composition a)
Detected in b) m/z Chemical 
composition
Structural
composition a)
Detected in b)
milk urine milk urine
511 Hex2Fuc1 1-9 1,3-9 1825 Hex6HexNAc4 1,3,4,6,7,9 none
657 Hex2Fuc2 1,3-9 1,3-9 1898 Hex5HexNAc3Fuc3 1-10 1-3,5-7, 10
730 Hex3HexNAc1 1-10 1-10 1971 Hex6HexNAc4Fuc1 1-10 none
876 Hex3HexNAc1Fuc1 1-10 1-10 2044 Hex5HexNAc3Fuc4 3-9 5,6
1022 Hex3HexNAc1Fuc2 1-10 1-10 2117 Hex6HexNAc4Fuc2 1-10 1
1095 Hex4HexNAc2 1-10 1-10 2190 Hex7HexNAc5 3-8 none
1168 Hex3HexNAc1Fuc3 3-9 6,7,9 2263 Hex6HexNAc4Fuc3 1-10 1
1241 Hex4HexNAc2Fuc1 1-10 1-10 2336 Hex7HexNAc5Fuc1 1,3,4 none
1387 Hex4HexNAc2Fuc2 1-10 1-10 2409 Hex6HexNAc4Fuc4 2-9 none
1460 Hex5HexNAc3 1-10 3,5,6,9, 10
2482 Hex7HexNAc5Fuc2 2-4,6,7 none
1533 Hex4HexNAc2Fuc3 1-10 1,3-10 2555 Hex8HexNAc6 4,6 none
1606 Hex5HexNAc3Fuc1 1-10
1,3,5,6,1
0 2628 Hex7HexNAc5Fuc3 2,4,6 none
1679 Hex4HexNAc2Fuc4 3-9 none 2701 Hex8HexNAc6Fuc1 4 none
1752 Hex5HexNAc3Fuc2 1-10
1-3,5-7, 
10 2774 Hex7HexNAc5Fuc4 2,4,6 none
The m/z values refer to monoisotopic [M+Na]+ ions.
a) Structural examples for the various isomers, according CGF notation using GlycoWorkbench (Ceroni et al. 2008): Square, N-acetyl-D-glucosamine; filled circle, glucose; open 
circle, Gal; triangle, fucose.
b) Subject number is indicated if the listed oligosaccharide species was detected in any of the 36 h samples. 
3×
4×
3×
4×
3×
2×
4×
2×
2×2×
3×3×
4×
2×
2×
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Table 3-2 Statistically significant 13C-enrichment of neutral OS in mothers’ milk and infants’ urine over 36 h
Net time after 13C-galactose
0–4 4–8 8–12 12–16 16–20 20–24 24–28 28–32 32–36
Milk 1 1023*; 1242; 1388* 1023
#; 1242#; 1388#; 
1607*; 1899*
512; 1023#; 1096; 
1242#; 1388#; 1607
n.s. n.s. n.s. n.s. n.s. n.s.
Urine 1 a) 1388 n.s. – – 512#; 877#; 1388* – – – 877; 1388
Milk 2
731*; 877*; 1023; 
1388#; 1534*; 1753*
731*; 877; 
1023;1242;1388#; 
1534; 1753#
731*; 877#; 1023; 
1242; 1388#; 1534#; 
1753*
– 1388*; 1534* 1388* n.s. 1388 1534
Urine 2 n.s. n.s. 877#; 1023# – n.s. – 877 877 –
Milk 3
512; 731; 1023; 1096; 
1242; 1388
512#; 731#; 877#; 
1023#; 1096#; 1242#; 
1388#; 1534#; 1607*
n.s. n.s. – n.s. 1023; 1242 n.s. 1534
Urine 3 – n.s. n.s. 731; 1023 – n.s. 731 – n.s.
Milk 4 877; 1023; 1242#; 1388#; 1534#
1242#; 1388#; 1534# 877; 1388* n.s. n.s. n.s. 1242#; 1388#; 1534* 1388* n.s.
Urine 4 n.s. n.s. 731; 877*; 1388# 731 n.s. – 1388 1023 –
Milk 5 – 1388* 1388* 1388 – 1388#; 1534* – 1388#; 1534 1388
Urine 5
n.s. 1242* 512; 731*; 1023; 
1242#
– 1242* 1242# 1023* 731*; 877*; 1023*; 
1242
–
Milk 6
512; 1023#; 1096; 
1534#; 1607*;
1023#; 1534#; 1607#; 
1899*
731; 1023#; 1534*; 
1607
– n.s. 1023*; 1534; 1899 731; 1023#; 1534*; 
1899*
512; 1023*; 1607 1607
Urine 6 1242#; 1534# 512*; 1023; 1534 731*; 1534 – 512*; 1023*; 1534 512# 512*; 1023*; 1242*; 1534#
512; 731*; 877; 1023*; 
1242; 1534*
731; 1534
Milk 7 b)
n.s. 731#; 877*; 1023; 
1242#; 1388; 1534#
731#; 877*; 1023; 
1242#; 1388*; 1534*
– 731 731; 877; 1242*; 1534 877; 1242; 1534* 1242 877
Milk 8
n.s. 731#; 877#; 1023#;
1242#; 1388#; 1534; 
1607*; 1753*
731#; 877#; 1023#; 
1242#; 1388#; 1534*; 
1607*; 1753#
731#; 877#; 1023#; 
1242#; 1388#; 1534; 
1607; 1753*
– 1023; 1242; 1388* 1388 n.s. n.s.
Urine 8 a) 1023 n.s. 877; 1534* – – 877; 1023 – 731; 1023 n.s.
Milk 9 a) 877* 877#;1023#; 1388* 877#;1023*;1388 877 – n.s. n.s. n.s. 877#
Urine 9 a) – 877 512; 731*; 877*; 1388 512; 731#; 877 – 731*; 877#; 1023; 1388
– 731; 1388* n.s.
Milk 10 n.s. 731; 877*; 1242 n.s. 731*; 877 – n.s. n.s. 731 n.s.
Urine 10 a) n.s. 731 n.s. n.s. n.s. n.s. n.s. n.s. n.s.
The m/z of oligosaccharides (OS) are given for [M+1+Na]+ ions, as analyzed by MALDI-TOF-MS, which are significantly enriched when compared with baseline with P < 0.05 or 
with P < 0.01 (*), or P < 0.001 (#); n.s., not significant; –, no data. For OS structures see Table 3-1. 
a) Due to a lack of baseline sample in woman 9 and infants 1, 8–10, multiple comparisons were performed on the basis of values calculated from the chemical formula of the 
glycan and natural H, C, N, O isotope abundances (see explanation in the Materials and methods and Results sections). 
b) No statistical analysis was performed for urine 7 due to unclear documentation of urine collection time.
- 36 -
3.3.2 Time course of the urinary excretion of OS in breastfed infants
As determined from fAM+1 in MALDI-TOF-MS, the excretion of labeled OS in infants’ urine was 
less pronounced than in milk and did not exhibit a uniform time pattern. Nevertheless, when com-
pared with baseline, an increase of the fAM+1 values could be seen in many OS structures, with a 
maximum at 8–12 h after 13C-Gal ingestion (Fig. 3-4). Accordingly, a significant increase of the 
isotopomer abundances was observed for the period between 4 and 16 h and at 20 h after 13C-
Gal ingestion (Table 3-2).
Fig. 3-4 Fractional abundances of the oligosaccharide isotopomers M+1 (fAM+1) in urine samples of nine 
infants during 36 h after their mothers’ oral 13C-Gal intake. Each curve represents the time course of the 
oligosaccharide with the m/z value given for [M+1+Na]+ ions, as analyzed by MALDI-TOF-MS. For struc-
tures see Table 3-1; m/z 1176 refers to the internal standard maltoheptaose. Discontinuations in the graphs 
1, 2, 6, 8–10 are caused by a lack of a urine sample when there was fecal contamination or insufficient 
volume. For the same reason, baseline values in graphs 1, 8–10 were not measured, but calculated from the 
chemical formula of the glycan and natural H, C, N, O isotope abundances (see explanation in the Materials 
and methods and Results sections). Open circle with dashed line: Values with 10–15%RSD within the trip-
licate measurements. Otherwise the RSD was below 10%.
3.3.3 Method validation parameters
Sample preparation did not show any effects on the fAM+1 of the OS isotopomers, as indicated by 
percent relative standard deviation (%RSD) values not exceeding the variations originating from 
the MALDI-TOF-MS instrument: The %RSD values from three different preparations of the same 
infant’s urine and mother’s milk, with fAM+1 values averaged from the analysis of three sample 
spots each, ranged from 0.85 (m/z 731) to 4.72 (m/z 1534) and 0.14 (m/z 1753) to 5.06 (m/z
1023), respectively. The spot-to-spot repeatability (intra-sample) of the fAM+1 values ranged from 
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1.11 (m/z 877) to 2.95 (m/z 1534) and from 0.66 (m/z 1388) to 5.27 (m/z 1607) %RSD, as meas-
ured from 10 different spots of one infant’s urine and mother’s milk OS preparation. The variation 
within the triplicate was monitored for each molecular species in each sample, as the signal inten-
sity of the larger OS, in particular, in the urine was highly subject-dependent. Most %RSD values 
were within the range measured for repeatability evaluation. However, a few OS species reached 
values of 10–15% (especially m/z 1242, 1534) in some samples. Those data have been marked 
in the diagrams (Fig. 3-4, Supporting Information Fig. S3-1) and excluded from the statistical
tests. The same applies to low-abundant OS species having poor isotopomer patterns. Another 
uncertainty was the M+1 isotopomer peak of sialyllactose, an acidic OS detectable in the positive 
ion mode, which overlapped with the M isotopomer of difucosyllactose at m/z 657 (see also
(Blank et al. 2011)). Therefore, we excluded difucosyllactose from further analyses. The resolu-
tion of the M+1 OS isotopomers ranged from 6,500 to >12,000.
Structural identity of the OS was confirmed by fragmentation analysis (see also (Blank et al.
2011)). Furthermore, MALDI-TOF-MS runs with or without preceding SPE steps with blanks of 
pure water or dextran hydrolysate, or single HMO in water confirmed the absence of the OS spe-
cies detected in the real samples, which are listed in Table 3-1. Hence, an experimental cross-
contamination of individual HMO samples could be excluded.
The internal standard detected at m/z 1176 did not exhibit significant variations in fAM+1 over time, 
as was also confirmed by statistical evaluation (Fig. 3-3 and Fig. 3-4; Table 3-2). As an additional
control for instrument-related effects on the measured fAM+1 values, we compared them with theo-
retical fAM+1 values calculated from the natural isotopic H, C, N and O abundances and the chem-
ical formula of the OS (see Fig. 3-3B and Fig. 3-4).
3.4 Discussion
Our noninvasive study design comprised sample collection over 36 h with 10 time intervals, re-
sulting in a finer time scale, but also in large numbers of samples with low sample volumes and 
low analyte concentrations in many cases. Thus, our approach, including automated SPE com-
bined with rapid and sensitive MALDI-TOF-MS analysis (see also (Blank et al. 2011)), facilitates 
comprehensive in vivo metabolic studies with stable isotopes in infants, beyond a clinical setting.
To our knowledge, no comparable studies have been done so far to simultaneously trace the fate 
of >10 distinct glycans over time via two organisms, beginning from their biosynthesis in the 
mother up to their excretion in vivo in her infant. Several publications are available on studies 
applying 13C tracers for elucidating the fate of single hexoses in infants and lactating women 
(Kalderon et al. 1989; Lapidot 1990; Sunehag et al. 2002), having their focus on monosaccha-
rides only.
3.4.1 Isotopomer abundances in mother–child pairs over time
Isotopomer enrichment in milk OS, as measured by MALDI-TOF-MS, was observed in all 10 
women a few hours after tracer ingestion, followed by a decline at 12–20 h (Fig. 3-3A). This pat-
tern was, except for fucosyllactose, homogeneous in all analyzed OS, which indicates a succes-
sive incorporation of the 13C tracer into distinct HMO in the mammary gland after the single-dose 
application. Our previous IRMS data from whole milk and total neutral or acidic OS fractions 
showed a similar time pattern (Rudloff et al. 2006). As has previously been suggested, the two-
and three-maximum patterns over time in total enrichment of milk fractions might be explained by 
the secondary utilization of the tracer from the carbohydrate storage in other compartments 
(Rudloff et al. 2006), such as glycogen, since the second maximum appears after night fast. Slight 
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variations in the time pattern of tracer enrichment have been observed in more complex milk OS
with m/z ≥ 1753, equivalent with difucosylated octaoses and larger structures (Fig. 3-3A and C). 
Since each molecular species in our data set represents a pool of various structural isomers, this 
is not surprising due to very likely differences in the kinetics of the biosynthesis of each isomer, 
which should be more pronounced in complex than in small OS species with less isomers.
The strong inter-individual and inter-structural variation in the tracer enrichment of the urinary OS
over time (Fig. 3-4), in particular, if compared with a rather uniform pattern in milk, is an intriguing 
new finding. Moreover, it is surprising due to the fact that the overall MALDI-TOF-MS profiles from 
urinary OS resembled those from mother’s milk (Fig. 3-2), which is in line with previous publica-
tions without stable isotope labeling (Chaturvedi et al. 2001; De Leoz et al. 2013). Various expla-
nations are possible for this striking deviation. First, despite the normalization to creatinine, the 
amount of labeled OS in the urine varied, as time points for diaper change were not explicitly reg-
ulated. Secondly, gastrointestinal transit time may vary to a high extent, especially in infants 
(Sievers et al. 1993). After 1 h of gastric transit (Vivatvakin et al. 2010) HMO are thought to reach 
the proximal small intestine intact (Gnoth et al. 2000). Then, various other individual factors, such 
as absorption, circulation and the excretion of the OS, may have contributed to the variations in 
time. This can, in part, explain the delayed increase of isotopomer enrichment in several OS spe-
cies in the urine of infants 2–5 and 10.
Regarding the metabolic fate of single OS species in each mother–child pair, we partly observed 
the appearance of the same 13C-enriched OS in infants’ urine as in mothers’ milk at a similar net 
time after tracer ingestion (Table 3-2). This indicates the excretion of intact HMO in infants’ urine 
after intestinal absorption, even for large and fucosylated OS, such as the mono-, di- and trifuco-
sylated hexaoses, with m/z 1242, 1388 and 1534, respectively. Strikingly, the 13C-enrichment of 
those OS in infants’ urine, but not in milk, seems to be higher than those of the tetraoses, m/z
731, 877, 1023, in urine 4, 5, 6, 8 and 9 (Fig. 3-4). One may speculate that the larger OS had
been excreted in their intact form, originating from mother’s milk, whereas tetraoses may, at least 
to a certain extent, reflect degradation products from larger HMO, which had lost the 13C tracer. 
Rudloff et al. reported that LNT was found to comprise the label in both Gal moieties (Rudloff et 
al. 2006). Unfortunately, further examination by means of fragmentation was not possible due to
poor resolution of the isotopomers in the fragmentation mode. Furthermore, comparability be-
tween the OS species might be limited by accuracy considerations as discussed below.
An unexpected observation was that the excretion of labeled OS in the urine of infants 1 and 9 
was still significant at 28–36 h, although the enrichment in milk had been nonsignificant already 
about 16–20 h before. This finding suggests that OS from milk may stay in infant’s organism for 
several hours after absorption before being excreted via urine. Keeping in mind the various poten-
tial functions of HMO, including both, intestinal as well as systemic effects (Bode 2012), the ques-
tion regarding retention time within the gut and child’s organism seems crucial for a better under-
standing of their biological role in vivo. In this context, it is noteworthy that we also determined the 
isotopomer abundances in six fecal samples available from infant 1 between 8 and 32 h after 13C-
Gal application to the mother (Supporting Information Fig. S3-1). The time pattern of the fAM+1
varied remarkably between OS species. Interestingly, differences over time in the intestinal ap-
pearance of the same OS species in HMO-fed rats were recently reported by (Jantscher-Krenn et 
al. 2013). In vitro experiments on the transport of HMO by intestinal Caco-2 cells indicated the 
possibility of re-secretion of some OS structures (Gnoth et al. 2001), probably causing variations 
in their intestinal transit time. As soon as stable isotope-labeled HMO structures are available in
future, studies applying singly labeled components to breastfed infants, preferably with collection 
of feces and urine for >36 h, should provide a more detailed insight into the metabolic fate of dis-
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tinct structures. Since larger/smaller HMO may be degraded/modified to structures, which them-
selves resemble HMO structures again, stable isotope labeling techniques are the method of 
choice for the elucidation of their structure-specific metabolic fate in the infant.
In addition to the fAM+1, we monitored the values for fAM+2. The overall time patterns were similar 
to those of M+1. However, because of lower precision and higher variation in the fAM+2 of the in-
ternal standard, we excluded the M+2 data from our calculations. The resulting uncertainty can be
neglected here due to the low levels of precursor enrichment (Hellerstein and Neese 1999).
3.4.2 Methodical considerations
Spot urine samples are known to vary in the concentration of the excreted substances, i.e., OS as 
well as peptides and other interfering hydrophilic substances (Gowans and Fraser 1987). Conse-
quently, we standardized the urine volume for sample preparation to the creatinine concentration 
to assure comparability between the urine samples during SPE and MALDI-TOF-MS analysis 
(see also (Peelen et al. 1994). Urinary creatinine excretion is known to be constant throughout the 
day and is therefore a common parameter for the excretion rate of various urinary analytes 
(Srivastava et al. 2007). In our samples, urinary creatinine concentration and, thus, presumably
the analyte concentration varied by a factor of about 10.
The preparative and analytical procedure was validated based on the MALDI-TOF-MS signal 
intensity and the fractional abundance precision and the resolution of the isotopomers. Support-
ively, we matched the measured baseline isotopomer abundances to their theoretical value and 
monitored the fAM+1 of the internal standard. In six women, we observed positive deviation of the 
baseline fAM+1 from theoretical values in milk OS at m/z 512 and 876 by 8–26 and 6–12%RSD, 
respectively. This may be due to the chemical addition of hydrogen in the ion source, which is 
reported to increase with analyte concentration (Hellerstein and Neese 1999). Congruously, these 
two molecular species count among the most abundant in the MALDI mass spectra from milk. 
Negative deviation from the expected theoretical values by 8% was observed in three women for 
the ions at m/z 1096, Hex4HexNAc2, an OS species which was low-abundant in most samples.
3.4.3 Conclusions
MALDI-TOF-MS has been proven as a suitable technique for the determination of OS isotopomer 
enrichment in human milk and infants’ urine after in vivo labeling using a 13C tracer. Following this 
approach, we were able to trace the metabolic fate of carbohydrates from the biosynthesis of 
individual OS species in the mammary gland to their excretion in the breastfed child over the 
course of time, and thus to discriminate between original HMO and other nonlabeled OS originat-
ing from possible endogenous sources or from HMO degradation. The direct comparison of OS
from milk and urine allowed us to detect remarkable differences in the time course and extent of
tracer enrichment between single OS species in infants’ urine. Former investigations from other 
groups did not suggest any modifications or notable utilization of HMO after absorption, as non-
labeled urinary OS were analyzed, which reflected the specific profile found in mother’s milk. 
Thus, we provide new indications for the role of HMO within infant’s organism, which has possibly 
been underestimated so far. Consequently, differentiated investigations in infants with single, 
stable isotope-labeled HMO are still much-needed for a better understanding of the biology of 
HMO.
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3.5 Materials and Methods
13C-Gal (D-Gal; 1-13C, purity >99%) was obtained from Eurisotop (Saint-Aubin Cedex, France). 
Maltoheptaose (analytical grade), water, acetonitrile (ACN; HPLC grade), NH4HCO3 and 6-aza-2-
thiothymine (ATT) were purchased from Sigma- Aldrich, Steinheim, Germany. Trifluoroacetic acid 
(TFA; ULCMS grade) was purchased from LGC Standards,Wesel, Germany 
Subjects and study design
Exclusively breastfeeding women (n = 10; 3–6 months postpartum) and their healthy, term infants 
participated in the study. The consumption of naturally 13C-rich food was restricted. The study was 
approved by the ethics’ committee of the University of Giessen. Written informed consent was 
obtained from all women. In the morning, mothers orally ingested a single dose Gal bolus consist-
ing of 23 g Gal + 2 or 4 g 13C-Gal, dissolved in 50 mL of drinking water (Rudloff et al. 2006; 
Rudloff et al. 2012).
Sample collection
Milk (5–10 mL) had been obtained by manual expression before the Gal bolus was given (base-
line value) and at the beginning of each nursing during the following 36 h (Fig. 3-1). Infants’ urine 
was collected in diapers consisting of cellulose, free of other adsorptive material (Procter & Gam-
ble, Frankfurt, Germany). In three infants, adhesive bags were used additionally for urine collec-
tion and were changed/emptied before each nursing and immediately frozen at −20°C, as well as 
the diapers. For urine extraction, diapers uncontaminated with feces were thawed and mechani-
cally pressed. In previous experiments, it was verified that the urine collection via diapers and 
urine bags did not affect HMO analysis (Rudloff et al. 2012). The time course of isotopomer en-
richment could not be analyzed in infant 7 due to an unclear documentation of urine collection 
time.
Isolation of OS from human milk and infants’ urine
HMO were prepared for extraction as described by (Blank et al. 2011). Fifty microliters of milk 
were centrifuged (14,000 × g) at room temperature for 20 min after the addition of 450 μL pure 
water. The aqueous phase was transferred into a 96-well plate. SPE with porous graphitic carbon 
(PGC) cartridges (HyperSep-96 Wells, 25 mg; Thermo Scientific, Bellefonte PA) was performed 
via a Hamilton Microlab Starlet liquid handling system (HamiltonRobotics, Reno, NV). Cartridges 
were equilibrated with 2 × 250 μL 40% ACN in water (v/v), followed by 2 × 250 μL 20% ACN in 
water (v/v), both containing 0.1% (v/ v) TFA. Prior to and after sample loading, the cartridges were
washed with 5 × 500 μL 0.1% aqueous TFA and fully dried by vacuum. OS were eluted with 400 
μL aqueous 40/0.1% ACN/TFA solution and dried overnight in a vacuum centrifuge (Blank et al.
2011).
SPE of OS from urine was performed manually using a Chromabond Vacuum manifold (Ma-
cherey-Nagel, Düren, Germany) with PGC cartridges (HyperSep Hypercarb 50 mg; Thermo Sci-
entific, Bellefonte PA). After centrifugation (14,000 × g, 20 min, 4°C), 2–4 mL of diluted urine were 
loaded onto PGC cartridges, which were equilibrated as described for milk in the previous para-
graph, but with 2 × 1 mL each. Following the washing with 5 × 1 mL 0.1% aqueous TFA, OS were 
eluted in two fractions using 2 × 250 μL aqueous 40/0.1% ACN/TFA solution. For normalization of 
the amount of urinary constituents applied in the extraction procedure, creatinine concentration 
was determined using a colorimetric kit from R&D Systems (Parameter™, Minneapolis, MN).
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OS analysis by MALDI-TOF-MS
OS were re-suspended in HPLC grade water and mixed with maltoheptaose as an isotopically 
nonenriched internal standard. The matrix, 35 mM ATT in 25 mM aqueous NH4HCO3, was pipet-
ted in triplicate onto a MALDI AnchorChip™ 600 target plate (Bruker, Bremen, Germany) and 
mixed 1:1 with the OS sample. The matrix-sample spots were dried under cold air. Mass spectra
were acquired using an Ultraflex I instrument (Bruker, Bremen, Germany), equipped with a nitro-
gen laser emitting at 337 nm. In the positive ion reflector mode, the voltage was set to 25 kV for 
acceleration, 26.3 kV for the reflector and 1.715 kV for the detector. Matrix ion deflection was off 
due to its impact on the detection of ions with m/z < 700. OS profiles were acquired in the mass 
range of m/z 360–3000. For calibration, dextran hydrolysate was used. Structural identification
was performed by MALDI-TOF/TOF-MS in the laser-induced dissociation mode, as described by 
(Blank et al. 2011). Data acquisition and analysis were done by the flexControl and flexAnalysis 
3.0 software (Bruker, Bremen, Germany), respectively. The isotopomer peaks were detected by 
the Centroid algorithm. Fractional abundances for each OS isotopomer M+1 were calculated as:
fAM+1 (%) =
ூಾశభ× ଵ଴଴
ூಾା ூಾశభ
where IM is the intensity (height) of the mass isotopomer containing 1H, 12C, 14N, 16O and IM+1 is 
the intensity of its first isotopic peak (Fig. 3-1).
The theoretical fAM+1 were calculated by the Isotope Pattern Utility (flexAnalysis 3.0, Bruker, Bre-
men, Germany) based on the chemical formula of the OS and a natural abundance of the 13C-
isotope of 1.082%.
Statistical analysis
The fAM+1 of triplicate MALDI-MS measurements were processed in SPSS Statistics 20.0 (IBM, 
Ehningen, Germany) by one-way analysis of variance followed by Dunnett’s one-tailed t-test, 
comparing the means of triplicates for each time point with the baseline sample. In case of une-
qual group variances– i.e. a significant Levene’s test–Kruskal–Wallis H-test, followed by Dunnett’s 
T3 post hoc test were run instead. The threshold for significance was set at P < 0.05.
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3.6 Supporting Information
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the following.
Fig. S3-1 Fractional abundances of the oligo-
saccharide isotopomers M+1 (fAM+1) in fecal 
samples of infant 1 during 36 h after the 
mother’s oral 13C-Gal intake. Each curve 
represents the time course of the oligosaccha-
ride with the m/z value given for [M+1+Na]+
ions, as analyzed by MALDI-TOF-MS. For 
structures see Table 3–1; m/z 1176 refers to 
the internal standard maltoheptaose. Baseline 
values were not measured, but calculated 
from the chemical formula of the glycan and 
natural H, C, N, O isotope abundances. Open 
circle with dashed line: value with 10–
15%RSD within the triplicate measurements.
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4 Metabolic fate of neutral human milk oligosaccharides in 
exclusively breastfed infants (Manuscript 3)
4.1 Abstract
Scope: Various biological effects have been postulated for human milk oligosaccharides (HMO),
as deduced from in vitro, animal, and epidemiological studies. Little is known about their metabol-
ic fate in vivo in the breast-fed infant, which is presented here.
Methods and results: Human milk and infant urine and feces were collected from ten mother-
child pairs and analyzed by MALDI-TOF-MS (/MS), accompanied by high-performance anion
exchange chromatography with pulsed amperometric detection. Previously, we detected intact
small and complex HMO in infant urine, which had been absorbed from gut, as verified via intrin-
sic 13C-labeling. Our current work reveals the presence of novel HMO metabolites in urine and 
feces of breast-fed infants. The novel metabolites were identified as acetylated HMO and other 
HMO-like structures, produced by the infants or by their gut microbiota. The finding of secretor- or 
Lewis-specific HMO in the feces/urine of infants fed with nonsecretor or Lewis-negative milk sug-
gested a correspondent modification in the infant. Conclusion: Our study reveals new insights 
into the metabolism of neutral HMO in exclusively breast-fed infants and provides further indica-
tions for multiple factors influencing HMO metabolism and functions that should be considered in 
future in vivo investigations.
4.2 Introduction
OS are the third most abundant component in human milk with concentrations ranging from 7 to
20 g/L (Thurl et al. 2010). The quantity and structural variety are unique among mammalian spe-
cies: Over 150 distinct structures with various structural isomers, which are lacking in bovine milk-
based infant formula, have been described so far. Since HMO are enzymatic products of different
glycosyltransferases in the mammary gland and, therefore, evolve high structural variety, it is not 
surprising that their absorption and metabolism may largely be dependent on individual struc-
tures, including specific structural motifs such as Fuc and sialic acid (Gnoth et al. 2001). HMO are 
marginally digested by human intestinal enzymes (Gnoth et al. 2000), whereas infant gut microbi-
ota can utilize various HMO structures as carbohydrate source (Garrido et al. 2012; Kitaoka 2012; 
Marcobal et al. 2011).
Biosynthesis starts with lactose as the backbone of HMO, which can be elongated with GlcNAc
and Gal residues to form GlcNAc-1-3Gal or GlcNAc-1-4Gal units, resulting in the main core struc-
tures LNT and neo-LNT, respectively. These structures can be further elongated and branched, or
also modified by the attachment of α1-2-/α1-3- or α1-4-linked Fuc and/or N-acetylneuraminic acid, 
the latter forming acidic HMO (Blank et al. 2012a). α-Fuc-(1→4)[Gal-β-(1→3)]-GlcNAc residues 
are referred to as Lea epitope, α-Fuc-(1→2)-β-Gal as Se or blood group H epitope. Four different 
milk groups have been described in women referring to the presence or absence of these two 
epitopes on HMO resulting from the expression of the respective glycosyltransferases in the 
mammary gland (Blank et al. 2012a; Thurl et al. 2010).
Many beneficial effects of breast-feeding might be associated with the presence of specific HMO, 
such as the lower prevalence of infections of the respiratory, intestinal, and urogenital tract, or of 
autoimmune diseases due to their postulated prebiotic, anti-infective, and immunomodulatory 
effects (Bode 2012; Kunz et al. 2014; Schack-Nielsen and Michaelsen 2007). However, because 
of ethical and analytical limitations, most studies have been performed in vitro or in animals, giv-
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ing only limited insight into the functions and metabolic pathways of HMO in the breast-fed child. 
Human metabolic studies are usually restricted to the comparison of the OS profile in mother’s 
milk with those in infant urine and feces to keep study design noninvasive in these particularly 
vulnerable subpopulations, since interventional studies in formula-fed infants are not feasible as 
long as synthetic HMO are hardly affordable or available for use in humans (Rudloff and Kunz 
2012).
Thus, our knowledge of the in vivo metabolism of HMO is limited, since studies on the excretion of 
single OS structures in infants either included only one or two study subject(s) (De Leoz et al.
2013; Rudloff et al. 2012; Sabharwal et al. 1988a; Sabharwal et al. 1984; Sabharwal et al. 1988b)
or detected only few OS structures (Goehring et al. 2014; Rudloff et al. 1996; Sabharwal et al.
1991). Among those, only the publications by Sabharwal et al. described possible modification 
products, i.e. from blood group A transferase, in infants’ feces, whereas other groups reported 
that the patterns of urinary and fecal OS in breast-fed infants resembled those of their mothers’ 
milk (Chaturvedi et al. 2001; Coppa et al. 2001). More recently, OS in milk and infants’ feces from 
ten mother–child pairs were investigated by CE with laser-induced fluorescence and ESI-MS, 
providing information on the possible modifications taking place in the infants’ gut (Albrecht et al.
2011a). However, data on urinary metabolites providing information on the processes within the 
infant’s organism after the absorption of HMO are lacking.
In previous studies with and without intrinsic stable isotope labeling of HMO, we found a renal 
excretion of 1–3% of HMO structures in the urine of exclusively breast-fed preterm and full-term 
infants analyzed by HPAEC-PAD (Rudloff et al. 1996) and IRMS or fast atom bombardment-MS 
(Rudloff et al. 2012). A large variety of neutral and acidic OS, and even trifucosylated hexaoses 
as found in milk were detected. Recently, we reported on the time course of distinct HMO in ex-
clusively breast-fed infants as traced via 13C-labeling and measured by MALDI-TOF-MS (Dotz et 
al. 2014). Thereby we revealed time and structure-dependent variations, suggesting significant
metabolization and/or the coexcretion of structurally related non-HMO. In the present study, we 
compare the presence of individual OS structures from mothers’ milk with those in the urine and 
feces of their exclusively breast-fed infants by using a sensitive and rapid MALDI-TOF-MS(/MS) 
approach, supported by isomer-specific HPAEC-PAD analysis. We also describe possible HMO 
metabolites, which are reported for the first time for infant urine and infant feces.
4.3 Materials and Methods
Subjects
Ten exclusively breast-feeding women participated in the study with their healthy term infants, 
aged 2–6 months, and gave their written informed consent. All procedures involving human sub-
jects were approved by the ethics committee of the University of Giessen (permission number 
77/00) (Rudloff et al. 2012).
Sample collection
Milk (5–10 mL) was obtained by manual expression at the beginning of each nursing during 36 h. 
Infant urine and feces were collected during the same 36 h in absorber-free diapers (Procter & 
Gamble, Frankfurt, Germany). In three infants, adhesive bags were used additionally for urine 
collection and were changed before each nursing and immediately frozen at –20°C, as well as the 
diapers. Urine diapers were visually examined for any fecal contamination. For urine extraction,
diapers were thawed and mechanically pressed (Rudloff et al. 2012). Mothers were advised to 
immediately change the diapers after defecation to avoid urinary contamination.
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Sample preparation and analysis
Chemicals were purchased from the following providers: maltoheptaose (analytical grade), water, 
ACN (HPLC grade), ammonium bicarbonate, ATT, and 2,5- dihydroxybenzoic acid from Sigma-
Aldrich (Steinheim, Germany); TFA (ULC-MS grade) from LGC Standards (Wesel, Germany), 
sodium hydroxide from Baker (Deventer, The Netherlands); anhydrous sodium acetate from Di-
onex (Idstein, Germany), and water (Rotisolv ULC-MS) from Carl Roth (Karlsruhe, Germany). OS 
standards for HPAEC-PAD identification were either from Elicityl (Crolles, France), Dextra (Read-
ing, UK), Glycom A/S (Copenhagen, Denmark), or Carbosynth Ltd (Berkshire, UK).
OS extraction
HMO were extracted as previously described (Blank et al. 2011). Briefly, milk was centrifuged 
after the addition of pure water. SPE with porous graphitic carbon cartridges (HyperSep-96Wells, 
25 mg; Thermo Scientific, Bellefonte, PA, USA) was performed via a Hamilton Microlab Starlet 
liquid handling system (Hamilton Robotics, Reno, NV, USA). Cartridges were equilibrated with 
40% ACN in water v/v, followed by 20% ACN, both containing 0.1% TFA. Prior to and after sam-
ple loading, cartridges were washed with 0.1% aqueous TFA and fully dried by vacuum. OS were 
eluted with 40% ACN containing 0.1% TFA (Blank et al. 2011).
Extraction of OS from urine was performed manually using a Chromabond Vacuum manifold (Ma-
cherey-Nagel, Düren, Germany) with porous graphitic carbon cartridges (HyperSep Hypercarb 50 
mg) (Dotz et al. 2014). Briefly, after centrifugation, urine was loaded onto cartridges, which were 
equilibrated as described above. Following to washing with 0.1% aqueous TFA, OS were eluted 
in two fractions using aqueous 40/0.1% ACN/TFA solution. For normalization of the amount of 
urinary constituents applied in the extraction procedure, creatinine concentration was determined 
using a colorimetric kit from R&D Systems (ParameterTM, Minneapolis, MN, USA).
Fecal samples from diapers were thawed and dissolved in water (15 mg/mL) in duplicates, pas-
teurized (20 min, 65°C), and gently stirred for 1.5 h at 20°C prior to two-step centrifugation 
(10 000 × g, 15 min, 4°C) and filtration through a 0.45 µm nylon membrane (Rotilabo, Carl Roth). 
Extraction was performed automated as described in (Blank et al. 2011) for HMO extraction.
OS analysis
After elution, OS were dried overnight in a vacuum centrifuge, and resuspended in pure water. An 
HPAEC-PAD system, ICS-5000, equipped with a Carbo Pac PA-1 column (250 × 4 mm; 30°C) 
and a guard column, was operated by Chromeleon 6.80 software (all: Dionex). The gradient pa-
rameters at a constant flow rate of 0.5 mL/min were as follows: 100% eluent A, 0.1 M sodium 
hydroxide in water (0–15 min); 100% eluent B, 0.1 M sodium hydroxide and 0.25 M sodium ace-
tate in water (83–87 min); 100% eluent A (87–107 min). External OS standards were used for 
identification.
Mass spectra were acquired using an Ultraflex I instrument (Bruker Daltonics, Bremen, Germany), 
equipped with a nitrogen laser emitting at 337 nm; a dextran hydrolysate was used to calibrate the 
equipment and the analytical method (Blank et al. 2011). Maltoheptaose was added as internal 
standard to OS extracts to assure comparable concentration in all samples. In triplicate, the OS 
from 36 h milk and infants’ urine and fecal samples each were mixed 1:1 with ATT matrix (35 mM 
in 25 mM aqueous ammonium bicarbonate) on a MALDI AnchorChipTM 600 target plate (Bruker 
Daltonics). The matrix-sample spots were dried under cold air. OS profiles were acquired in posi-
tive-ion reflectron mode over a mass range of m/z 360–3000 (Dotz et al. 2014). In addition, 0.25–
1 µL of the OS extracts from milk, urine, and feces each were applied in triplicate onto the target 
plate, dried under cold air, and resuspended with 0.5–1 µL aqueous 32 mM 2,5-dihydroxybenzoic 
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acid/0.1% TFA matrix solution, which was again dried under cold air. This “reverse thin layer 
method,” modified from (Nishikaze and Amano 2009), results in higher sensitivity and improved 
S/N ratio in the low molecular mass range when applied to either standards or sample extracts. 
Acquisition was performed in the mass range of m/z 340–3200, with matrix ion deflection for ions 
with m/z < 300. The OS nature of the detected ions was confirmed by MALDI-TOF/TOF-MS in the 
laser-induced dissociation mode, as described in (Blank et al. 2011). Data acquisition and analy-
sis were performed by flexControl and flexAnalysis 3.0 software (Bruker Daltonics), respectively.
4.4 Results
During the 36-h study, milk and infant urine samples were available from all ten mother–child 
pairs, whereas fecal samples were only obtainable from six children. Consequently, 98 milk, 73 
urine, and 17 fecal samples were analyzed via MALDI-TOF-MS, whereas one to two distinct 
samples of each type from each mother–child pair were analyzed by HPAEC-PAD to obtain Se-
and Le-specific HMO profiles after isomer separation.
4.4.1 Overall OS profiles in infant urine and feces compared to milk
Over 70 OS compositions have been detected by MALDI-TOF-MS in the 36-h sample set as 
listed in Supporting Information Table S4–1. More than 20 OS species thereof have not been 
described for breast-fed infants so far. Table 4-1 contains mainly those molecular species detect-
ed in urine or feces that are different from those in milk, indicating possible HMO metabolites or 
OS of non-HMO origin.
In Fig. 4-1, MALDI-TOF mass spectra from milk, urine, and fecal OS from two mother–child pairs 
are shown, with colored structures representing HMO, and unfilled figures for newly found OS 
species. The urine of infant a2 (left panel) contained a variety of OS species that have not been 
described previously, while complex HMO were hardly detectable, so that LN(n)T and its monofu-
cosylated form dominated the urinary OS profile. In contrast, urinary OS in infant b2 still showed a 
structural diversity similar to milk, though the relative intensities of fucosylated OS at m/z 511, 
657, 1022, and 1387 were lower than those of nonfucosylated OS at m/z 730, 1095, 1460 (Fig. 
4-1, right panel). Analogously, urinary mono- and difucosylated Hex2 as well as complex HMO 
were reduced in infant b5 (Supporting Information Fig. S4-1E). The urinary OS of infants a1 and c 
showed patterns similar to their mothers’ milk with a comparable diversity of structures, but with 
some additional non-HMO structures. In infants b1, b3-4, b6-7, Hex2Fuc1 increased and was the 
predominant peak, whereas larger HMO with m/z > 1200 decreased as compared to milk (Sup-
porting Information Fig. S4-1A–H). 
Various OS species have been detected in feces only, in particular, in samples from infants a2 
and b1, e.g. ions at m/z 1282.5, 1298.4, 1339.5, or 1542.6. At the same time, complex HMO were 
hardly detectable in the feces of these two infants (Table 4-1; Fig. 4-1; Supporting Information Fig. 
S4-1B). The fecal OS profile of infant b2 showed a strong shift toward low- or nonfucosylated 
HMO (Fig. 4-1), with LN(n)T now being most prominent. In infant b3, LN(n)T was also relatively 
increased in feces compared to milk, whereas the opposite was the case in infant c, in whom, in 
addition, a relative increase of larger, more complex fecal HMO was observed (Supporting Infor-
mation Fig. S4-1C and H). A strong increase in the larger HMO and non-HMO structures at m/z
1079 and 1444 was observed in infant a1 (Supporting Information Fig. S4-1A). The presence of 
LNT has been confirmed in all urine and fecal samples analyzed by HPAEC-PAD, while its isomer 
LN(n)T was not detectable in the urine of infants b1 and b5 (Table 4-2).
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Fig. 4-1 MALDI-TOF-MS profiles of oligosaccharides in mother's milk, infant urine and feces from moth-
er-child pair a2 (left panel) and b2 (right panel), as detected with 2,5-dihydroxybenzoic acid/TFA matrix. 
Ac, acetyl-; H, hexose; N, N-acetylhexosamine; F, fucose; pink diamond, N-acetylneuraminic acid; un-
known oligosaccharides: open circle, hexose; open square, N-acetylhexosamine. Asterisks indicate non-
oligosaccharide origin.
The urinary and fecal OS profiles as measured via HPAEC-PAD showed many variations as 
compared to the corresponding milk samples. Besides shifts in the relative intensities of the single 
HMO peaks, additional peaks, e.g. at t = 27.5 min, were detected in many samples (Fig. 4-2B). 
However, those could not be further characterized.
4.4.2 Possible modification and degradation products
Mainly in infants’ urine, and in very low concentrations also in some milk and fecal samples, we 
detected acetylated (Ac) OS (Table 4-1). Those were Ac1Hex2Fuc1, Ac1Hex3HexNAc1, 
Ac1Hex3HexNAc1Fuc1/2, and Ac1Hex4HexNAc2Fuc2 at m/z 553, 772, 918, 1064, and 1429, respec-
tively. Accordingly, MALDI-TOF/TOF-MS analyses confirmed the presence of characteristic frag-
ment ions (Fig. 4-3; Supporting Information Table S4-2). Acetylated HMO fragments (m/z 772 and 
918) as well as isomer-specific glycosidic bond cleavage or cross-ring fragmentation products 
could be assigned for Ac-Lacto-N-difucohexaose (LNdFH) II and I, respectively. The loss of the 
Ac residue, reflected in the cross-ring fragments of Ac-LNdFH I at m/z 816 and 962, suggests its 
attachment to glucose. We can exclude instrument-related adduction of Ac residues, as no ions at 
m/z corresponding to acetylated maltoheptaose, added as internal standard prior to the MALDI-
TOF analysis, were detected. Neither do we expect modifications during sample preparation, as 
we still detected the respective acetylated structures in infant urine after an alternative extraction 
procedure via gel filtration, avoiding solvents containing acetyl residues. Moreover, we could not 
detect molecular species corresponding to acetylated OS in urinary samples of an infant from 
another cohort, exclusively fed with commercial galacto-OS-enriched formula (unpublished data). 
Consequently, as far as we know, this is the first report on acetylated neutral OS in humans.
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Table 4-1 OS from mothers’ milk and infants’ urine and feces (excerpt)
m/z
[M+Na]+
Composition Occurrence in MALDI-TOF-MSb) Referencec)
Ac H N F MS/MSa) milk urine feces urine feces
553.2 1 2 0 1 yes none (a2),b1-2,(b3,b5),b6-7,c (c)
569.2 1 3 0 0 yes (a2,b2) all (b4) (a2),b3
771.3 0 2 2 0 yes none a1-2,b1-5,(b6),b7,c a1,(a2),b1-2
772.2 1 3 1 0 yes (a1-2,b1-6,c) a2,b1-3,b5,(b6),c a2
819.3 0 3 0 2 - none b4 none d)
860.3 0 2 1 2 yes (a1,b1,b3-7,c) (a1),a2,b1-3,b5-7 a1,(a2),(b3),(c) e)
917.3 0 2 2 1 yes none (a1-2,b3-4,b6-7) a1,c
918.3 1 3 1 1 yes (a1,b1-7) (a1),a2,(b1),b2-6,(b7),c none
933.3 0 3 2 0 yes (b3-5,b7,c) (all) a1-2,b2,c
1064.4 1 3 1 2 yes a1, b1-4 a1-2, b1-7 none
1079.4 0 3 2 1 yes (all) (all) a1,(a2),b1,(b2),c e)
1136.4 0 3 3 0 - none (a1-2,b2,b6) (a1),a2,b1
1184.4 0 4 1 2 yes (b1-2),b3,(b4-7),c b1,b4,c b1,c d)
1225.4 0 3 2 2 yes (a1-2),(b1-6),b7,(c) (all) a1-2,b1,c e)
1282.5 0 3 3 1 - none none (a1),a2,(b1)
1298.4 0 4 3 0 - none none (a1),b1
1339.5 0 3 4 0 - none none (a1),a2,b1,(b3)
1371.5 0 3 2 3 yes (a1,b1-b7,c) (a2),b3,(b5),b6 none
1403.5 0 5 2 1 yes (all) (a1,b2,c) a1,c
1429.5 1 4 2 2 yes (a1,b2,b6-7) a1-2,(b1-5),b6,(b7),c none
1444.5 0 4 3 1 - none (a1,c) a1-2,(b1)
1542.6 0 3 5 0 - none none (a1),a2,b1
1631.6 0 3 4 2 - none none a2,(b1)
1745.6 0 3 6 0 - none none b1
1793.6 0 4 4 2 - none none a2
a) Yes, composition confirmed via MS/MS (see Supporting Information Table 2); -, no reliable MS/MS spectra available 
due to, e.g., low abundance.
b) Letters a, b, and c were assigned according to the Le- and Se-specific HPAEC-PAD profiles from milk, e.g. Fig. 2.
c) Reference number is given if one or more compounds with the respective m/z value were previously described. 
d) (Albrecht et al. 2011a); e) (Sabharwal et al. 1984)
Brackets indicate low intensity, i.e. S/N ratio <20. Ac, Acetyl; H, Hex; N, HexNAc; F, Fuc.
It is noteworthy that we also analyzed urine samples from women a2 and b1 (Supporting Infor-
mation Fig. S4-2). Interestingly, the MALDI-TOF-MS profiles of the OS in these women’s urine 
were more similar to those of their infants’ urine than to milk, containing higher proportions of 
Ac1Hex3HexNAc1 and other non-HMO.
The majority of the OS structures newly detected in infant urine or feces showed a higher propor-
tion of HexNAc units than in original HMO, many of which were nonfucosylated. Only few struc-
tures, e.g. at m/z 1184 or 1403, had a lower proportion of HexNAc (Table 4-1 and Supporting 
Information Table S4-1). Via MALDI-TOF/TOF-MS/MS, we confirmed the OS composition of 
these structures (Supporting Information Table S4-2), and evaluated the site of fucosylation in 
Hex2HexNAc1Fuc1 at m/z 714, which revealed Se-specific Hex1Fuc1-fragments in the milk of 
women b2,5,6, and c, and in the feces of infant b2. In contrast, in almost all urine samples, only 
HexNAc1Fuc1 fragments were detected (Supporting Information Fig. S4-3).
4.4.3 Le- and Se-specific OS in milk, infants’ urine and feces
Table 4-2 gives an overview of the major neutral isomeric OS structures detected in milk and in-
fant urine and feces from ten mother–child pairs via HPAEC-PAD. The presence of Le as well as 
Se-specific structures, such as LNFP II, 2’-fucosyllactose (2’FL), or LNdFH I, in milk of women b1-
7, is characteristic for the Leb phenotype (Fig. 4-2A). Accordingly, the absence of Le-specific OS 
in milk along with the presence of α1-2-fucosylated structures is typical for Le−/Se+, as detected 
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in woman c (Fig. 4-2A). Women a1 and a2 were classified as Lea, since their milk contained α1-4-
fucosylated OS, but was lacking Se-specific structures (Fig. 4-2A).
The Se-specific OS 2’FL, di-FL, LNFP I, and LNdFH I were detected not only in the urine and 
feces from infants fed Se+ milk (subjects b1-7, c), but also in samples from infants a1 and/or a2, 
though fed non-Se milk (Fig. 4-2B, Table 4-2). The abundance of di-FL in the urine samples 
available from infant a1 was sufficient to confirm its identity in MALDI-TOF/TOF-MS/MS by the 
detection of its mono- and defucosylated fragments at m/z 511 and 365, respectively (not shown). 
Le-specific LNFP II was detected in the feces of infant c, fed Le−/Se+ milk, which is lacking Le 
epitopes.
Table 4-2 Major neutral OS in mothers’ milk and infants’ urine and feces, detected by HPAEC-PAD
Peak 
no.
Oligo-
saccharide
Structure a) RT b)
[min]
Epi-
tope
Detected in c) m/z e)
[M+Na]+milk urine feces d)
1 LNdFH I .
.
.
.
.
.
.
.
.
13.9 Le, Se b1-7 a1,b1-3,b5-7 a1,b1,b3 1022.4
2 3-FL 14.2 a1, c b2,b4,b6-7,c b1-2 511.2
3 LNFP II 16.6 Le a1-2,b1-7 a1-2,b1-4,b6 a1-2,b1,c 876.3
4 Di-FL 18.5 Se 1,b1-7 a1,b1-7 a2,b1,b3,c 657.2
5 Lac 20.7 all all a1-2,b1-3,c 365.1
6 2’FL 24.5 Se b1-7, c a1-2,b1-7,c a2,b1-3,c 511.2
7 LNFP I 31.1 Se b1-7, c a1,c a1,b3,c 876.3
8 LNnT 34.6 all a1-2,b2-4,b6-7,c a1-2,b1-3,c 730.2
9 LNT 40.5 all all a1-2,b1-3,c 730.2
a) Blue circle, glucose; yellow circle, galactose; blue square, N-acetylglucosamine, red triangle, fucose; for 
linkage designation, see Fig. 4-3. 
b) Retention time in HPAEC-PAD. 
c) Letters a, b, and c were assigned according to the Lewis (Le) and secretor (Se)-specific HPAEC-PAD 
profiles from milk, e.g. Fig. 4-2. Se, α-fucosyl-(1→2)-β-galactosyl-; Le, α-fucosyl-(1→4)[galactosyl-β-(1→3)]-
N-acetylglucosaminyl-. 
d) Fecal samples were only available from infants a1-2, b1-3, and c. Infants’ samples with Le/Se-specific 
structures, not matching the Le/Se-specificity of their mother’s milk, are labeled gray; 
e) as detected in MALDI-TOF-MS, see Supporting Information Table S4-1.
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Fig. 4-2 HPAEC-PAD profiles of major OS in 
(A) milk from women b2 (Le+/Se+), c 
(Le−/Se+), and a1 (Le+/Se−); (B) urine and 
feces from infant a1 and feces from infant c. For 
OS structures see Table 4-2. An excerpt of 12–
44 min out of the total run of 107 min is shown.
Se-specific LNFP I could not be detected in any of the analyzed urine samples of the infants fed 
Leb milk. The same applied for LNFP I and its Le-specific isomer LNFP II in two of three infants’ 
feces, which were obtainable from Leb-fed infants (Table 4-2).
4.5 Discussion
Our simplified and rapid method for OS extraction from only 50 µL of milk and 2–4 mL of infant 
urine and 15 mg of fecal samples (see also (Blank et al. 2011; Dotz et al. 2014)), as compared to 
10- to 60-fold higher sample requirement in (Albrecht et al. 2011a; De Leoz et al. 2013; Rudloff et 
al. 1996), enabled us to acquire OS profiles from repeated sample collection over 36 h. Thus, 
intra-individual variation over time could be compensated to some extent. Moreover, our MALDI-
TOF-MS technique provides higher resolution than chromatography methods, which have been 
used conventionally for HMO analysis (Chaturvedi et al. 2001; Coppa et al. 2001; Rudloff et al.
2012; Rudloff et al. 1996; Thurl et al. 2010).
Urinary OS in breast-fed infants seem not simply to reflect the pattern found in their mothers’ milk: 
The overall MALDI-TOF-MS profiles showed variation in terms of diversity of HMO-related peaks 
or the relative intensities of fucosylated versus nonfucosylated structures in most infants as com-
pared to their mothers’ milk. This finding was also confirmed by our HPAEC-PAD data, showing 
some shifts between the relative abundances of the single isomeric HMO structures. In the only 
publication reporting on the urinary versus milk OS profiles, the authors argued the converse 
(Chaturvedi et al. 2001). However, the authors did not show any data on the individual structures 
detected in urine. In contrast, in a recent publication, some major HMO structures consistently 
showed better correlations between the levels in mother’s milk and infant plasma than infant urine 
(Goehring et al. 2014), supporting our finding of altered OS profiles in breast-fed infants’ urine, 
and furthermore suggesting an enrichment or depletion of certain structures “after” intestinal ab-
sorption. In this regard, the absence of Se-specific LNFP I in the urine of all seven infants fed Leb
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milk was most intriguing, considering its predominance in milk of Leb individuals (Fig. 4-2A, 
peak 7) with concentrations around 1–2 g/L, making it the second largest component after 2’FL 
(Thurl et al. 2010). Since we were able to detect LNFP I in the urine of infant c as well as LNFP II 
in most of the Leb-fed infants, selective intestinal or systemic utilization of LNFP I seems more 
likely than a reduced absorption of this specific structure only in Leb-fed infants.
Fig. 4-3 MALDI-TOF/TOF-MS/MS of oligosaccharides at m/z 1064 in urine from infant b2. Ac, acetyl; F, 
fucose; H, hexose; N, N-acetylhexosamine. Solid and dashed red lines indicate isomer-specific fragmenta-
tion in Ac-lacto-N-difucohexaose I and II, respectively; black arrows apply to both isomers.
Our investigation of modification products of HMO revealed a novel type of OS in humans, i.e. 
acetylated neutral HMO in breast-fed infants’ and breast-feeding women’s urine. So far, only few 
studies revealed the significance of O-acetylation in OS, limited to acetylated sialic acids, e.g. as 
found in milk of echidna (Kamerling et al. 1982; Oftedal et al. 2014). O-acetylated sialic acids play 
an important role in human immunology, bacterial and viral infections, and are linked to type I 
diabetes, rheumatoid arthritis, and autoimmune disorders (Muthana et al. 2012), processes that 
HMO and/or breast-feeding are also associated with (Bode 2012; Kunz et al. 2014; Schack-
Nielsen and Michaelsen 2007). A detailed structural characterization and the examination of the 
biological role of acetylated HMO in future studies is required to enhance our knowledge of the 
beneficial effects of breast-feeding on mother and child.
As further indication for HMO modification, we detected urinary LNFP I, di-FL, and LNdFH I in 
infant a1, though fed non-Se milk. Among those, only LNdFH I, which is Leb-specific, has been 
reported before in the urine of an infant fed non-Se milk (De Leoz et al. 2013). Nevertheless, di-
FL has previously been detected in the urine of starved Se-individuals (Lundblad 1978), which 
can be explained by the activity of α-2-FucT, found in various tissues besides the gastrointestinal 
tract (Watkins 1995). Recently, a novel sialylated lactosamine structure was detected in formula-
and breast-fed infants’ plasma, along with unexpectedly high concentrations of its other isomers 
(Ruhaak et al. 2014). Future studies should reveal the origin and biological role of these unex-
pected compounds in the infant.
With regard to fecal OS, we could roughly identify three groups of infants, as far as possible from 
only six individuals, i.e. (i) infants a1 and c with MALDI-TOF-MS profiles showing similar or even 
higher complexity than their mothers’ milk, (ii) infants b2 and b3 with decreased relative intensities 
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of fucosylated HMO, and (iii) infants a2 and b1 with reduced HMO diversity or relative intensities 
of HMO, respectively, but increased number and intensity of non-HMO. For the first, the overall 
profiles were comparable with urine. Nevertheless, unexpected HMO structures were detected in 
the feces of infants a1, a2, and c (Fig. 4-2, Table 4-2). This suggests α-2-FucT activity (Sabharwal
et al. 1988a), as described above also for urine, and α-4-FucT in the gut of infant c. Potential en-
dogenous or xenobiotic sources of HMO-analogs are also conceivable, since human glycolipids 
and microbial lipo-OS share some identical or similar substructural features with HMO (Houliston
et al. 2011). However, the detection of these substructures would require the activity of specific 
endoglycosidases, which have not been described in humans so far. The fact that we were able 
to detect LNT and LNnT in many infants’ urine and all fecal samples (Table 4-2) is contradictory to 
the findings of Albrecht (Albrecht et al. 2011a). This may be explained by an ongoing degradation 
of HMO in the fecal slurries, kept overnight at 4°C by Albrecht et al. In contrast, we pasteurized 
the fecal samples directly after thawing to inactivate any bacterial activity prior to OS extraction.
The urinary Hex2HexNAc1Fuc1 at m/z 714, bearing a HexNAc-Fuc epitope (Fig. 4-2, Supporting 
Information Fig. S4-3), may be a degalactosylated or deglucosylated cleavage product from LNFP 
II or III. Its presence in the urine of both, infants as well as lactating women, indicates intense 
degradation or modification of the precursors in circulation or body cells. In our recent report on 
the excretion of intrinsically labeled HMO in the same sample set as presented here, rather poor 
tracer enrichment of smaller urinary OS at m/z < 1200 was determined in infants a2 and b2 (alias 
infants 10 and 5 in (Dotz et al. 2014)). This indicates a coabundance of structurally related OS not 
originating from mother’s milk. Since endogenous sources for such unlabeled HMO-like structures 
in urine are rather unlikely, as discussed above, a contribution from degradation products after the 
loss of the 13C-tracer may be an alternative explanation.
The detection of additional OS structures with higher proportion of HexNAc as compared to origi-
nal HMO, especially the larger ones in the feces of infants a2 and b1 (Table 4-1), suggest intesti-
nal cleavage of the reducing-end glucose along with a modification by HexNAc-transferases, such 
as blood group A transferase (Albrecht et al. 2011a; Sabharwal et al. 1988b). In addition, the re-
lease of structurally related OS from mucins or glycoproteins by microbial or intestinal enzymes is 
a probable explanation (Dallas et al. 2012; Marcobal et al. 2011). A direct contribution of OS from 
plasma glycoproteins to the urinary profile is unlikely, since the few free neutral OS, which were 
detected recently in human serum (Iwatsuka et al. 2013), did not match the urinary OS composi-
tions of our cohort. Nevertheless, a few HMO-like structures were recently detected in exclusively 
formula-fed infants’ plasma (Goehring et al. 2014; Ruhaak et al. 2014), suggesting endogenous 
origin. The formula itself, since based on bovine milk, may also be a possible source.
Analogously, the OS with higher proportion of Hex found in a few infants’ urine and fecal samples
may be the products of blood group B transferase. However, the formation of Leb, blood group A, 
and B-active structures implies the presence of Se/H epitopes (Watkins 1995). Consequently, in 
infants fed Lea milk, the consecutive action of two distinct glycosyltransferases has to take place, 
which is energy-consuming, and therefore indicating to play an important role in the infant’s gut 
and organism. α1,2-Fucosylated HMO were shown to be protective against pathogenic intestinal 
bacteria not only in vitro, in vivo in rats, and ex vivo, but also in a prospective epidemiological
study (Morrow et al. 2004; Ruiz-Palacios et al. 2003). Lea and Le-negative phenotypes were
shown to be associated with recurrent urinary tract infections in women and children, respectively 
(Jantausch et al. 1994; Sheinfeld et al. 1989). Consequently, the presence or absence of Le and 
Se epitopes on epithelial surfaces of the intestinal and urinary tract as well as on soluble agents 
such as OS seems to have an impact on host–pathogen interactions.
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Within the infant gastrointestinal tract, microbiota is known to be the key element in HMO metabo-
lization (Dallas et al. 2012; Garrido et al. 2012; Marcobal et al. 2011). In turn, the composition of 
endogenous (host) as well as exogenous (mother’s milk) glycans, especially those bearing the Se 
epitope, is thought to influence infant gut microbiota composition (Garrido et al. 2012; Wacklin et 
al. 2011). In the current work we have provided further indications for an involvement of ABO and 
Le-related fucosyltransferases in the modification of HMO, not only in the infant’s gut, but also 
after absorption. The similar trend toward less fucosylation in infant b2’s urine and feces points to 
an onset of intense utilization over the entire Fuc-HMO range in the upper segments of the gut, 
where absorption mainly takes place. In a recent study with rats, a decrease in the relative abun-
dances of 2’FL and LNT were detected already in parts of the small intestine (Jantscher-Krenn et 
al. 2013). Since the impact of salivary, gastric, and small intestinal glycosidases on human milk 
glycan degradation is estimated to be negligible (Dallas et al. 2012; Gnoth et al. 2000), the contri-
bution of HMO absorption or utilization by microorganisms in the small intestine might be of 
greater significance than estimated before. However, an evidence for that can only be provided by 
studies with applications of single, stable isotope-labeled HMO structures with blood sample col-
lection in infants, which implies some ethical and technical constraints (see also (Ruhaak et al.
2014)).
In summary, via the combination of simplified OS extraction, rapid MALDI-TOF-MS, and isomer 
separation by HPAEC, we compared OS profiles from 36-h milk, urine, and fecal samples collect-
ed from ten mother–child pairs. Additional MALDI-TOF/TOF-MS/MS analyses revealed novel OS 
structures in infants’ feces and urine, most likely degradation or modification products from micro-
bial and endogenous enzymes in the infants’ gut and organism. For the first time, we report on 
acetylated neutral HMO in infants’ urine, which might have other functions and bioactivity as com-
pared to original HMO. Moreover, by means of HPAEC-PAD we found Se- and Le-specific HMO 
in infant feces and, for the first time, in urine, which were not present in their mothers’ milk, and 
therefore must have been synthesized by the infant. This finding may be relevant for future meta-
bolic and functional studies of HMO, which should consider the Le, ABO blood group, and Se 
status of the infants as an important cofactor in addition to the infants’ age and microbial composi-
tion in the gut.
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Table S4-1 Oligosaccharides from mothers’ milk, infants’ urine and feces
m/z
[M+Na]+
Compo-
sitiona) Occurrence in MALDI-TOF-MS
b) Referencec)
Ac H N F milk Infant urine Infant feces Infanturine
Infant
feces
406.1 0 1 1 0 none a2,(b3),b4,(b6-7) a1-2,b1-3, c
511.2 0 2 0 1 all (a1-2),b1-b7,c a1,b1-3,c (Chester et 
al. 1981)
(Sabharwal
et al.
1988a)
552.2 0 1 1 1 (a1,b3-5,b7) (a1),a2,b1-3,(b5),b6-7,c b3,c (Rudloff et 
al. 2012)
553.2 1 2 0 1 none (a2),b1-2,(b3,b5),b6-7,c (c)
568.2 0 2 1 0 all all all (b3)
569.2 1 3 0 0 (a2,b2) all (b4) (a2),b3
657.2 0 2 0 2 (a1),b1-7,c a1,b1-7,c (a1-2),b1-3,c (Chester et 
al. 1981)
(Sabharwal
et al.
1988a)
673.2 0 3 0 1 (b1-6),b7,(c) (b1-4,b7,c) (a1),b1-2,c (Albrecht et 
al. 2011a)
714.2 0 2 1 1 all all a1,(b1),b2,(b3),c (Rudloff et 
al. 2012)
(Sabharwal
et al. 1991)
730.2 0 3 1 0 all all all (Rudloff et 
al. 2012)
(Sabharwal
et al.
1988a)
771.3 0 2 2 0 none a1-2,b1-5,(b6),b7,c a1,(a2),b1-2
772.2 1 3 1 0 (a1-2,b1-6,c) a2,b1-3,b5,(b6),c a2
860.3 0 2 1 2 (a1,b1,b3-7,c) (a1),a2,b1-3,b5-7 a1,(a2),(b3),(c) (Sabharwal
et al. 1984)
876.3 0 3 1 1 all all a1,b1-3,c (Rudloff et 
al. 2012)
(Sabharwal
et al.
1988a)
901.3 0 1 2 2 (a1,a2,b1-3,b5-7,c) (a2,b1-2,b5-7,c) none
917.3 0 2 2 1 none (a1-2,b3-4,b6-7) a1,c
918.3 1 3 1 1 (a1,b1-7) (a1),a2,(b1),b2-6,(b7),c none
933.3 0 3 2 0 (b3-5,b7,c) (all) a1-2,b2,c
1022.4 0 3 1 2 all (c),a1-2,b1-7 a1,b1-3,c (Dotz et al.
2014)
(Sabharwal
et al. 1991)
1038.3 0 4 1 1 all (all) a1,b1-2,c (Albrecht et 
al. 2011a)
1047.4 0 1 2 3 (a1,b1,b3-7) (a1,b1,b3,b5-7) (a2)
1054.3 0 5 1 0 (b3) (all) (c)
1063.4 0 2 2 2 none (all) c
1064.4 1 3 1 2 a1,b1,b3-4 (a1,b1-7) none
1079.4 0 3 2 1 (all) (all) a1,(a2),b1,(b2),c (Sabharwal
et al. 1984)
1095.4 0 4 2 0 all (a1-2,b1),b2,(b3-7,c) a1,b1-2,(b3),(c) (Dotz et al.
2014)
(Albrecht et 
al. 2011a)
1136.4 0 3 3 0 none (a1-2,b2,b6) (a1),a2,b1
1168.4 0 3 1 3 b1-4,(b5),b6-7 (b1,b3-4,b6) none (Dotz et al.
2014)
1184.4 0 4 1 2 (b1-2),b3,(b4-7),c b1,b4,c b1,c (Albrecht et 
al. 2011a)
1225.4 0 3 2 2 (a1-2),(b1-6),b7,(c) (all) a1-2,b1,c (Sabharwal
et al. 1984)
1241.4 0 4 2 1 all (a1-2,b1),b2-3,(b4-7,c) a1,b1-3,c (Dotz et al.
2014)
(Sabharwal
et al.
1988b)
1267.4 1 3 2 2 (b3,b6) (all) none
1282.5 0 3 3 1 none none (a1),a2,(b1)
1298.4 0 4 3 0 none none (a1),b1
1339.5 0 3 4 0 none none (a1),a2,b1,(b3)
1371.5 0 3 2 3 (a1,b1-b7,c) (a2),b3,(b5),b6 none
1387.5 0 4 2 2 all a1,(a2),b1-b7,c a1,(b1),b2,(b3),c (Rudloff et 
al. 2012)
(Sabharwal
et al.
1988b)
1403.5 0 5 2 1 (all) (a1,b2,c) a1,c
1428.5 0 3 3 2 none none (a1-2)
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1429.5 1 4 2 2 (a1,b2,b6-7) a1-2,(b1-5),b6,(b7),c none
1444.5 0 4 3 1 none (a1,c) a1-2,(b1)
1460.5 0 5 3 0 all (a2,b1-3,b5-6) a1,(b1),b2-3 (Dotz et al.
2014)
1485.7 0 3 4 1 none none a2
1533.5 0 4 2 3 all (a1-2),b1-7,(c) a1,b1-3,c (Rudloff et 
al. 2012)
(Sabharwal
et al.
1988a)
1542.6 0 3 5 0 none none (a1),a2,b1
1590.6 0 4 3 2 (a1,b1,b3,b5-7) (b5-6,c) a1,(a2,b1),c
1606.6 0 5 3 1 all (a2,b2-3,b5,c) a1,b2,(b3),c (Dotz et al.
2014)
(Albrecht et 
al. 2011a)
1631.6 0 3 4 2 none none a2,(b1)
1679.6 0 4 2 4 b1-b7 none none
1688.6 0 3 5 1 none none a2
1736.6 0 4 3 3 (b1-2,b5-7) (a2,b3-6) none
1745.6 0 3 6 0 none none b1
1752.6 0 5 3 2 all (a1-2,b2-5,b7,c) a1,b2,(b3),c (Dotz et al.
2014)
(Albrecht et 
al. 2011a)
1777.6 0 3 4 3 none none a2
1793.6 0 4 4 2 none none a2
1802.7 0 1 5 4 none none b1
1825.6 0 6 4 0 (b4),b5,(b7) none b2,(b3)
1850.7 0 4 5 1 none none (a2)
1898.7 0 5 3 3 all (a1-2,b2-5,c) a1,(b1),b3,c (Dotz et al.
2014)
(Albrecht et 
al. 2011a)
1948.7 0 1 5 5 none none b1
1971.7 0 6 4 1 (a1-2,b1-
4),b5,(b6),b7,(c)
none b2,(b3)
1996.7 0 4 5 2 none none (a2)
2005.8 0 1 6 4 none none (b1)
2044.7 0 5 3 4 (b2,b3),b4,(b5-6),b7 (b2,b3) none (Dotz et al.
2014)
(Albrecht et 
al. 2011a)
2117.8 0 6 4 2 a1,(a2),b1,(b2),b3-
5,(b6-7,c)
(c) (a1,b3) (Dotz et al.
2014)
2190.8 0 7 5 0 (b1-5,b7) none none
2208.8 0 1 7 4 none none (b1)
2263.8 0 6 4 3 a1,(b1),b2-3,(b4-
6),b7,(c)
(c) a1,c (Dotz et al.
2014)
2336.8 0 7 5 1 (b5,b7,c) none none
2409.9 0 6 4 4 (a1,b1-6),b7 none none
2482.9 0 7 5 2 (a1,b3-5,b7) none none
2555.9 0 8 6 0 (b3,b7) none none
2628.9 0 7 5 3 (a1,b3,b7) none none
2702.0 0 8 6 1 (b7) none none
2775.0 0 7 5 4 (a1,b3,b7) none none
a) Ac, acetyl-; H, hexose; N, N-acetylhexosamine; F, fucose; 
b) Letters a, b, and c were assigned to the mother-child pairs according to the Lewis and secretor-specific 
HPAEC-PAD profiles from milk as shown in Fig. 2. 
c) Reference number is given if one or more compounds with the respective m/z value were previously de-
scribed. Brackets indicate low intensity, i.e. signal-to-noise ratio<20. 
Supporting Information Table S4–2 (extensive Excel file) is available online at the publisher’s site.
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5.1 Abstract
Beneficial effects have been proposed for human milk oligosaccharides (HMO), as deduced main-
ly from in vitro studies. To date, in vivo evidence of the link between certain oligosaccharide struc-
tures in milk and their consumption by infant gut microbiota is missing. Although many studies 
have described HMO patterns in human milk from larger cohorts, data on the excretion of HMO 
and possible metabolites from the infant gut are still very limited. However, from smaller-scale 
studies an age-dependency according to infant gut maturation and microbiota adaptation has 
previously been hypothesized. To further investigate this, we profiled fecal oligosaccharides from 
term-born infants who were exclusively breast-fed, formula-fed or mixed-fed at the age of six 
weeks, and from a follow-up of a subgroup at six months of age (INFABIO study). Automated 
matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF-MS) 
analyses revealed the presence of HMO and metabolites in the feces of most, but not all breast-
fed infants at six weeks, with highly varying patterns. Formula-fed infants at six weeks and most 
of the breast-fed infants at six months did not excrete HMO-like structures in their feces, the latter 
corresponding to the hypothesis of age-dependency. Together with our previous results that were 
contradictory to what has been proposed by others, here, we suggest alternative explanations for 
the described age and feeding-mode dependency of oligosaccharide excretion in infants below 
six months of age.
5.2 Introduction
OS as a major solid fraction of human milk are thought to have beneficial effects for the breast-fed 
infant, as is known from various in vitro and some animal studies (Bode and Jantscher-Krenn 
2012; Kunz et al. 2014; Smilowitz et al. 2014). Interventional studies in infants are lacking to date 
due to a scarce availability of single human milk OS (HMO) for human use (Rudloff and Kunz 
2012). The high structural diversity of HMO, which notably are lacking in bovine milk-based infant 
formulas, hampers acquiring a sophisticated knowledge on ‘what structures are important’. Meta-
bolic studies might help in this regard by showing which structures are utilized at which sites of 
the infant´s organism. 
HMO were found to be only marginally digested by human intestinal enzymes (Engfer et al. 2000; 
Gnoth et al. 2000), while infant gut microbiota can utilize certain HMO as sole carbohydrate 
source in vitro (Marcobal et al. 2010; Yu et al. 2013). In particular, Bifidobacteria and Bacteroides
are known to consume various HMO in a structure-specific manner in vitro (Asakuma et al. 2011; 
Marcobal et al. 2011; Satoh et al. 2013). This has indirectly been linked to previously reported 
differences in fecal microbial composition between breastfed and formula-fed infants. 
Only very recently, studies trying to prove a direct link between HMO structures and their prebiotic 
function in vivo in infants have been reported. A recent proof-of-concept study indicated an asso-
ciation between the fecal HMO composition and gut microbiota of two breastfed infants over time, 
though both parameters differed substantially between the two infants (De Leoz et al. 2015). An-
other recent investigation showed a relationship between the fecal microbiome of exclusively 
breastfed infants (n=16) and OS composition in milk that was ingested by these infants (Wang et 
al. 2015). However, since the variety of both OS and microbiota composition is vast, reliable ana-
lytics, optimally in a high-throughput manner for large-scale omic studies, are inevitable for a bet-
ter understanding of their interaction and relation to health and disease. The importance of inte-
grated metagenomic and metabolomic information on systems biology level in the adult organism 
has been recognized recently (Aw and Fukuda 2015).
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First attempts to profile fecal OS and possible metabolites of HMO in vivo in infants by modern 
omics-suitable methods have been undertaken recently. However, studies either included only 
one or two study subject(s) (De Leoz et al. 2015; De Leoz et al. 2013), or showed data from 
premature infants (Albrecht et al. 2011b; De Leoz et al. 2013), whose intestinal function may be 
very different from healthy term infants. Only one publication reported on fecal OS follow-up data 
from ten term infants, but this time no comparison was drawn with formula-fed babies as negative 
controls for HMO ingestion (Albrecht et al. 2011a). 
Previously, we reported on the metabolic fate of HMO in ten exclusively breast-fed infants by 
comparing MALDI-TOF-MS(/MS) data from mother’s milk, infant urine and feces and by tracking 
in vivo 13C-labeled HMO (Dotz et al. 2014; Dotz et al. 2015). Here we present an automated high-
throughput glycomic method, which we applied on fecal samples from in total 24 term infants who 
were breastfed, formula-fed or mixed-fed. Thus, we take a first step towards an integrated omics 
approach for a better understanding of the structure-function relationship of HMO in the early 
childhood.
5.3 Materials and Methods
Subjects 
Fecal samples were collected from 24 full-term infants participating in the Diet and Environment 
longitudinal study of the European project INFABIO at the ages of 6 weeks and 6 months. From 
two infants, 2 different fecal samples each were obtained at the age of 6 months. The data pre-
sented in the current work were obtained from infants recruited from the region of Dusseldorf 
(Germany) only. Written informed consent was obtained from all mothers. Information on events 
concerning pregnancy and delivery as well as the feeding method, health history of the baby, and 
antibiotic treatment of both mother and child, were obtained from the mothers via repeated ques-
tionnaires (Fallani et al. 2010).
Sample collection
Fecal samples were placed in a sterile plastic box and maintained under anaerobic conditions at 
4°C using anaerocult A (Merck, Nogent sur Marne, France) for a maximum of 4 hours before pro-
cessing. After homogenization by mechanical kneading for 3 minutes, aliquots of 1 g (wet weight) 
were added to 9 mL of anaerobic phosphate-buffered saline and mixed again. Fecal slurries were 
centrifuged at 5000 x g at 20°C for 15 min, and thereafter, the supernatants were filtered through 
a 0.22 µm membrane. Filtrates were kept frozen at –20°C prior to further processing and analysis. 
Sample preparation and analysis
Chemicals were purchased from the following suppliers: maltoheptaose (analytical grade), water, 
ACN (HPLC grade), and 2,5-dihydroxybenzoic acid from Sigma-Aldrich (Steinheim, Germany), 
TFA (ULC-MS grade) from LGC Standards (Wesel, Germany).
In duplicates, OS were extracted automated as previously described (Blank et al. 2011; Dotz et al.
2015), with few modifications. Briefly, SPE on PGC cartridges (HyperSep-96 Wells, 25 mg; Ther-
mo Scientific, Bellefonte PA, USA) was performed using a Hamilton Microlab Starlet liquid han-
dling system (Hamilton Robotics, Reno, NV, USA). Cartridges were equilibrated with 40% ACN 
and 0.1 % TFA in water (v/v), followed by 20% ACN and 0.1 % TFA, and washed with 0.1% 
aqueous TFA. Thawed fecal filtrates were loaded onto the cartridges and eluted with 40% ACN 
containing 0.1% TFA. The eluates were fully dried by vacuum.
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OS were re-suspended in pure water and mixed with maltoheptaose, functioning as positive con-
trol and as internal standard during MALDI-TOF-MS analysis. Mass spectra were acquired using 
an Ultraflex I instrument (Bruker Daltonics, Bremen, Germany), equipped with a nitrogen laser 
emitting at 337 nm; a dextran hydrolysate was used to calibrate the equipment and the analytical 
method (Blank et al. 2011; Dotz et al. 2015). Fecal OS extracts were pipetted in duplicates onto a 
MALDI target plate by the lab robot, and were allowed to dry. Subsequently, samples were re-
suspended in 1 µL 2,5-dihydroxybenzoic acid matrix solution (5 mg/mL 25% ACN) by the lab ro-
bot, and were allowed to dry. 
OS profiles were acquired in positive-ion reflectron mode over a mass range of m/z 300–3000. 
Data acquisition and analysis were performed by flexControl and flexAnalysis 3.0 software 
(Bruker Daltonics, Bremen, Germany), respectively. 
5.4 Results
In total, 24 fecal samples were available from infants who were exclusively breast-fed (B), 7 sam-
ples from exclusively formula-fed (F), and 6 from mixed-fed (M) infants (Table 5-1). Samples were 
not always available at both time points (6 weeks/months) from the same infant. For example, 
from the six infants who were exclusively formula-fed at 6 weeks, no follow-up sample could be 
obtained at 6 months of age. In contrast, for infants 13–15 fecal samples were only available at 
the age of 6 months.
Table 5-1 Cohort sub-groups with sample IDs according to age and feeding mode
Age breast-fed (B) mixed-fed (M) formula-fed (F)
6 weeks 1B – 12B a) 16M – 18M 19F – 24F
6 months 1BB – 7BB, 
13XB – 15XB
16MM – 18MM 12BF
a) Sample IDs: number indicating participant ID, first and second letters indicating feeding mode at 6 weeks 
and 6 months, respectively; X stands for unknown feeding mode at the age of 6 weeks
Since spectra obtained from fecal samples contained numerous background peaks as well as 
detector noise up to an m/z of 700 (Fig. 5-1, upper panel), a minimum cut-off of m/z 700 was set 
for all further data analysis. This was also observed in pure water blanks that have undergone the 
same preparation procedure as the fecal specimens (not shown).
5.4.1 Oligosaccharide profiles in infants’ feces at six weeks
In total, more than 50 signals matching possible OS compositions have been detected by MALDI-
TOF-MS in the sample set at the age of 6 weeks (Supporting Information Table S5–1). Most of 
these detected species were obtained from samples of exclusively breastfed or mixed-fed infants,
and were matching m/z values as seen in many milk samples, as exemplified in Fig. 5-1 (lower 
panel). 
Among the 12 exclusively breastfed infants a variety of OS profiles was observed at six weeks. In 
seven infants many OS species as known from human milk could be detected, i.e. infants 2B, 4B, 
7B, 9B–12B (Fig. 5-2 and Table 5-2, HMO group). 
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Fig. 5-1 MALDI-TOF mass spectra of a fecal sample from a breastfed infant at 6 weeks (upper panel) and a 
milk sample (lower panel) from the INFABIO cohort. Suggested structures as known from milk oligosac-
charide species: blue circle, glucose; yellow circle, galactose; blue square, N-acetylglucosamine; red trian-
gle, fucose; pink diamond, N-acetylneuraminic acid; unknown oligosaccharide: open circle, hexose; open 
square, N-acetylhexosamine. Asterisk indicates non-oligosaccharide origin.
Feces of infants 3B, 5B and 8B showed an OS profile clearly distinguishable from milk, where 
certain OS species predominated and common, especially larger HMO were clearly diminished 
(Fig. 5-2). For example, in infant 5B hardly any OS > m/z 1600 could be detected, whereas difu-
cosylated LN(n)T at m/z 1022 was dominating the profile (Supporting Information Fig S5–1). In 
infants 1B, 3B and 8B non-typical HMO structures, such as Hex2HexNAc1Fuc1 at m/z 714.2, 
Hex2HexNAc2 at 771.3, Hex3HexNAc2Fuc1 at m/z 1079.4 or Hex3HexNAc2Fuc2 at 1225.4, were 
increased relatively to common HMO signals (Fig. 5-2 and Table 5-2, N>H-2 groups versus ≥ 
hexaoses group). Furthermore, in child 1B intensities were very low (Supporting Information Table 
S5-1). No OS species were detected in infant 6B (not shown).
The mixed-fed infant 16M showed an OS profile similar to that of 5B (Supporting Information Fig.
S5–1), whereas no OS matching HMO or possible metabolite compositions could be detected in 
the feces of the other two mixed-fed babies 17M and 18M, neither in the six formula-fed infants 
19F–24F (not shown).
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Table 5-2 Oligosaccharide groups derived from relative intensities of fecal oligosaccharides
OS group 5B 9B 1B 4B 7B 10B 12B 2B 11B 8B 3B
HMO 100.0 92.9 84.6 94.0 91.9 96.8 93.3 90.3 96.7 30.1 70.9
Fucosylated 95.0 83.3 75.8 66.3 47.9 77.7 88.1 87.9 91.6 50.8 93.7
A-active 2.6 7.0 57.4 2.8 1.3 2.8 5.2 4.7 3.1 38.1 93.3
N>H-2 2.6 7.9 64.0 5.3 7.8 3.9 7.2 9.2 4.1 59.9 95.3
N<H-2 1.3 2.0 0.0 1.3 0.6 1.8 1.8 1.4 3.1 0.0 0.0
≤tetraoses 93.5 75.2 91.2 56.4 51.4 73.5 54.5 58.3 68.9 75.6 70.5
≥hexaoses 5.2 16.9 0.0 38.8 41.5 23.7 40.2 34.1 26.0 5.5 0.9
MALDI-TOF-MS signal intensities of each putative oligosaccharide species (Supporting Information Table S5–1) were 
divided by the intensity sum of all detected oligosaccharide species from that list; arithmetic means of these relative inten-
sities were calculated from the technical quadruplicates (preparation duplicate × MALDI-TOF-MS spot duplicate), and 
were summed into groups. OS groups were created as follows: HMO = 714 + 730 + 876 + 1022 + 1038 + 1064 + 1095 + 
1168 + 1184 + 1241 + 1387 + 1460 + 1533 + 1606 + 1679 + 1752 + 1825 + 1898 + 1971 + 2044 + 2117 + 2190 + 2263 + 
2336 + 2409 + 2482 + 2555 + 2628 + 2701 + 2774 (all m/z detected in human milk except for low-abundant ones, as 
based on Table S4–1 in Chapter 4); Fucosylated: all species containing at least one fucose; A-active: 714 + 860 + 1079 + 
1225 (corresponding to masses of A-tetrasaccharide up to A heptasaccharide); N>H-2 or N<H-2: all species containing a 
higher/lower proportion of HexNAc as compared to HMO core structures (Hex2HexNAc1)n; ≤ tetraoses: only species con-
taining up to four core monosaccharides (Hex and/or HexNAc); ≥ hexaoses: only species containing at least six core 
monosaccharides.
Fig. 5-2 Relative signal intensities of fecal oligosaccharides and oligosaccharide groups from 10 exclusively 
breastfed infants. For explanation, see Table 5-2.
5.4.2 Oligosaccharides in infants’ feces at six months
In 10 out of 14 infants at 6 months of age, no signals matching HMO or potential metabolites 
could be detected. That were fecal samples from i) exclusively breastfed infants 2BB–4BB, 6BB, 
7BB, 15XB, or ii) mixed-fed infants 16MM-18MM, or iii) infant 12BF, who was exclusively formula-
fed at the age of six months (not shown). The spectra from the repeatedly obtained samples in 
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infants 2B and 3B were consistent thereby. In contrast, in three exclusively breastfed infants mul-
tiple OS signals were detected by MALDI-TOF-MS. However, OS concentration in the fecal ex-
tracts seemed very low, as could be seen in the relatively high signal of the spiked standard 
maltoheptaose (Fig. 5-3). Furthermore, in the exclusively breast-fed infant 13XB only the OS spe-
cies Hex3HexNAc3 at m/z 1136 was observed (not shown).
Fig. 5-3 MALDI-TOF mass spectra of fecal oligosaccharides from exclusively breastfed infants at the age 
of six months. Only molecular species matching HMO or possible metabolites according to Table S4–1 in 
Chapter 4 Supporting Information were annotated.
5.5 Discussion
Our automated and rapid method for OS extraction from infant feces as previously described 
(Dotz et al. 2015) has successfully been applied on fecal specimens from a sub-cohort of the 
INFABIO study. In addition, it has been modified to enable reliable automated spotting and meas-
uring. Initially, fecal samples were collected for a characterization of the intestinal microbiome 
(Fallani et al. 2010). The HMO-containing supernatant resulting in course of the extraction of bac-
terial cells from feces has now been proven suitable for OS analysis by our MALDI-TOF-MS ap-
proach.
At the age of six weeks three different groups of exclusively breast-fed full-term infants could be 
assigned on the basis of their fecal OS profiles: i) high diversity with up to 30 HMO-like structures 
- 70 -
in an individual sample, ii) predominance of only one or a few OS with low signal intensities in 
some cases, and iii) no OS (Table 5-3). 
Table 5-3 Oligosaccharide (OS) diversity in feces of exclusively breastfed infants at 6 weeks / months of 
age
Age High diversity of OS (>10) Few OS (5–7) No OS
6 weeks 2B, 4B, 7B, 9B–12B a) (1B), 3B, 5B and 8B 6B
6 months 1BB 5BB, (14XB) 2BB–4BB, 6BB, 7BB, 13XB, 15XB
a) for sample ID definitions and abbreviations, see Table 5-1
Brackets indicate very low intensity as compared to spiking standard maltoheptaose.
The majority of the six weeks old infants were among the first group, but each profile still was 
unique and some showed very specific features. For example, in the fecal OS profile of infant 7B, 
which is shown in Fig. 5-1 (upper panel), the proportion of non-fucosylated OS, e.g. at m/z 1095 
or 1460, was clearly increased compared to the profiles known from milk as analyzed by the 
same (Fig. 5-1, lower panel) or comparable methods (Blank et al. 2011; Dotz et al. 2015). Previ-
ously, we have reported on the same apparent trend in another infant’s fecal and also urinary OS 
profile (infant b2 in (Dotz et al. 2015)). This indicates a higher fucosidase activity in these infants’ 
guts. Intriguingly, we detected a remarkably high relative intensity signal at m/z 933 in the same 
infant. This Hex3HexNAc2 structure has been detected in other fecal samples in our investigations 
and also by others (Albrecht et al. 2011a; Albrecht et al. 2011b), but only in one other case it was 
found to be as increased (infant a2 in (Dotz et al. 2015)). 
The profiles in the second group were not very consistent, except for the overall lower abundance 
of larger OS as compared to the first group. For instance, infant 5B had reduced abundances of 
larger OS structures and a remarkably high proportion of difucosylated LNT (isomers) at m/z
1022, which on the other hand could not be detected in infants 1B and 3B. However, the latter 
might be a consequence of an anyhow lower presence of this molecular species in milk, as known 
from Lewis a and some Lewis negative milk samples (Blank et al. 2011). This could not be proven 
here due to a lack of mother’s milk samples. The predominance of the signal at m/z 1022 was 
also observed in the mixed-fed infant 16M (Supporting Information Fig. S5–1) and reported by 
Albrecht and colleagues in one infant (A2) (Albrecht et al. 2011b). An intriguing finding was the 
huge relative abundance of structures with a high proportion of HexNAc to Hex in infants 1B, 3B 
and 8B (Table 5-2), as we have reported previously in a small cohort (Dotz et al. 2015). To a ma-
jor part, this can be attributed to an attachment of a GalNAc by the action of blood group A en-
zyme at the intestinal mucosa (Albrecht et al. 2011a; Sabharwal et al. 1984), as can be seen in
the great overlap of the N>H-2 group and the group of presumably A-active OS in Table 5-2. 
The absence of OS signals in the feces of exclusively breast-fed infant 6B at six weeks as well as 
in most fecal samples obtained at the age of six months (7 out of 10), might either reflect a highly 
effective degradation/consumption in the gut or simply be a result of two major methodical limita-
tions. First, a fecal sample (aliquot) taken only once might be not representative due to the well-
known heterogeneity and high variability of the water content/viscosity of fecal samples, especial-
ly in infants. Here, we analyzed two different aliquots from the same fecal sample. However, mul-
tiple samples were available from only two infants. A second important methodical consideration 
which has been ignored in fecal OS profiling studies so far is the high variability in frequency of 
feedings and/or defecation, which is strongly associated with infant age and feeding mode (Tunc
et al. 2008). In older and in formula-fed infants stool frequency is lower than in younger and 
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breast-fed infants. This should in turn have a substantial impact on the microbial metabolization 
efficiency of single OS structures, possibly even more than mere microbiota composition. Marco-
bal and colleagues have shown that Bacteroides species have a sequential degradation pattern 
for HMO with different preferences after approximately 5 vs. 15 hours of in vitro incubation 
(Marcobal et al. 2011). Future studies should take these aspects into consideration by, e.g., doc-
umenting stool frequency and collecting fecal specimens repeatedly over a few days to assure 
representative OS profiling. Having these data available might have helped explaining why we 
could hardly detect any OS signals in the feces of infant 1 at six weeks, in contrast to the follow-
up sample at six months. So far, that finding is contradictory to the reports of Albrecht and col-
leagues, who claimed a gradual decrease of HMO abundance with age, hypothesizing an associ-
ation with gut (microbiota) maturity (Albrecht et al. 2011a). 
Moreover, sample treatment in different laboratories may have contributed to inconsistencies of 
data on HMO excretion in infant feces. Contrary to our previous (Dotz et al. 2015) and our current 
results, others were not able to detect LNT in any of the fecal samples (Albrecht et al. 2011a; 
Albrecht et al. 2011b). This could be due to an ongoing degradation/metabolization of OS during 
incubation prior to extraction. In contrast, we performed a short incubation in phosphate-saline 
buffer after thorough homogenization. Previously, a simple 1-hour incubation in water after 20-min 
pasteurization was also shown sufficient for a reliable fecal OS profiling by MALDI-TOF-MS
(Chapter 4) (Dotz et al. 2015). Thus, our approach for automated extraction, MALDI-plate spot-
ting and TOF-MS measurement presented here clearly features the highest rapidness and 
throughput among all MS-based methods for the analysis of fecal OS from infants published dur-
ing the recent years (see (Albrecht et al. 2010; De Leoz et al. 2015; De Leoz et al. 2013) and our 
comments in (Dotz and Kunz 2013)). It only takes approximately 10–15 hours for the preparation 
and analysis of up to 96 samples, sample drying included. Consequently, our approach is particu-
larly valuable as it will enable large-scale studies with straightforward analysis of both intestinal 
microbiome of infants as well as its possible HMO metabolites. Moreover, oligosaccharides from 
milk samples can also be analyzed by the same approach without major modifications (Blank et 
al. 2011; Dotz et al. 2015), allowing for gaining as much of an insight into the structure-function 
relationship of HMO as is possible from non-invasive studies.
Overall, our findings provide further evidence for the excretion of intact and metabolized OS struc-
tures originating from human milk in case of breast-fed infants. Although the excretion patterns of 
HMO structures and metabolites showed an association with age as suggested previously by 
others, we have seen exceptions and have proposed alternative hypotheses according to our
previously unpublished data. Future large-scale follow-up studies are required to further reveal 
the factors influencing the high variability and temporal dynamics of infant gut microbiota and 
HMO composition, providing a crucial basis for our understanding of the unique interaction be-
tween these two. 
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5.6 Supporting Information
Table S5-1. Relative intensities of neutral oligosaccharides in exclusively breast-fed infants’ feces, detected 
by MALDI-TOF-MS at the age of 6 weeks
Infant ID a)
m/z b) H N F 5B 9B 1B 4B 7B 10B 12B 2B 11B 8B 3B
714.2 2 1 1 2.6 1.0 48.6 0.1 0.0 1.4 1.4 0.0 1.1 15.4 66.2
730.2 3 1 0 5.0 16.2 24.2 25.1 27.4 21.2 9.0 6.1 7.6 2.0 4.2
771.3 2 2 0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 16.3 0.0
860.3 2 1 2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.7 0.0
876.3 3 1 1 11.5 32.7 11.8 24.5 18.7 40.0 34.1 39.1 34.3 2.1 0.0
892.3 4 1 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 25.4 0.0
901.3 1 2 2 0.0 0.0 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
917.3 2 2 1 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0
933.3 3 2 0 0.0 0.2 0.0 1.6 5.6 0.2 0.5 2.0 0.1 0.0 1.6
1022.4 3 1 2 74.4 25.1 0.0 6.4 5.0 10.3 10.0 13.0 24.8 3.2 0.0
1038.3 4 1 1 1.3 1.8 0.0 0.5 0.2 1.1 0.9 0.8 1.9 0.0 0.0
1063.4 2 2 2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0
1064.4 3 1 2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.0
1079.4 3 2 1 0.0 3.5 8.8 2.5 1.1 1.3 2.5 3.8 1.0 12.9 27.0
1095.4 4 2 0 0.0 0.3 0.0 5.7 15.6 0.9 2.0 2.6 0.6 0.0 0.5
1136.4 3 3 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 4.4 0.0
1168.4 3 1 3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.0
1184.4 4 1 2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0
1225.4 3 2 2 0.0 2.4 0.0 0.1 0.2 0.1 1.3 1.0 0.8 6.0 0.0
1241.4 4 2 1 0.0 3.7 0.0 13.5 9.6 6.1 10.8 9.5 5.6 0.0 0.0
1267.4 3 2 2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
1298.4 4 3 0 0.0 0.0 0.0 0.1 0.4 0.0 0.2 0.7 0.0 0.0 0.0
1339.5 3 4 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0
1371.5 3 2 3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0
1387.5 4 2 2 3.7 6.9 0.0 9.9 6.1 11.1 13.3 8.5 10.0 0.0 0.0
1403.5 5 2 1 0.0 0.2 0.0 0.8 0.3 0.6 0.9 0.5 0.3 0.0 0.0
1444.5 4 3 1 0.0 0.2 0.0 0.4 0.3 0.1 0.7 1.1 0.2 0.0 0.4
1460.5 5 3 0 0.0 0.0 0.0 0.9 2.0 0.0 0.2 0.6 0.0 0.0 0.0
1533.5 4 2 3 1.5 3.9 0.0 1.0 1.1 0.6 4.3 2.7 4.7 0.0 0.0
1590.6 4 3 2 0.0 0.5 0.0 0.1 0.1 0.3 0.6 0.7 0.2 0.0 0.0
1606.6 5 3 1 0.0 0.1 0.0 2.0 1.7 0.6 1.6 1.7 0.4 0.0 0.0
1679.6 4 2 4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0
1736.6 4 3 3 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0
1752.6 5 3 2 0.0 0.5 0.0 1.8 1.2 1.6 2.6 2.3 1.5 0.0 0.0
1825.6 6 4 0 0.0 0.0 0.0 0.3 0.9 0.0 0.0 0.1 0.0 0.0 0.0
1898.7 5 3 3 0.0 0.5 0.0 0.6 0.6 1.4 1.6 1.4 1.3 0.0 0.0
1971.7 6 4 1 0.0 0.0 0.0 0.7 0.7 0.0 0.1 0.4 0.0 0.0 0.0
2044.7 5 3 4 0.0 0.0 0.0 0.0 0.1 0.0 0.4 0.4 0.5 0.0 0.0
2117.7 6 4 2 0.0 0.0 0.0 0.6 0.4 0.1 0.4 0.5 0.1 0.0 0.0
2190.8 7 5 0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0
2263.8 6 4 3 0.0 0.0 0.0 0.2 0.1 0.1 0.3 0.3 0.2 0.0 0.0
2409.9 6 4 4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0
SUM 15,606 49,625 1,819 74,991 74,701 56,108 56,519 53,095 72,516 4,868 11,246
1175.4 7 0 0 66.1 15.6 1454.4 11.2 18.7 17.6 12.7 19.8 19.6 354.6 114.7
a) Number indicates participant ID; B, breast-fed
b) MALDI-TOF-MS signal intensities of each putative oligosaccharide species with monoisotopic [M+Na]+ were divided by 
the absolute intensity sum (SUM) of all detected oligosaccharide species from that list; arithmetic means of these relative 
intensities were calculated from the technical quadruplicates (preparation duplicate × MALDI-TOF-MS spot duplicate). H, 
number of hexoses; N, number of N-acetylhexosamines; F, number of fucoses. M/z 1175.4 indicates internal standard 
maltoheptaose.
Only signals with a relative intensity of ≥0.1 are included.
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Fig. S5-1 MALDI-TOF mass spectra of oligosaccharides from feces of the mixed-fed infant 16M (top) and 
the exclusively breast-fed infant 5B (bottom) at the age of six weeks. Maltoheptaose was added prior to 
analysis as positive control.
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Chapter 6
6 General discussion*
Breastfeeding is beneficial to both mother and child, not only during infancy, but also later in life
(Chapter 1). Partly digestible OS ingested by the infant via breast milk are postulated to have 
various beneficial effects. However, their metabolic fate in vivo in healthy term infants had not 
been investigated in detail prior to the studies presented in this work. In the following, the analyti-
cal methodology that had to be developed first as well as data obtained by these methods are 
discussed.
6.1 HMO analysis by MALDI-TOF-MS and HPAEC-PAD
By using our developed method for profiling OS in MALDI-TOF-MS, approx. 80 distinct molecular 
species could be detected when taken together milk, infant urine and feces extracts (Chapter 4). 
By adjustments of the method for high-throughput screening of HMO (Blank et al. 2011) (Chapter
2), in this work we were able to also extract and detect fecal OS using a lab robot for the laborious 
steps. However, extraction and detection of OS from urine was more challenging due to low and 
highly varying concentrations of the analytes and higher abundance of interfering hydrophilic 
compounds. These issues were addressed by normalizing the applied urine volume to the creati-
nine concentration and by performing manual SPE instead of using the lab robot allowing for 
more controlled/slower processing at critical steps such as sample application and elution. Never-
theless, OS extraction from feces is not trivial either. As we discussed previously, the common 
procedure for OS extraction by keeping watery fecal slurries overnight might result in ongoing 
degradation/metabolization of OS during incubation. This might have occurred in the studies of 
Albrecht and coworkers (Albrecht et al. 2011a; Albrecht et al. 2011b), as they were not able to 
detect LNT in fecal samples in contrast to our results (Chapters 4 & 5). Strikingly, De Leoz and 
coworkers also reported on the presence of LNT in all fecal samples of in total three infants, alt-
hough they also kept the fecal samples as water slurries overnight (De Leoz et al. 2015; De Leoz
et al. 2013). However, the authors were still applying laborious Folch extraction and overnight 
incubation for their studies though claiming their method to be rapid and high-throughput. We 
criticized this in a short letter (Dotz and Kunz 2013). In contrast, we have found a short pasteuri-
zation and incubation step to be sufficient for a reliable fecal OS profiling by MALDI-TOF-MS.
The rapidness and sufficient isotopic resolution of our MALDI-TOF-MS approach enabled us to 
analyze replicates of milk and urine samples collected during 36 hours for tracing 13C-labeled 
HMO (Chapter 3). This approach can easily be applied to future bioavailability and metabolic 
studies with single stable-isotope labeled OS (Chapter 6.2).
The same extracts as used for MALDI-TOF could easily be injected into our established HPAEC-
PAD system for the additional evaluation of Le- and Se-specific structures after isomeric separa-
tion, since no derivatization is necessary for PAD (Kunz et al. 1996). Thereby, we could gain addi-
tional information on OS modifications taking place in the infants after ingestion of HMO. Howev-
er, HPAEC-PAD is not able to characterize novel structures, since identification is only done by 
* Manuscript in preparation, combined with Chapter 1
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retention time matching. Coupling of HPAEC to MS would have been desirable, but is recognized 
as very challenging due to the extremely high salt concentration at the HPAEC outlet.
Further limitations of our approach mainly originating from recognized MALDI-TOF-MS-typical 
problems are discussed in the following. Some of the detected signals may originate from potas-
sium adducts of the same species that is detected at m/z lower by 16 Da when sodiated, e.g.
[M+Na]+ = 1022 and [M+K]+ = 1038 (see Table S5-1). The addition of lithium acetate, sodium 
chloride, or potassium chloride to the matrix solution for a suppression of an adduct formation 
from the other salts as suggested in literature (Pfenninger et al. 1999) did not completely sup-
press the others, but even resulted in lower signal intensities for OS from infant feces or urine (not 
shown). Using a high-resolution MS, e.g. an FT-capable instrument, would be another alternative, 
which was not available for our studies, however. In-source fragmentation as a well-known issue 
in MALDI-TOF-MS analysis (Zaia 2010), may also have contributed to some detection uncertain-
ty. Therefore, care has been taken not to apply too high laser intensity during the measurements. 
Moreover, due to the well-known problem of sialic acid loss during MALDI-TOF-MS analysis, es-
pecially in the positive-ion reflectron mode (Zaia 2010), we were not able to reliably analyze acidic 
HMO in our samples (Chapter 4). LC-MS approaches with softer ES ionization or derivatization of 
the sialylated species by permethylation or other techniques would enable detection of sialylated 
OS, however, at a cost of lower throughput, higher sample consumption and substantially higher 
efforts (Chapter 1.5.5). Some of the mass overlaps and uncertainties could be resolved by frag-
mentation in MALDI-TOF/TOF (Chapter 4). This technique was indispensable for the characteri-
zation of novel structures, in particular acetylated HMO.
In spite of the aforementioned methodical constraints, our approach for automated extraction, 
MALDI-plate spotting and TOF MS measurement presented here clearly features the highest 
rapidness and throughput among all MS-based methods for the analysis of fecal and milk OS 
published during the recent years (see (Albrecht et al. 2010; De Leoz et al. 2015; De Leoz et al.
2013). Our approach starting from thawed samples until having the mass spectra available takes 
approximately 10–15 hours for 96 samples if overnight SpeedVac drying after SPE is also count-
ed. The only manual steps are pipetting samples before and after incubation and filtration of each 
sample via syringe filters. However, in principle these steps can also be easily accomplished by a 
lab robot on well plates. As pointed out in Chapter 2, the here presented MALDI-TOF-MS ap-
proach, together with other state-of-the-art analytical techniques, will allow for gaining as much of 
an insight into the structure-function relationship of HMO as is possible from non-invasive studies
in the near future.
6.2 Metabolic fate of milk oligosaccharides in infants
Deduced from our findings described in Chapters 3, 4, and 5, intact, degraded and modified 
HMO are passing through the entire gastrointestinal tract and are clearly able to be absorbed in 
vivo by the breastfed infant. This has been shown by characterizing various HMO-like structures
in infant feces and urine, respectively. The various (classes of) metabolites as detected in our 
studies, are summarized in Table 6-1. Our finding of acetylated neutral OS in infants’ and lactat-
ing women’s urines is novel. O-acetylated sialic acid motifs have been detected on OS in Tasma-
nian echidna milk (Oftedal et al. 2014). In general, O-acetylation of sialylated glycans plays an 
important role in human immunology, bacterial and viral infections, and is linked to type I diabe-
tes, rheumatoid arthritis and autoimmune disorders. However, the role of and the possible metab-
olization sites/mechanisms leading to the formation of neutral acetylated HMO is to be investigat-
ed in the future. We hypothesize that HMO are enzymatically acetylated in the infants’ and wom-
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en’s liver, kidneys’, or other body cells excluding gut (Fig. 6-1). A contribution of the intestine to 
the acetylation of HMO at least in women is unlikely, as it would imply secretion from circulation 
into the gut with subsequent re-absorption.
Another class of possible urinary OS metabolites is reported in literature from a study in infants 
having the lysosomal storage disease galactosialidosis (Bruggink et al. 2010). That is HMO-like 
structures with gluconic acid at the reducing end, most likely following a C1-oxidation of the Glc 
residue. If that modification occurred in our samples, it would have overlapped with potassium 
adducts of the usual HMO peaks due to the mass difference of +16 Da. In addition, urinary OS 
bearing myo-inositol instead of Glc at the reducing end have been reported in pregnant Se wom-
en (Hallgren et al. 1977). Future studies should investigate the metabolic pathways and the role of 
glycans excreted in the urine of breastfed and formula-fed infants also in the context of disorders 
in glycan metabolism. That data, together with a more detailed knowledge on glycans in pregnant 
and lactating women’s urines, may boost our understanding of the role of the various glycan 
structures circulating pre- and postnatally in the mother’s and baby’s body. Urinary glycans / me-
tabolites furthermore bear great potential in terms of biomarker discovery not only in the context 
of congenital disorders of glycosylation (Bruggink et al. 2010; Peelen et al. 1994), but also for 
monitoring of placental and fetal functionality (Dessi and Fanos 2013; Hallgren et al. 1977).
Table 6-1 Summary of possible HMO metabolites as presented in Chapters 4 and 5
Detected OS species Possible metabolite class Detected in
+42 Da acetylation infants’ & lactating women’s 
urine
> proportion of HexNAc compared 
to original HMO
cleavage of terminal hexoses, attach-
ment of BG A (GalNAc)
infant urine & feces
> proportion of Hex compared to 
original HMO
attachment of BG B (Gal) infant urine & feces
additional Le epitope feces of infant fed Le-negative 
milk
additional Se epitope urine and feces of infants fed 
non-Se milk
Regarding the overall OS profiles, infant urine showed less inter-individual variation than feces, as 
could be seen in MALDI-TOF-MS and HPAEC-PAD profiles (Chapter 4). In general, smaller in-
tact structures were detected and variation in the relative intensities of fucosylated vs. non-
fucosylated species was observed, when compared to the respective milk profiles. Certain struc-
tures seemed to be strongly depleted in urine, such as the Se-specific LNFP I. Previously, an 
indication for different intestinal absorption or tubular re-absorption of fucosylated OS between Se 
and non-Se starved adults was reported (Lundblad 1966). Moreover, our data from intrinsic 13C-
labeling and tracing of a variety of HMO until their excretion in infants’ urine revealed remarkable 
differences in the temporal dynamics of HMO absorption and excretion (Chapter 3). Fecal profiles 
in exclusively breastfed infants could be classified as follows: i) high diversity with many HMO-
like, also complex structures, ii) predominance of only one or a few OS or OS groups (e.g. fuco-
sylated vs. non-fucosylated), and iii) no OS or only a few with very low signal intensities (Chap-
ters 4 & 5).
Finding HMO-like structures only in feces of exclusively and in one partially breastfed, but not 
exclusively formula-fed infants further points at the role of these compounds within the infant’s 
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gut. Urine samples from formula-fed infants were not available for our studies which would have 
helped distinguishing OS from endogenous origin and mother’s milk to further reveal the rele-
vance of HMO within the infant’s organism. However, in a recent publication from another group 
measurable amounts of lactosyl-OS were found in the urine of both breastfed and formula-fed 
infants. Intriguingly, much higher total amounts and more complex (fucosylated) structures clearly 
originating from human milk have been found (only) in breastfed infants’ urine (Goehring et al.
2014). Importantly, the concentrations and variety of structures was strongly correlated between 
OS in the infants’ urine/plasma and the ingested mother’s milk (Goehring et al. 2014). Conse-
quently, the contribution of dietary glycans seems more significant than the baseline excretion of, 
e.g. blood-group and Se-specific, OS as also found in starved adults (Lundblad 1978). This was 
shown for the urinary excretion of A- and B-trisaccharide (Chester et al. 1979) as well as other, 
e.g. Le- and Se-specific, OS in adults orally given (ga)lactose (Strecker et al. 1976). These non-
complex dietary saccharides might experience modifications by blood group glycosyltransferases 
in intestinal cells prior to their uptake in circulation and their renal excretion (Chester et al. 1979). 
Assuming a protective effect of HMO against uropathogenic bacteria (Lin et al. 2014), the renal 
excretion of bioactive HMO in infants or endogenously modified HMO-like sub-structures, also in 
adults, could possibly benefit individuals at any age, if relevant amounts of active structures are 
excreted via kidneys. Moreover, those OS circulate in the organism before renal excretion so that 
even systemic effects, analogously to those speculated for infants (Chapter 1.3), can be antici-
pated. Especially the urine of pregnant and lactating women contains a variety (Fig. S4-3) and 
significant amounts of lactosyl-OS (Hallgren et al. 1977), that probably originate from HMO syn-
thesis in the mammary gland as speculated in Chapter 4 (Supporting Information Fig. S4–2).
Future research should investigate the role of certain HMO-like structures in context of their anti-
microbial properties not only in the pediatric field, but also as candidates for novel antibiotics in 
general.
A contribution of HMO-like structures to the OS pool in infant feces and urine from sources other 
than original HMO is very likely in spite of the fact that we used 13C-labeling strategy. Degradation 
products from larger HMO which resemble smaller HMO structures (Chapter 2.2) and still were 
carrying the label would not be distinguishable from the same, but intact structures originating 
from milk. Moreover, 13C-labeled galactose that has been applied to lactating women in our exper-
iment has also been incorporated into proteins or lipids present in their milk (Rudloff et al. 2006). 
Given the possibility of releasing HMO-like structures from glycoconjugates (Fig. 1-2), by yet un-
known mechanisms in the infant’s gut, this would have generated additional uncertainty in the 
overall pool of 13C-enriched OS that we have measured (Chapter 3). OS released from glycoli-
pids by a yet undescribed endoglycosylceramidase were proposed as possible source of lactosyl-
OS in urine (Bruggink et al. 2010; Dotz et al. 2015; Lundblad 1966). However, already in the 70’s 
it was shown that inducing (ga)lactosuria clearly decreased urinary excretion of OS with reducing-
end glucose (Strecker et al. 1976). The authors pointed out that transglycosylation of highly
abundant, free saccharides in plasma, i.e. normally Glc, is therefore more likely. In pediatrics, 
future studies with application of single stable-isotope labeled HMO structures to formula-fed in-
fants will enable a clear distinction between endogenous, xenobiotic and milk OS. Nevertheless, 
this work in total provides a unique additional insight into relevant sites and aspects possibly in-
fluencing degradation, metabolization and modifications taking place throughout the entire lifetime 
of the human milk glycome, starting from biosynthesis until the excretion in infants, as depicted in
Fig. 6-1.
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Fig. 6-1 Metabolic fate of human milk oligosaccharides with postulated sites of modification and degrada-
tion. Pathways are depicted by solid lines, possible influencing factors by dashed lines.
The main factor determining structural variety and concentration of OS in milk is the Le and Se 
status of the mother. HMO composition is thought to have an impact on microbiota composition in 
the infant’s gut. Gut microbiota in turn is a major metabolization factor of HMO. However, the in-
fant’s age – possibly linked to feeding/stool frequency, gastrointestinal transit time and gut matu-
ration (Chapter 5, (Albrecht et al. 2011a)) – as well as the infant’s Le/Se phenotype and ABO
blood group also seem to contribute to the overall pool of OS excreted in feces and urine of 
breastfed infants. Yet unknown sites of metabolization such as for the here described acetylation 
are to be explored in the future. Again, isotopically labeled single HMO structures will be of great 
importance in that context. Their urgent need is demonstrated by our further finding of selective 
utilization of LNFP I or the intense defucosylation taking place prior to absorption of HMO into 
circulation (Chapter 4). Contrary to what has been postulated before, the latter finding indicates 
that some metabolization, i.e. fucosidase activity, might already occur in the small intestine, where 
HMO absorption, but not yet microbial fermentation, is thought mainly to take place. Chapter 3
shows an overall overlap of the urinary 13C-HMO excretion time profiles with those of HMO secre-
tion in milk, at least regarding larger HMO structures. This supports the hypothesis of an early 
absorption. An early metabolization of HMO has also been found in rats previously (Jantscher-
Krenn et al. 2013). However, although animal studies can in general be useful in investigation of 
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HMO digestion and fermentation, care must be taken when specific structural motifs are ana-
lyzed. For example, the small-intestinal mucins of mice are dominated by sialylated OS and the 
colon mucins by fucosylated structures, which is reversed in humans (Holmen Larsson et al.
2013). Mucin glycosylation is expected to have a strong impact on gut colonization (Tailford et al.
2015), and thus HMO metabolization, throughout the gastrointestinal tract. The individual gut mu-
cin glycosylation in infants should therefore be kept in mind as one of the factors probably biasing 
future clinical studies on microbiota-HMO correlation.
Finally, the question ‘What structures really matter’ remains unresolved. However, the structural 
diversity found in infants’ urine and feces can even exceed that of human milk due to the addi-
tional modifications as described in this work. Reducing HMO’s functional spectrum to their prebi-
otic effects seems even more short-sighted when the large variety and amounts of structures 
found in urine and plasma of breastfed infants as well as pregnant and lactating women is taken 
into account. Currently, prebiotic OS produced from plants or biotechnologically, such as fructo-
OS or galacto-OS are added to commercial formulas (Eiwegger et al. 2010). Their structures do 
not resemble HMO in any regard, i.e. GlcNAc, Fuc, N-acetylneuraminic acid are not present in 
those structures; linkage and branching patterns also differ significantly (Bode 2012). Attempts 
are being made to extract HMO-like structures from bovine milk (Zivkovic and Barile 2011). How-
ever, amounts of fucosylated OS are very low, there is a predominance of type II over type I struc-
tures, which is reverse in human milk, and bovine milk contains non-human and therefore poten-
tially allergenic structural motifs (Albrecht et al. 2014; Bode 2012). Moreover, it is very likely that 
the spectrum of OS structures as a whole, in interaction with the different aspects mentioned 
above and with other glycans present in human milk, may exert its optimal effects.
Therefore, future research should focus on the evaluation of the metabolic pathways of neutral 
and sialylated glycans, including glycolipids, glycoproteins/peptides as well as free OS, not only in 
the breastfed infant, but also in its mother. Le/Se and ABO blood group should be determined in 
both mother and child, using reliable analytics. Moreover, preferably several fecal and urine sam-
ples should be collected over a longer time period for improved representativeness, and feed-
ing/stool frequency should be documented. Next to the production of stable-isotope labeled single 
HMO for human use and as standards for quantitative glycomics, reliable cutting-edge glyco-
analytical methodologies with improved data analysis tools will be very much needed in the future 
to substantially promote our understanding of the unique biological benefits of breastfeeding in 
the context of glycobiology.
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Zusammenfassung (summary in German)
Humanmilch enthält eine Vielzahl an komplexen Kohlenhydraten, die sich biosynthetisch von dem 
Milchzucker Laktose ableiten. Ihre Konzentrationen betragen mit ca. 5–20 Gramm pro Liter etwa 
ein Zehntel des Gehalts von Laktose. Bisher wurden zahlreiche biologische Effekte von Human-
milcholigosacchariden (HMO) anhand von Ergebnissen aus in vitro Studien beschrieben. Sie 
sollen u.a. präbiotisch und antiinfektiös im Darm des gestillten Säuglings wirken. Darüber hinaus 
könnten sie auch immunmodulierende und andere positive Eigenschaften im Körper haben, so-
fern die aktiven Substanzen im Dünndarm absorbiert werden. Um den endgültigen Beweis für die 
Wirksamkeit der einzelnen Substanzen beim Säugling in vivo zu erbringen, wären Interventions-
studien mit Einzelsubstanzen notwendig. Diese sind aufgrund mangelnder Verfügbarkeit syntheti-
scher HMO bislang nicht möglich. Daher wurden in der vorliegenden Arbeit der Metabolismus und 
die möglichen Ausscheidungswege von HMO direkt beim gestillten Säugling untersucht, um so 
Hinweise auf deren Struktur-Funktionsbeziehungen in vivo zu erhalten. Dafür wurde eine analyti-
sche Plattform entwickelt, die eine effiziente und zuverlässige Identifizierung von Oligosacchari-
den aus Muttermilch, Säuglingsurin und –fäzes ermöglicht.
In Kapitel 1 der vorliegenden Arbeit werden die aktuellen Kenntnisse zum Metabolismus und der 
Funktion von HMO sowie die gängigsten Methoden der Glykananalytik anhand von Literatur vor-
gestellt. Kapitel 2 verdeutlicht die große Relevanz der modernen Glykananalytik für die Erfor-
schung der Struktur-Funktionsbeziehungen von HMO mit Fokus auf spezifische HMO-Strukturen 
mit Lewis- oder Sekretorepitopen (genetisch determinierte Blutgruppenantigene in Humanmilch).
Kapitel 3 beschreibt die praktischen Studien zum Zeitverlauf der HMO-Ausscheidung im Säug-
lingsurin 36 Stunden nach Einzelgabe von 13C-Galaktose an die Mütter. Mittels Matrix-
unterstützter Laser Desorption/Ionizations-Massenspektrometrie mit Flugzeitanalysator (MALDI-
TOF-MS) wurden bei allen zehn Säuglingen intakte, auch sehr komplexe HMO detektiert. Aller-
dings war die Exkretion bestimmter Strukturen bei manchen Kindern verzögert, was auf eine indi-
viduell längere Darmpassage oder Blutzirkulation dieser hinweist. Des Weiteren gab es Hinweise 
auf eine unerwartet frühe Metabolisierung bestimmter Strukturen in oberen Darmabschnitten. 
Die möglichen Metaboliten nach ihrem Abbau oder Modifikation und/oder Aufnahme im Darm 
wurden bei derselben Probandengruppe mittels MALDI-TOF-MS und Flüssigchromatographie 
untersucht (Kapitel 4). Diese konnten mittels Tandem-MS als acetylierte HMO oder verschiedene 
HMO-Abbauprodukte charakterisiert werden, zusätzlich zu HMO-Strukturen, die offenbar erst 
nach der Aufnahme von den Enzymen des Kindes mit Lewis- und/oder Sekretorepitopen verse-
hen worden waren. Einige Hinweise auf strukturspezifische Utilisation im Darm oder Organismus
des Säuglings wurden darüber hinaus erlangt, beispielsweise aufgrund stark verminderter Aus-
scheidung von Lakto-N-tetraose im Stuhl oder Lacto-N-fukopentaose I im Urin.
Die Oligosaccharidmuster von weiteren 24 Säuglingen wurden ebenfalls mittels MALDI-TOF-MS 
untersucht (Kapitel 5). Dabei wurden drei Untergruppen anhand der HMO-Muster im Stuhl der 
gestillten Säuglinge im Alter von sechs Wochen beobachtet: i) hohe Diversität an Oligosaccharid-
strukturen mit Dominanz von intakten HMO, ii) wenige Oligosaccharide mit eher niedriger Signal-
intensität und iii) keine HMO oder HMO-Metaboliten. Im Alter von sechs Monaten wurden bei den 
gestillten Säuglingen keine oder sehr wenige HMO(Metaboliten) detektiert. Des Weiteren konnten 
bei den formelernährten und bei zwei von drei gemischt ernährten Säuglingen keine Oligosaccha-
ride im Stuhl detektiert werden.
In Kapitel 6 werden die neuen Erkenntnisse auf der Basis vorhandener Literatur abschließend 
diskutiert und es werden Perspektiven für künftige Humanstudien über HMO aufgezeigt.
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